Lipids with branched tail structures
Novel cationic lipids and lipid nanoparticles enhance nucleic acid delivery by protecting against degradation and ensuring intracellular access, addressing the limitations of current methods.
Patent Information
- Application Number
- PCT/US2026/027821
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Current nucleic acid delivery methods face challenges such as susceptibility to nuclease digestion in plasma and limited intracellular access, necessitating improved cationic lipids and lipid nanoparticles for effective protection and delivery.
Development of novel cationic lipids and lipid nanoparticles, combined with neutral lipids, cholesterol, and polymer conjugated lipids, to form nanoparticles that encapsulate therapeutic nucleic acids, enhancing protection and intracellular delivery.
The novel lipid nanoparticles provide increased activity and tolerability of nucleic acids, improving the therapeutic index by protecting against degradation and facilitating intracellular delivery.
Smart Images

Figure US2026027821_19112026_PF_FP_ABST
Abstract
Description
[0001] LIPIDS WITH BRANCHED TAIL STRUCTURES
[0002] BACKGROUND
[0003] Technical Field
[0004] The present disclosure generally relates to novel cationic lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer conjugated lipids, to form lipid nanoparticles with oligonucleotides, to facilitate the intracellular delivery of therapeutic nucleic acids (e.g., oligonucleotides, messenger RNA) both in vitro and in vivo.
[0005] Description of Related Art
[0006] There are many challenges associated with the delivery of nucleic acids to achieve a desired response in a biological system. Nucleic acid-based therapeutics have enormous potential but there remains a need for more effective delivery of nucleic acids to appropriate sites within a cell or organism to realize this potential. Therapeutic nucleic acids include, e.g., messenger RNA (mRNA), antisense oligonucleotides, ribozymes, DNAzymes, plasmids, immune stimulating nucleic acids, antagomir, antimir, mimic, supermir, and aptamers. Some nucleic acids, such as mRNA or plasmids, can be used to induce expression of specific cellular products as would be useful in the treatment of, for example, diseases related to a deficiency of a protein or enzyme. The therapeutic applications of translatable nucleotide delivery are extremely broad as constructs can be synthesized to produce any chosen protein sequence, whether indigenous to the system. The expression products of the nucleic acid can augment existing levels of protein, replace missing or non-functional versions of a protein, or introduce a new protein and associated functionality in a cell or organism.
[0007] BRIEF SUMMARY
[0008] Nucleic acids, such as miRNA inhibitors, can be used to modulate expression of specific cellular products that are regulated by miRNA as would be useful in the treatment of, for example, diseases related to protein deficiency or enzyme. The therapeutic applications of miRNA inhibition are extremely broad as constructs can be synthesized to inhibit one or more miRNA that would in turn regulate the expression of mRNA products. The inhibition of endogenous miRNA can augment its downstream target endogenous protein expression and restore proper function in a cell or organism to treat disease associated with a specific miRNA or a group of miRNA.
[0009] Other nucleic acids can down-regulate intracellular levels of specific mRNA and, as a result, down-regulate the synthesis of the corresponding proteins through processes such as RNA interference (RNAi) or complementary binding of antisense RNA. The therapeutic applications of antisense oligonucleotide and RNAi are also extremely broad, since oligonucleotide constructs can be synthesized with any nucleotide sequence directed against a target mRNA. Targets may include mRNAs from normal cells, mRNAs associated with disease-states, such as cancer, and mRNAs of infectious agents, such as viruses. To date, antisense oligonucleotide constructs have shown the ability to specifically down-regulate target proteins through degradation of the cognate mRNA in both in vitro and in vivo models. In addition, antisense oligonucleotide constructs are currently being evaluated in clinical studies.
[0010] However, two problems are currently facing use oligonucleotides in therapeutic contexts. First, free RNAs are susceptible to nuclease digestion in plasma. Second, free RNAs have limited ability to gain access to the intracellular compartment where the relevant translation machinery resides. Lipid nanoparticles formed from cationic lipids with other lipid components, such as neutral lipids, cholesterol, PEG, PEGylated lipids, and oligonucleotides have been used to block degradation of the RNAs in plasma and facilitate the cellular uptake of the oligonucleotides.
[0011] There remains a need for improved cationic lipids and lipid nanoparticles for the delivery of oligonucleotides. Preferably, these lipid nanoparticles would provide optimal drug to lipid ratios, protect the nucleic acid from degradation and clearance in serum, be suitable for systemic delivery, and provide intracellular delivery of the nucleic acid. In addition, these lipid-nucleic acid particles should be well-tolerated and provide an adequate therapeutic index, such that patient treatment at an effective dose of the nucleic acid is not associated with unacceptable toxicity and / or risk to the patient. The present disclosure provides these and related advantages.
[0012] In brief, the present disclosure provides lipid compounds, including stereoisomers, pharmaceutically acceptable salts, or tautomers thereof, which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids (including, for example, all sterols) and / or their analogs, and / or polymer conjugated lipids to form lipid nanoparticles for the delivery of therapeutic agents. In some instances, lipid nanoparticles are used to deliver nucleic acids such as antisense and / or messenger RNA.
[0013] Methods for use of such lipid nanoparticles for treatment of various diseases or conditions, such as those caused by infectious entities and / or insufficiency of a protein, are also provided.
[0014] In one embodiment, the present disclosure provides compounds having the following structure of Formula (I):
[0015] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein Rla, Rlb, R2a, R2b, R3, R4a, R4b, L1, L2, L3, and L4are as defined herein.
[0016] Pharmaceutical compositions comprising one or more of the foregoing compounds of Formula (I) and a therapeutic agent are also provided. In some embodiments, the pharmaceutical compositions further comprise one or more components selected from neutral lipids, charged lipids, steroids, and polymer conjugated lipids. In some embodiments, the compounds of Formula (I) combine with other components, such as neutral lipids, charged lipids, steroids, and / or polymer conjugated lipids to form lipid nanoparticles (LNPs). Such LNPs may encapsulate therapeutic agents, such as nucleic acids. In some embodiments, the LNPs are useful for delivery of the therapeutic agent.
[0017] In other embodiments, the present disclosure provides a method for administering a therapeutic agent to a patient in need thereof, the method comprising preparing a composition of lipid nanoparticles comprising the compound of Formula (I) and a therapeutic agent and delivering the composition to the patient. Such methods are useful for inducing expression of a protein in a subject, for example for expressing an antigen for purposes of vaccination or a gene editing protein.
[0018] These and other aspects of the disclosure will be apparent upon reference to the following detailed description.
[0019] DETAILED DESCRIPTION
[0020] In the following description, certain specific details are set forth to provide a thorough understanding of various embodiments of the disclosure. However, one skilled in the art will understand that the embodiments of the disclosure may be practiced without these details.
[0021] The present disclosure is based, in part, upon the discovery of novel cationic lipids that provide advantages when used in lipid nanoparticles for the in vivo delivery of an active or therapeutic agent such as a nucleic acid into a cell of a mammal. Embodiments of the presentdisclosure provide nucleic acid-lipid nanoparticle compositions comprising one or more of the novel cationic lipids described herein that provide increased activity of the nucleic acid and improved tolerability of the compositions in vivo, resulting in a significant increase in the therapeutic index as compared to nucleic acid-lipid nanoparticle compositions previously described.
[0022] In certain embodiments, the present disclosure provides novel cationic lipids that enable the formulation of improved compositions for the in vitro and in vivo delivery of mRNA and / or other oligonucleotides. In some embodiments, these improved lipid nanoparticle compositions are useful for expression of protein encoded by mRNA. In other embodiments, these improved lipid nanoparticles compositions are useful for upregulation of endogenous protein expression by delivering miRNA inhibitors targeting one specific miRNA or a group of miRNA regulating one target mRNA or several mRNA. In other embodiments, these improved lipid nanoparticle compositions are useful for down-regulating (e.g., silencing) the protein levels and / or mRNA levels of target genes. In some other embodiments, lipid nanoparticles are also useful for delivery of mRNA and plasmids for expression of transgenes. In yet other embodiments, the lipid nanoparticle compositions are useful for inducing a pharmacological effect resulting from expression of a protein, e.g., increased production of red blood cells through the delivery of a suitable erythropoietin mRNA, or protection against infection through delivery of mRNA encoding for a suitable antibody.
[0023] The lipid nanoparticles and compositions of the present disclosure may be used for a variety of purposes, including the delivery of encapsulated or associated (e.g., complexed) therapeutic agents such as nucleic acids to cells, both in vitro and in vivo. Accordingly, embodiments of the present disclosure provide methods of treating or preventing diseases or disorders in a subject in need thereof by contacting the subject with a lipid nanoparticle that encapsulates or is associated with a suitable therapeutic agent, wherein the lipid nanoparticle comprises one or more of the novel cationic lipids described herein.
[0024] As described herein, embodiments of the lipid nanoparticles of the present disclosure are particularly useful for the delivery of nucleic acids, including, e.g., mRNA, antisense oligonucleotide, plasmid DNA, microRNA (miRNA), miRNA inhibitors (antagomirs / antimirs), messenger-RNA-interfering complementary RNA (micRNA), DNA, multivalent RNA, dicer substrate RNA, complementary DNA (cDNA), etc. Therefore, the lipid nanoparticles and compositions of the present disclosure may be used to induce expression of a desired protein both in vitro and in vivo by contacting cells with a lipid nanoparticle comprising one or more novel cationic lipids described herein, wherein the lipid nanoparticle encapsulates or is associated with a nucleic acid that is expressed to produce the desired protein (e.g., a messengerRNA or plasmid encoding the desired protein). Alternatively, the lipid nanoparticles and compositions of the present disclosure may be used to decrease the expression of target genes and proteins both in vitro and in vivo by contacting cells with a lipid nanoparticle comprising one or more novel cationic lipids described herein, wherein the lipid nanoparticle encapsulates or is associated with a nucleic acid that reduces target gene expression (e.g., an antisense oligonucleotide or small interfering RNA (siRNA)). The lipid nanoparticles and compositions of the present disclosure may also be used for co-delivery of different nucleic acids (e.g., mRNA and plasmid DNA) separately or in combination, such as may be useful to provide an effect requiring co-localization of different nucleic acids (e.g., mRNA encoding for a suitable gene modifying enzyme and DNA segment(s) for incorporation into the host genome).
[0025] Nucleic acids for use with this disclosure may be prepared according to any available technique. For mRNA, the primary methodology of preparation is, but not limited to, enzymatic synthesis (also termed in vitro transcription) which currently represents the most efficient method to produce long sequence-specific mRNA. In vitro transcription describes a process of template-directed synthesis of RNA molecules from an engineered DNA template comprised of an upstream bacteriophage promoter sequence (e.g., including but not limited to that from the T7, T3, and SP6 coliphage) linked to a downstream sequence encoding the gene of interest. Template DNA can be prepared for in vitro transcription from a number of sources with appropriate techniques which are well known in the art including, but not limited to, plasmid DNA and polymerase chain reaction amplification (see Linpinsel, J. L. and Conn, G. L., General protocols for preparation of plasmid DNA template and Bowman, J. C., Azizi, B., Lenz, T. K., Ray, P., and Williams, L. D. in RNA in vitro transcription and RNA purification by denaturing PAGE in Recombinant and in vitro RNA syntheses Methods v. 941 Conn G. L. (ed), New York, N. Y. Humana Press, 2012).
[0026] Transcription of the RNA occurs in vitro using the linearized DNA template in the presence of the corresponding RNA polymerase and adenosine, guanosine, uridine, and cytidine ribonucleoside triphosphates (rNTPs) under conditions that support polymerase activity while minimizing potential degradation of the resultant mRNA transcripts. In vitro transcription can be performed using a variety of commercially available kits including but not limited to RiboMax Large Scale RNA Production System (Promega), MegaScript Transcription kits (Life Technologies) as well as with commercially available reagents including RNA polymerases and rNTPs. The methodology for in vitro transcription of mRNA is well known in the art. (see, e.g., Losick, R., 1972, In vitro transcription, Ann Rev Biochem v.41 409-46; Kamakaka, R. T. and Kraus, W. L. 2001. In Vitro Transcription. Current Protocols in Cell Biology. 2:11.6:11.6.1-11.6.17; Beckert, B. And Masquida, B., (2010) Synthesis of RNA by In Vitro Transcription inRNA in Methods in Molecular Biology v. 703 (Neilson, H. Ed), New York, N. Y. Humana Press, 2010; Brunelle, J. L. and Green, R., 2013, Chapter Five -In vitro transcription from plasmid or PCR-amplified DNA, Methods in Enzymology v. 530, 101-114; all of which are incorporated herein by reference).
[0027] The desired in vitro transcribed mRNA is then purified from the undesired components of the transcription or associated reactions (including unincorporated rNTPs, protein enzyme, salts, short RNA oligos etc I). Techniques for the isolation of the mRNA transcripts are well known in the art. Well known procedures include phenol / chloroform extraction or precipitation with either alcohol (ethanol, isopropanol) in the presence of monovalent cations or lithium chloride.
[0028] Additional, non-limiting examples of purification procedures which can be used include size exclusion chromatography (Lukavsky, P. J. and Puglisi, J. D., 2004, Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides, RNA v.10, 889-893), silica-based affinity chromatography and polyacrylamide gel electrophoresis (Bowman, J. C., Azizi, B., Lenz, T. K., Ray, P., and Williams, L. D. in RNA in vitro transcription and RNA purification by denaturing PAGE in Recombinant and in vitro RNA syntheses Methods v. 941 Conn G. L. (ed), New York, N. Y. Humana Press, 2012 ). Purification can be performed using a variety of commercially available kits including but not limited to SV Total Isolation System (Promega) and In Vitro Transcription Cleanup and Concentration Kit (Norgen Biotek).
[0029] Furthermore, while reverse transcription can yield large quantities of mRNA, the products can contain several aberrant RNA impurities associated with undesired polymerase activity which may need to be removed from the full-length mRNA preparation. These include short RNAs that result from abortive transcription initiation as well as double-stranded RNA (dsRNA) generated by RNA-dependent RNA polymerase activity, RNA-primed transcription from RNA templates and self-complementary 3' extension. It has been demonstrated that these contaminants with dsRNA structures can lead to undesired immunostimulatory activity through interaction with various innate immune sensors in eukaryotic cells that function to recognize specific nucleic acid structures and induce potent immune responses. This in turn can dramatically reduce mRNA translation since protein synthesis is reduced during the innate cellular immune response. Therefore, additional techniques to remove these dsRNA contaminants have been developed and are known in the art including but not limited to scalable HPLC purification (see, e.g., Kariko, K., Muramatsu, H., Ludwig, J. And Weissman, D., 2011, Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA, Nucl Acid Res, v. 39 el42; Weissman, D., Pardi, N., Muramatsu, H., and Kariko, K., HPLC Purification of in vitro transcribed long RNA in Synthetic Messenger RNA and Cell Metabolism Modulation in
[0030] Methods in Molecular Biology v.969 (Rabinovich, P. H. Ed), 2013). HPLC purified mRNA has been reported to be translated at much greater levels, particularly in primary cells and in vivo.
[0031] A significant variety of modifications have been described in the art which are used to alter specific properties of in vitro transcribed mRNA and improve its utility. These include but are not limited to modifications to the 5' and 3' termini of the mRNA. Endogenous eukaryotic mRNA typically contains a cap structure on the 5 '-end of a mature molecule which plays an important role in mediating binding of the mRNA Cap Binding Protein (CBP), which is in turn responsible for enhancing mRNA stability in the cell and efficiency of mRNA translation.
[0032] Therefore, the highest levels of protein expression are achieved with capped mRNA transcripts. The 5 '-cap contains a 5 '-5 '-triphosphate linkage between the 5 '-most nucleotide and guanine nucleotide. The conjugated guanine nucleotide is methylated at the N7 position. Additional modifications include methylation of the ultimate and penultimate most 5 '-nucleotides on the 2'-hydroxyl group.
[0033] Multiple distinct cap structures can be used to generate the 5'-cap of in vitro transcribed synthetic mRNA. 5 '-capping of synthetic mRNA can be performed co-transcriptionally with chemical cap analogs (i.e., capping during in vitro transcription). For example, the Anti -Reverse Cap Analog (ARC A) cap contains a 5 '-5 '-triphosphate guanine-guanine linkage where one guanine contains an N7 methyl group as well as a 3'-O-methyl group. However, up to 20% of transcripts remain uncapped during this co-transcriptional process and the synthetic cap analog is not identical to the 5 '-cap structure of an authentic cellular mRNA, potentially reducing translatability and cellular stability. Alternatively, synthetic mRNA molecules may also be enzymatically capped post-transcriptionally. These may generate a more authentic 5 '-cap structure that more closely mimics, either structurally or functionally, the endogenous 5'-cap which have enhanced the binding of cap binding proteins, increased half-life, reduced susceptibility to 5' endonucleases and / or reduced 5' decapping. Numerous synthetic 5'-cap analogs have been developed and are known in the art to enhance mRNA stability and translatability (see, e.g., Grudzien-Nogalska, E., Kowalska, J., Su, W., Kuhn, A. N., Slepenkov, S. V., Darynkiewicz, E., Sahin, U., Jemielity, J., and Rhoads, R. E., Synthetic mRNAs with superior translation and stability properties in Synthetic Messenger RNA and Cell Metabolism Modulation in Methods in Molecular Biology v.969 (Rabinovich, P. H. Ed), 2013).
[0034] On the 3 '-terminus, a long chain of adenine nucleotides (poly-A tail) is normally added to mRNA molecules during RNA processing. Immediately after transcription, the 3' end of the transcript is cleaved to free a 3 '-hydroxyl to which poly-A polymerase adds a chain of adenine nucleotides to the RNA in a process called polyadenylation. The poly-A tail has been extensively shown to enhance both translational efficiency and stability of mRNA (see Bernstein, P. andRoss, J., 1989, Poly (A), poly (A) binding protein and the regulation of mRNA stability, Trends Bio Sci v. 14373-377; Guhaniyogi, J. And Brewer, G., 2001, Regulation of mRNA stability in mammalian cells, Gene, v. 265, 11-23; Dreyfus, M. And Regnier, P., 2002, The poly (A) tail of mRNAs: Bodyguard in eukaryotes, scavenger in bacteria, Cell, v.111, 611-613).
[0035] Poly (A) tailing of in vitro transcribed mRNA can be achieved using various approaches including, but not limited to, cloning of a poly (T) tract into the DNA template or by post-transcriptional addition using Poly (A) polymerase. The first case allows in vitro transcription of mRNA with poly (A) tails of defined length, depending on the size of the poly (T) tract, but requires additional manipulation of the template. The latter case involves the enzymatic addition of a poly (A) tail to in vitro transcribed mRNA using poly (A) polymerase which catalyzes the incorporation of adenine residues onto the 3 'termini of RNA, requiring no additional manipulation of the DNA template, but results in mRNA with poly(A) tails of heterogenous length. 5 '-capping and 3 '-poly (A) tailing can be performed using a variety of commercially available kits including, but not limited to Poly (A) Polymerase Tailing kit (EpiCenter), mMESSAGE mMACHINE T7 Ultra kit and Poly (A) Tailing kit (Life Technologies) as well as with commercially available reagents, various ARCA caps, Poly (A) polymerase, etc.
[0036] In addition to 5' cap and 3' poly adenylation, other modifications of the in vitro transcripts have been reported to provide benefits as related to efficiency of translation and stability. It is well known in the art that pathogenic DNA and RNA can be recognized by a variety of sensors within eukaryotes and trigger potent innate immune responses. The ability to discriminate between pathogenic and self-DNA and RNA has been shown to be based, at least in part, on structure and nucleoside modifications since most nucleic acids from natural sources contain modified nucleosides. In contrast, in vitro synthesized RNA lacks these modifications, thus rendering it immunostimulatory which in turn can inhibit effective mRNA translation as outlined above. The introduction of modified nucleosides into in vitro transcribed mRNA can be used to prevent recognition and activation of RNA sensors, thus mitigating this undesired immunostimulatory activity and enhancing translation capacity (see, e.g., Kariko, K. And Weissman, D. 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr Opin Drug Discov Devel, v.10 523-532; Pardi, N., Muramatsu, H., Weissman, D., Kariko, K., In vitro transcription of long RNA containing modified nucleosides in Synthetic Messenger RNA and Cell Metabolism Modulation in Methods in Molecular Biology v.969 (Rabinovich, P. H. Ed), 2013); Kariko, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., Weissman, D., 2008, Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability, Mol Ther v.16, 1833-1840. Themodified nucleosides and nucleotides used in the synthesis of modified RNAs can be prepared, monitored, and utilized using general methods and procedures known in the art. A large variety of nucleoside modifications are available that may be incorporated alone or in combination with other modified nucleosides to some extent into the in vitro transcribed mRNA (see, e.g., US Publication No. 2012 / 0251618). In vitro synthesis of nucleoside-modified mRNA has been reported to have reduced ability to activate immune sensors with a concomitant enhanced translational capacity.
[0037] Other components of mRNA which can be modified to provide benefit in terms of translatability and stability include the 5' and 3' untranslated regions (UTR). Optimization of the UTRs (favorable 5' and 3' UTRs can be obtained from cellular or viral RNAs), either both or independently, have been shown to increase mRNA stability and translational efficiency of in vitro transcribed mRNA (see, e.g., Pardi, N., Muramatsu, H., Weissman, D., Kariko, K., In vitro transcription of long RNA containing modified nucleosides in Synthetic Messenger RNA and Cell Metabolism Modulation in Methods in Molecular Biology v.969 (Rabinovich, P. H. Ed), 2013).
[0038] In addition to mRNA, other nucleic acid payloads may be used for this disclosure. For oligonucleotides, methods of preparation include but are not limited to chemical synthesis and enzymatic, chemical cleavage of a longer precursor, in vitro transcription as described above, etc. Methods of synthesizing DNA and RNA nucleotides are widely used and well known in the art (see, e.g., Gait, M. J. (ed.)Oligonucleotide synthesis: a practical approach, Oxford [Oxfordshire], Washington, D. C.: IRL Press, 1984; and Herdewijn, P. (ed.) Oligonucleotide synthesis: methods and applications, Methods in Molecular Biology, v. 288 (Clifton, N. J.) Totowa, N. J.: Humana Press, 2005; both of which are incorporated herein by reference).
[0039] For plasmid DNA, preparation for use with this disclosure commonly utilizes but is not limited to expansion and isolation of the plasmid DNA in vitro in a liquid culture of bacteria containing the plasmid of interest. The presence of a gene in the plasmid of interest that encodes resistance to a particular antibiotic (penicillin, kanamycin, etc.) allows those bacteria containing the plasmid of interest to selective grow in antibiotic-containing cultures. Methods of isolating plasmid DNA are widely used and well known in the art (see, e.g., Heilig, J., Elbing, K. L. and Brent, R (2001) Large-Scale Preparation of Plasmid DNA. Current Protocols in Molecular Biology. 41:11:1.7:1.7.1-1.7.16; Rozkov, A., Larsson, B., Gillstrom, S., Bjomestedt, R. and Schmidt, S. R. (2008), Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture. Biotechnol. Bioeng., 99: 557-566; and US6197553B1). Plasmid isolation can be performed using a variety of commercially available kits including, butnot limited to Plasmid Plus (Qiagen), GenJET plasmid MaxiPrep (Thermo) and Pure Yield MaxiPrep (Promega) kits as well as commercially available reagents.
[0040] Various exemplary embodiments of Formula (I), lipid nanoparticles and compositions comprising the same, and their use to deliver active or therapeutic agents such as nucleic acids to modulate gene and protein expression, are described in further detail below.
[0041] As used herein, the following terms have the meanings ascribed to them unless specified otherwise.
[0042] Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open and inclusive sense, that is, as “including, but not limited to.”
[0043] Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0044] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs. As used in the specification and claims, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
[0045] The phrase “induce expression of a desired protein” refers to the ability of a nucleic acid to increase expression of the desired protein. To examine the extent of protein expression, a test sample (e.g, a sample of cells in culture expressing the desired protein) or a test mammal (e.g, a mammal such as a human or an animal model such as a rodent (e.g., mouse) or a non-human primate (e.g., monkey) model) is contacted with a nucleic acid (e.g., nucleic acid in combination with a lipid of the present disclosure). Expression of the desired protein in the test sample or test animal is compared to expression of the desired protein in a control sample (e.g., a sample of cells in culture expressing the desired protein) or a control mammal (e.g., a mammal such as a human or an animal model such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model) that is not contacted with or administered the nucleic acid. When the desired protein is present in a control sample or a control mammal, the expression of a desired protein in a control sample or a control mammal may be assigned to a value of 1.0. In some embodiments, inducing expression of a desired protein is achieved when the ratio of desired protein expression in the test sample or the test mammal to the level of desired protein expression in the control sample or thecontrol mammal is greater than 1, for example, about 1.1, 1.5, 2.0. 5.0 or 10.0. When a desired protein is not present in a control sample or a control mammal, inducing expression of a desired protein is achieved when any measurable level of the desired protein in the test sample or the test mammal is detected. One of ordinary skill in the art will understand appropriate assays to determine the level of protein expression in a sample, for example dot blots, northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, and phenotypic assays, or assays based on reporter proteins that can produce fluorescence or luminescence under appropriate conditions.
[0046] The phrase “inhibiting expression of a target gene” refers to the ability of a nucleic acid to silence, reduce, or inhibit the expression of a target gene. To examine the extent of gene silencing, a test sample (e.g., a sample of cells in culture expressing the target gene) or a test mammal (e.g., a human, rodent, non-human primate, efc.) model is contacted with a nucleic acid that silences, reduces, or inhibits expression of the target gene. Expression of the target gene in the test sample or test animal is compared to expression of the target gene in a control sample (e.g., a sample of cells in culture expressing the target gene) or a control mammal (e.g., a human, rodent, non-human primate, efc.) that is not contacted with or administered the nucleic acid. The expression of the target gene in a control sample or a control mammal may be assigned a value of 100%. In particular embodiments, silencing, inhibition, or reduction of expression of a target gene is achieved when the level of target gene expression in the test sample or the test mammal relative to the level of target gene expression in the control sample or the control mammal is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. In other words, the nucleic acids are capable of silencing, reducing, or inhibiting the expression of a target gene by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% in a test sample or a test mammal relative to the level of target gene expression in a control sample or a control mammal not contacted with or administered the nucleic acid. Suitable assays for determining the level of target gene expression include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
[0047] An “effective amount” or “therapeutically effective amount” of an active agent or therapeutic agent such as a therapeutic nucleic acid is an amount sufficient to produce the desired effect, e.g., an increase or inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of the nucleic acid. An increase in expression of a target sequence is achieved when any measurable level is detected in the case of an expressionproduct that is not present in the absence of the nucleic acid. In the case where the expression product is present at some level prior to contact with the nucleic acid, an in increase in expression is achieved when the fold increase in value obtained with a nucleic acid such as mRNA relative to control is about 1.05, 1.1, 1.2, 1.3, 1.4, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 250, 500, 750, 1000, 5000, 10000 or greater. Inhibition of expression of a target gene or target sequence is achieved when the value obtained with a nucleic acid such as antisense oligonucleotide relative to the control is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. Suitable assays for measuring expression of a target gene or target sequence include, e.g., examination of protein or RNA levels using techniques known to those of skill in the art such as dot blots, northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, fluorescence or luminescence of suitable reporter proteins, as well as phenotypic assays known to those of skill in the art.
[0048] The term “nucleic acid” as used herein refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in either single- or double-stranded form and includes DNA, RNA, and hybrids thereof. DNA may be in the form of antisense molecules, plasmid DNA, cDNA, PCR products, or vectors. RNA may be in the form of small hairpin RNA (shRNA), messenger RNA (mRNA), antisense RNA, miRNA, micRNA, multivalent RNA, dicer substrate RNA or viral RNA (vRNA), and combinations thereof. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2'-O-methyl ribonucleotides, and peptide-nucleic acids (PNAs). Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer etal.„ Nucleic Acid Res., 19:5081 (1991); Ohtsuka etal.„ J. Biol. Chem., 260:2605-2608 (1985); Rossolini etal., Mol. Cell. Probes, 8:91-98 (1994)). “Nucleotides” contain sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups. “Bases” include purines and pyrimidines, which furtherinclude natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.
[0049] The term “gene” refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary to produce a polypeptide or precursor polypeptide.
[0050] “Gene product,” as used herein, refers to a product of a gene such as an RNA transcript or a polypeptide.
[0051] The term “lipid” refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are generally characterized by being poorly soluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) “simple lipids,” which include fats and oils as well as waxes; (2) “compound lipids,” which include phospholipids and glycolipids; and (3) “derived lipids” such as steroids.
[0052] A “steroid” is a compound comprising the following carbon skeleton:
[0053]
[0054] Non-limiting examples of steroids include cholesterol, and the like.
[0055] A “cationic lipid” refers to a lipid capable of being positively charged. Exemplary cationic lipids include one or more amine group(s) which bear the positive charge. Preferred cationic lipids are ionizable such that they can exist in a positively charged or neutral form depending on pH. The ionization of the cationic lipid affects the surface charge of the lipid nanoparticle under different pH conditions. This charge state can influence plasma protein absorption, blood clearance and tissue distribution (Semple, S. C., et al., Adv. Drug Deliv Rev 32:3-17 (1998)) as well as the ability to form endosomolytic non-bilayer structures (Hafez, I. M., et al., Gene Ther 8: 1188-1196 (2001)) critical to the intracellular delivery of nucleic acids.
[0056] The term “lipid nanoparticle” refers to particles having at least one dimension on the order of nanometers (e.g., 1-1,000 nm) which include one or more of the compounds of Formula (I) or other specified components. In some embodiments, lipid nanoparticles are included in a formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, tumor, and the like). In some embodiments, the lipid nanoparticles of the disclosure comprise a nucleic acid. Such lipidnanoparticles typically comprise a compound of Formula (I) and one or more excipients selected from neutral lipids, charged lipids, steroids, and polymer conjugated lipids. In some embodiments, the active agent or therapeutic agent, such as a nucleic acid, may be encapsulated in the lipid portion of the lipid nanoparticle or an aqueous space enveloped by some or all the lipid portion of the lipid nanoparticle, thereby protecting it from enzymatic degradation or other undesirable effects induced by the mechanisms of the host organism or cells, e.g., an adverse immune response.
[0057] In various embodiments, the lipid nanoparticles have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 40 nm to about 100 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm, and are substantially non-toxic. In certain embodiments, nucleic acids, when present in the lipid nanoparticles, are resistant in aqueous solution to degradation with a nuclease. Lipid nanoparticles comprising nucleic acids, and their method of preparation are disclosed in, e.g., U. S. Patent Publication Nos. 2004 / 0142025, 2007 / 0042031 and PCT Pub. Nos. WO 2013 / 016058 and WO 2013 / 086373, the full disclosures of which are herein incorporated by reference in their entirety for all purposes.
[0058] As used herein, “lipid encapsulated” refers to a lipid nanoparticle that provides an active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA), with full encapsulation, partial encapsulation, or both. In an embodiment, the nucleic acid (e.g., mRNA) is fully encapsulated in the lipid nanoparticle.
[0059] The term “polymer conjugated lipid” refers to a molecule comprising both a lipid portion and a polymer portion. An example of a polymer conjugated lipid is a pegylated lipid. The term “pegylated lipid” refers to a molecule comprising both a lipid portion and a polyethylene glycol portion. Pegylated lipids are known in the art and include
[0060] l-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG) and the like.
[0061] The term “neutral lipid” refers to any of several lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, but are not limited to, phosphotidylcholines such as l,2-Distearoyl- w-glycero-3-phosphocholine (DSPC), l,2-Dipalmitoyl- w-glycero-3 -phosphocholine (DPPC), l,2-Dimyristoyl- w-glycero-3-phosphocholine (DMPC), l-Palmitoyl-2-oleoyl-sw-glycero-3 -phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC), phophatidyl ethanolamines such as 1,2-Dioleoyl-.s / / -glycero-3 -phosphoethanol amine (DOPE), sphingomyelins (SM), ceramides, steroids such as sterols and their derivatives. Neutral lipids may be synthetic or naturally derived.
[0062] The term “charged lipid” refers to any of several lipid species that exist in either a positively charged or negatively charged form independent of the pH within a useful physiological range, e.g., pH ~3 to pH ~9. Charged lipids may be synthetic or naturally derived. Examples of charged lipids include phosphatidylserines, phosphatidic acids, phosphatidylglycerols, phosphatidylinositols, sterol hemi succinates, dialkyl trimethylammonium-propanes, (e.g., DOTAP, DOTMA), dialkyl dimethylaminopropanes, ethyl phosphocholines, dimethylaminoethane carbamoyl sterols (e.g., DC-Chol).
[0063] As used herein, the term “aqueous solution” refers to a composition comprising water.
[0064] “Systemic delivery,” as used herein, refers to delivery of a therapeutic product that can result in a broad exposure of an active agent within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. Systemic delivery of lipid nanoparticles can be by any means known in the art including, for example, intravenous, intraarterial, subcutaneous, and intraperitoneal delivery. In some embodiments, systemic delivery of lipid nanoparticles is by intravenous delivery.
[0065] “Local delivery,” as used herein, refers to delivery of an active agent directly to a target site within an organism. For example, an agent can be locally delivered by direct injection into a disease site such as a tumor, other target site such as a site of inflammation, or a target organ such as the liver, heart, pancreas, kidney, and the like. Local delivery can also include topical applications or localized injection techniques such as intramuscular, subcutaneous, or intradermal injection. Local delivery does not preclude a systemic pharmacological effect.
[0066] “Alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms that is saturated (i.e., contains no double and / or triple bonds), having from one to twenty-four carbon atoms (C1-C24 alkyl), one to sixteen carbon atoms (C1-C16 alkyl), one to twelve carbon atoms (C1-C12 alkyl), six to twenty-four carbon atoms (C6-C24 alkyl), one to eight carbon atoms (Ci-Cs alkyl) or one to six carbon atoms (Ci-Ce alkyl) and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1 -methylethyl (iso propyl), n-butyl, n-pentyl, 1,1 -dimethylethyl (t-butyl), 3 -methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted.
[0067] “Alkenyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms that contains at least one carbon-carbon double, having from one to twenty-four carbon atoms (C2-C24 alkenyl), one to twelve carbon atoms (C2-C12 alkenyl), six totwenty-four carbon atoms (C6-C24 alkenyl), two to sixteen carbon atoms (C2-C16 alkenyl), four to twelve carbon atoms (C4-C12 alkenyl), one to eight carbon atoms (C2-C8 alkenyl) or one to six carbon atoms (C2-C6 alkenyl) and which is attached to the rest of the molecule by a single bond, e.g., ethenyl, n-propenyl, 1 -methylethenyl, n-butenyl, n-pentenyl, 1,1 -dimethylethenyl, 3-methylhexenyl, 2-methylhexenyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted.
[0068] “Alkynyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms that contains at least one carbon-carbon triple bond, having from one to twenty-four carbon atoms (C2-C24 alkynyl), one to twelve carbon atoms (C2-C12 alkynyl), one to eight carbon atoms (C2-C8 alkynyl) or one to six carbon atoms (C2-C6 alkynyl) and which is attached to the rest of the molecule by a single bond, e.g., ethynyl, n-propynyl, 1-methylethynyl, n-butynyl, n-pentynyl, 1,1-dimethylethynyl, 3 -methylhexynyl, 2-methylhexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted.
[0069] “Alkylene” or “alkylene chain” refers to a straight or branched divalent saturated hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen. In some embodiments, an alkylene chain has from one to twenty -four carbon atoms (C1-C24 alkylene), one to fifteen carbon atoms (C1-C15 alkylene), one to twelve carbon atoms (C1-C12 alkylene), one to eight carbon atoms (Ci-Cs alkylene), one to six carbon atoms (Ci-Ce alkylene), four to six carbon atoms (C4-C6 alkylene), two to four carbon atoms (C2-C4 alkylene), one to two carbon atoms (C1-C2 alkylene), e.g., methylene, ethylene, propylene, w-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted.
[0070] “Cycloalkyl” or “carbocyclic ring” refers to a stable non aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen ring carbon atoms (C3-C15), from three to ten ring carbon atoms (C3-C10) or from three to eight ring carbon atoms (Cs-Cs), and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group is optionally substituted.
[0071] “Heterocyclyl” or “heterocyclic ring” refers to a stable 3- to 18-membered non-aromatic ring radical having one to twelve ring carbon atoms (e.g., two to twelve) and from one to six ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused, spirocyclic (“spiro-heterocyclyl”) and / or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical is optionally oxidized; the nitrogen atom is optionally quaternized; and the heterocyclyl radical is partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl,
[0072] 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and
[0073] 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclyl group is optionally substituted.
[0074] The term “substituted” used herein means any of the above groups (e.g., alkyl, hydroxyalkyl, alkenyl, alkynyl, alkylene, cycloalkyl, aryl, aralkyl or heterocyclyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; oxo groups (=0); hydroxyl groups (-0H); alkoxy groups (-0Ra, where Rais C1-C12 alkyl or cycloalkyl); carboxyl groups (-0C(=0)Raor -C(=0)0Ra, where Rais H, C1-C12 alkyl, or cycloalkyl); amine groups (-NRaRb, where Raand Rbare each independently H, C1-C12 alkyl, or cycloalkyl); C1-C12 alkyl groups; and cycloalkyl groups. In some embodiments the substituent is a C1-C12 alkyl group. In other embodiments, the substituent is a cycloalkyl group. In other embodiments, the substituent is a halo group, such as fluoro. In other embodiments, the substituent is an oxo group. In other embodiments, the substituent is an -OH group. In other embodiments, the substituent is an alkoxy group. In other embodiments, the substituent is a carboxyl group. In other embodiments, the substituent is an amine group.
[0075] “Optional” or “optionally” (e.g., optionally substituted) means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl radical may or may not be substituted and that the description includes both substituted alkyl radicals and alkyl radicals having no substitution. In some embodiments, “optionally substituted” means a particular radical is substituted with one or more substituents selected from the group consisting of halo (e.g., F,Cl, Br, and I), oxo (=0), hydroxyl (-0H), alkoxy (-0Ra, where Rais C1-C12 alkyl), cycloalkoxy (-0Ra, where Rais Cs-Cs cycloalkyl), carboxyl (-OC(=O)Raor -C(=0)0Ra, where Rais H, Ci-C12 alkyl, or Cs-Cs cycloalkyl), amine (-NRaRb, where Raand Rbare each independently H, Ci-C12 alkyl, or Cs-Cs cycloalkyl), C1-C12 alkyl, and Cs-Cs cycloalkyl.
[0076] In some embodiments, “optionally substituted” means substituted with one or more halo substituents. In some embodiments, “optionally substituted” means substituted with one or more oxo substituents. In some embodiments, “optionally substituted” means substituted with one or more -OH substituents. In certain embodiments, “optionally substituted” means substituted with one or more alkoxy substituents. In some embodiments, “optionally substituted” means substituted with one or more cycloalkoxy substituents. In certain embodiments, “optionally substituted” means substituted with one or more carboxy substituents. In some embodiments, “optionally substituted” means substituted with one or more amine substituents. In certain embodiments, “optionally substituted” means substituted with one or more C1-C12 alkyl substituents. In some embodiments, “optionally substituted” means substituted with one or more C3-C8 cycloalkyl substituents.
[0077] When a functional group is described as “optionally substituted,” and in turn, substituents on the functional group are also “optionally substituted” and so on, for the purposes of this disclosure, such iterations are limited to five, preferably such iterations are limited to two. In some embodiments, such iterations are limited to one. In some embodiments, such iterations are limited to zero.
[0078] This disclosure is also meant to encompass all pharmaceutically acceptable compounds of the compound of Formula (I) being isotopically labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as2H,3H,nC,13C,14C,13N,15N,150,170,180,31P,32P,35S,18F,36C1,123I, and125I, respectively. These radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action, or binding affinity to pharmacologically important site of action. Certain isotopically labelled compounds of Formula (I), for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotopes tritium, e.g.,3H, and carbon- 14, z.e.,14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
[0079] Substitution with heavier isotopes such as deuterium, z.e.,2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
[0080] Substitution with positron emitting isotopes, such asnC,18F,15O and13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically labeled compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Preparations and Examples as set out below using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously employed.
[0081] This disclosure is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the disclosure includes compounds produced by a process comprising administering a compound of this disclosure to a mammal for a period sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabeled compound of the disclosure in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood, or other biological samples.
[0082] “Mammal” includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
[0083] “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
[0084] “Pharmaceutically acceptable salt” includes both acid and base addition salts.
[0085] “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyl sulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic
[0086] acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene- 1,5-disulfonic acid, naphthal ene-2-sulfonic acid,
[0087] 1 -hydroxy -2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, -toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
[0088] “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropyl amine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol,
[0089] 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, A-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
[0090] Often crystallizations produce a solvate of the compound of the disclosure. As used herein, the term “solvate” refers to an aggregate that comprises one or more molecules of a compound of the disclosure with one or more molecules of solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present disclosure may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compound of the disclosure may be true solvates, while in other cases, the compound of the disclosure may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
[0091] A “pharmaceutical composition” refers to a formulation of a compound of the disclosure and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents, or excipients therefore.
[0092] “Treating” or “treatment” as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
[0093] (i) preventing the disease or condition from occurring in a mammal when such mammal is predisposed to the condition but has not yet been diagnosed as having it;
[0094] (ii) inhibiting the disease or condition, z.e., arresting its development;
[0095] (iii) relieving the disease or condition, z.e., causing regression of the disease or condition; or
[0096] (iv) relieving the symptoms resulting from the disease or condition, z.e., relieving pain without addressing the underlying disease or condition. As used herein, the terms “disease” and “condition” may be used interchangeably or may be different in that the malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
[0097] The compounds of the disclosure, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (5)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
[0098] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.
[0099] A “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any said compounds.
[0100] “N: P” represents the ratio of moles of lipid compound (z.e., compound of Formula (I)) to the moles of phosphate present as part of a nucleic acid backbone. In some embodiments, an N: P ranges from 2:1 to 30:1, for example 3:1 to 22:1. In other embodiments, N: P ranges from 6:1 to 20:1 or 2:1 to 12:1. Exemplary N: P ranges include about 3:1, about 6:1, about 9:1, about 12:1, and / or about 22:1. Other exemplary N: P ratios range from 4.5 to 8.5, from 5.0 to 8.0, from 5.5 to 7.5, from 6.0 to 7.0, from 6.1 to 6.9, from 6.2 to 6.8, from 6.3 to 6.7, from 6.4 to 6.6, or about (e.g., within 20% change of) 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 or 7.0.
[0101] Compounds
[0102] In an aspect, the disclosure provides novel lipid compounds which can combine with other lipid components such as neutral lipids, charged lipids, steroids, and / or polymer conjugated lipids to form lipid nanoparticles with oligonucleotides. Without wishing to be bound by theory, it is thought that these lipid nanoparticles shield oligonucleotides from degradation in the serum and provide effective delivery of oligonucleotides to cells in vitro and in vivo.
[0103] One embodiment provides a compound having the following Formula (I):
[0104]
[0105] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:
[0106] Rlaand Rlbare each independently C2-C16 alkyl;
[0107] R2ais hydrogen or C2-C16 alkyl;
[0108] R2bis C2-C16 alkyl;
[0109] R3is Ci-Cis alkyl, -C(=O)-Ci-Ci8 alkyl, -L3a-O-C(=O)-R3a, -L3a-C(=O)-O-R3a, -L3a-O-C(=O)-O-R3a;
[0110] R3ais C2-C10 alkyl;
[0111] L3ais Ci-Ce alkylene or *-C(=O)-Ci-Ce alkylene, wherein * represents a connection to the N of Formula (I) bound to R3;
[0112] R4aand R4bare each independently optionally substituted C1-C4 alkyl, optionally substituted C3-C8 cycloalkyl, or R4aand R4b, together with the nitrogen to which they are attached, join to form an optionally substituted 3-8-membered heterocyclyl;
[0113] L1is C1-C4 alkylene;
[0114] L2is C1-C4 alkylene, *-L2a-O-C(=O)-, *-L2a-C(=O)-O-, or *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2;
[0115] L2ais C1-C4 alkylene;
[0116] L3is C1-C10 alkylene, -C(=O)-Ci-C8alkylene, -L3b-O-C(=O)-L3c-, or -L3b-C(=O)-O-L3c-, or -L3b-O-C(=O)-O-L3c-;
[0117] L3band L3care each independently Ci-Cs alkylene; and
[0118] L4is Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene,
[0119] wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
[0120] One embodiment provides a compound having the following Formula (I):
[0121]
[0122] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:
[0123] Rlaand Rlbare each independently C2-C16 alkyl;
[0124] R2ais hydrogen or C2-C16 alkyl;
[0125] R2bis C2-C16 alkyl;
[0126] R3is Ci-Cis alkyl, -C(=O)-Ci-Ci8 alkyl, -L3a-O-C(=O)-R3a, -L3a-C(=O)-O-R3a, -L3a-O-C(=O)-O-R3a;
[0127] R3ais C2-C10 alkyl;
[0128] L3ais Ci-Ce alkylene or *-C(=O)-Ci-Ce alkylene, wherein * represents a connection to the N of Formula (I) bound to R3;
[0129] R4aand R4bare each independently optionally substituted C1-C4 alkyl, optionally substituted C3-C8 cycloalkyl, or R4aand R4b, together with the nitrogen to which they are attached, join to form an optionally substituted 3-8-membered heterocyclyl;
[0130] L1is C1-C4 alkylene;
[0131] L2is C1-C4 alkylene, *-L2a-O-C(=O)-, *-L2a-C(=O)-O-, or *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2;
[0132] L2ais C1-C4 alkylene;
[0133] L3is C1-C10 alkylene, -C(=O)-Ci-C8alkylene, -L3b-O-C(=O)-L3c-, -L3b-C(=O)-O-L3c-, or -L3b-O-C(=O)-O-L3c-;
[0134] L3bis Ci-Cs alkylene or -C(=O)-Ci-Cs alkylene;
[0135] L3Cis Ci-Cs alkylene; and
[0136] L4is Ci-Cs alkylene, -C(=O)-Ci-Cs alkylene, or -C(=O)-C3-Cs cycloalkylene, wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
[0137] In some embodiments, Rlais C4-C16 alkyl. In certain embodiments, Rlais C6-C12 alkyl. In certain embodiments, Rlais C4-C12 alkyl. In some embodiments, Rlais Ce-Cio alkyl. In some embodiments, Rlais C4-C10 alkyl. In certain embodiments, Rlais Ce alkyl, Cs alkyl, or C10 alkyl. In some embodiments, Rlais C4 alkyl, Ce alkyl, Cs alkyl, or C10 alkyl.
[0138] In some embodiments, Rlbis C4-C16 alkyl. In certain embodiments, Rlbis C6-C12 alkyl. In some embodiments, Rlbis Ce-Cio alkyl. In certain embodiments, Rlbis Ce alkyl, Cs alkyl, or C10 alkyl. In some embodiments, Rlbis C2-C16 alkyl. In certain embodiments, Rlbis C2-C12 alkyl. In some embodiments, Rlbis C2-C10 alkyl. In certain embodiments, Rlbis C2 alkyl, C4 alkyl, Ce alkyl, Cs alkyl, or C10 alkyl.
[0139] In certain embodiments, R2ais C4-C16 alkyl. In some embodiments, R2ais C6-C12 alkyl. In certain embodiments, R2ais Ce-Cio alkyl. In some embodiments, R2ais Ce alkyl, Cs alkyl, or C10 alkyl. In some embodiments, R2ais C4-C12 alkyl. In certain embodiments, R2ais C4-C10 alkyl. In some embodiments, R2ais C4 alkyl, Ce alkyl, Cs alkyl, or C10 alkyl. In certain embodiments, R2ais hydrogen.
[0140] In some embodiments, R2bis C4-C16 alkyl. In certain embodiments, R2bis C6-C12 alkyl. In some embodiments, R2bis Ce-Cio alkyl. In certain embodiments, R2bis Ce alkyl, Cs alkyl, or C10 alkyl. In some embodiments, R2bis C2-C16 alkyl. In certain embodiments, R2bis C2-C12 alkyl. In certain embodiments, R2bis C2-C10 alkyl. In some embodiments, R2bis C2 alkyl, C4 alkyl, Cs alkyl, Ce alkyl, C7 alkyl, Cs alkyl, or C10 alkyl.
[0141] In certain embodiments, R3is Ci-Cis alkyl. In some embodiments, R3is Ce alkyl, Cs alkyl, C10 alkyl, or C12 alkyl. In certain embodiments, R3is Cs alkyl or C10 alkyl. In some embodiments, R3is Ce alkyl, Cs alkyl, C10 alkyl, C12 alkyl, C12 alkyl, or Cie alkyl. In certain embodiments, R3is unbranched Cs alkyl, unbranched C10 alkyl, or branched Cie alkyl. In some embodiments, R3is -C(=O)-Ci-Cis alkyl. In certain embodiments, R3is -C(=O)-Cs-Ci8 alkyl. In some embodiments, R3has one of the following structures:
[0142]
[0143] In certain embodiments, R3has one of the following structures:
[0144]
[0145] In some embodiments, R3is -L3a-O-C(=O)-R3aor -L3a-C(=O)-O-R3a. In certain embodiments, R3is -L3a-O-C(=O)-O-R3a.
[0146] In certain embodiments, L3ais Ci-Ce alkylene. In some embodiments, L3ais *-C(=O)-Ci-Ce alkylene, wherein * represents a connection to the N of Formula (I) bound to R3.
[0147] In certain embodiments, R3ais C2-C6 alkyl. In some embodiments, R3ais C7-C10 alkyl. In some embodiments, R3has one of the following structures:
[0148]
[0149] In some embodiments, R3has one of the following structures:
[0150]
[0151] In certain embodiments, R4ais methyl, ethyl, n-propyl, or isopropyl. In some embodiments, R4ais methyl. In some embodiments, R4ais methyl, ethyl, n-propyl, isopropyl, or n-butyl.
[0152] In some embodiments, R4bis methyl, ethyl, n-propyl, or isopropyl. In certain embodiments, R4bis methyl. In some embodiments, R4aand R4bare both methyl. In some embodiments, R4bis methyl, ethyl, n-propyl, isopropyl, or n-butyl.
[0153] In certain embodiments, R4aand R4btogether with the nitrogen to which they are attached, join to form a 5-6-membered heterocyclyl. In some embodiments, R4aand R4btogether with the nitrogen to which they are attached, join to form an optionally substituted pyrrolidinyl.
[0154] In some embodiments, R4aand R4btogether with the nitrogen to which they are attached, join to form octahydrocyclopenta[c]pyrrolyl, pyrrolidinyl, or piperidinyl substituted with one or more -OH substituents.
[0155] In some embodiments, R4aand R4btogether with the nitrogen to which they are attached, join to form an optionally substituted pyrrolidinyl, piperidinyl, octahydrocyclopenta[c]pyrrolyl, or 7-azabicyclo[2.2.1]heptanyl. In some embodiments, R4aand R4btogether with the nitrogen towhich they are attached, join to form pyrrolidinyl or piperidinyl substituted with one or more -OH substituents.
[0156] R i4a
[0157] In certain embodiments,
[0158]
[0159] has one of the following structures:
[0160]
[0161] R
[0162] I4a
[0163] In certain embodiments,
[0164]
[0165] has one of the following structures:
[0166]
[0167] In some embodiments, L1is C1-C4 alkylene. In some embodiments, L1is methylene. In certain embodiments, L1ethylene, propylene, or butylene.
[0168] R1a
[0169]
[0170] In some embodiments, ' has one of the following structures:
[0171]
[0172] In certain embodiments, ' has one of the following structures:
[0173]
[0174] In certain embodiments, L2is C1-C4 alkylene. In some embodiments, L2is methylene. In certain embodiments, L2ethylene, propylene, or butylene.
[0175] In some embodiments, L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C14 alkyl. Incertain embodiments, L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C8 alkyl. In some embodiments, L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C14 alkyl, and R2bis C2-C14 alkyl. In certain embodiments, L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C8 alkyl, and R2bis C2-C8 alkyl. In some embodiments, L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C14 alkyl. In certain embodiments, L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C8 alkyl. In some embodiments, L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C14 alkyl, and R2bis C2-C14 alkyl. In some embodiments, L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C8 alkyl, and R2bis C2-C8 alkyl.
[0176] In some embodiments, L2ais C2 alkylene, C3 alkylene, or C4 alkylene. In some
[0177] R2a
[0178]
[0179] embodiments, L2ais Ci alkylene or C2 alkylene. In some embodiments, 1 has one of the following structures:
[0180]
[0181] Xv
[0182] In some embodiments, 1 has one of the following structures:
[0183]
[0184] In certain embodiments, L3is C3-C9 alkylene. In some embodiments, L3is C3 alkylene, C4 alkylene, Cs alkylene, Ce alkylene, Cs alkylene, or C9 alkylene. In certain embodiments, L3is -C(=O)-C2-C6alkylene. In certain embodiments, L3is -L3b-O-C(=O)-L3c- or -L3b-C(=O)-O-L3c-. In some embodiments, L3is -L3b-O-C(=O)-O-L3c. In certain embodiments, L3is -L3b-C(=O)-O-L3c-.
[0185] In some embodiments, L3bis C2-C6 alkylene. In certain embodiments, L3cis C2-C6 alkylene. In some embodiments, L3bis C2-C6 alkylene or -C(=O)-C2-C4 alkylene.
[0186] In certain embodiments, L4is Ci-Cs alkylene. In some embodiments, L4is C2-C4 alkylene. In some embodiments, L4is -C(=O)-Ci-Ce alkylene. In certain embodiments, L4is -C(=O)-Ci alkylene, -C(=O)-C2 alkylene, -C(=O)-C3 alkylene, or -C(=O)-Cs alkylene.
[0187] In some embodiments, L4is -C(=O)-C3-Cs cycloalkylene. In certain embodiments, L4has the following structure:
[0188] 0
[0189]
[0190] . In some embodiments, Rla, Rlb, R2a, and R2bare each independently C2-C16 alkyl, R3is Ci-Cis alkyl or -C(=O)-Ci-Cis alkyl, R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl, L1and L2are each independently C1-C4 alkylene, L3is C1-C10 alkylene, and L4is Ci-Cs alkylene or -C(=O)-Ci-Cs alkylene, wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
[0191] In certain embodiments, Rla, Rlb, and R2bare each independently C2-C16 alkyl, R2ais hydrogen or C2-C16 alkyl, R3is Ci-Cis alkyl or -C(=O)-Ci-Ci8 alkyl, R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl, L1is C1-C4 alkylene, L2is C1-C4 alkylene, *-L2a-O-C(=O)-, *-L2a-C(=O)-O-, or *-L2a-O-C(=O)-O- wherein * represents a connection to the N of Formula (I) bound to L2, L2ais C1-C4 alkylene, L3is C1-C10 alkylene, and L4is Ci-Cs alkylene or-C(=O)-Ci-Cs alkylene, wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
[0192] In some embodiments, Rla, Rlb, R2a, and R2bare each independently C2-C16 alkyl, R3is Ci-Cis alkyl, -C(=O)-Ci-Ci8 alkyl, -L3a-O-C(=O)-R3a, -L3a-C(=O)-O-R3a, or -L3a-O-C(=O)-O-R3a, R3ais C2-C10 alkyl, L3aand L3bare each independently Ci-Ce alkylene, R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl, L1and L2are each independently C1-C4 alkylene, L3is C1-C10 alkylene, and L4is Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene, wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
[0193] In certain embodiments, Rla, Rlb, R2a, and R2bare each independently C2-C16 alkyl, R3is Ci-Cis alkyl or -C(=O)-Ci-Ci8 alkyl, R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl, L1and L2are each independently C1-C4 alkylene, L3is C1-C10 alkylene, -C(=O)-Ci-C8alkylene, -L3b-O-C(=O)-L3c-, -L3b-C(=O)-O-L3c-, or -L3b-C(=O)-O-L3c-, L3band L3care each independently Ci-Cs alkylene, and L4is Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene, wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
[0194] In some embodiments, L1is optionally substituted with one or more oxo substituents. In certain embodiments, L1is substituted with one oxo substituent.
[0195] In some embodiments, L2is optionally substituted with one or more oxo substituents. In certain embodiments, L2is substituted with one oxo substituent.
[0196] In some embodiments, L2ais optionally substituted with one or more oxo substituents. In certain embodiments, L2ais substituted with one oxo substituent.
[0197] In some embodiments, L3is optionally substituted with one or more oxo substituents. In certain embodiments, L3is substituted with one oxo substituent.
[0198] In some embodiments, L3ais optionally substituted with one or more oxo substituents. In certain embodiments, L3ais substituted with one oxo substituent.
[0199] In some embodiments, L3bis optionally substituted with one or more oxo substituents. In certain embodiments, L3bis substituted with one oxo substituent.
[0200] In some embodiments, L3bis optionally substituted with one or more oxo substituents. In certain embodiments, L3bis substituted with one oxo substituent.
[0201] In some embodiments, L4is optionally substituted with one or more oxo substituents. In certain embodiments, L4is substituted with one oxo substituent.
[0202] In some embodiments, one or more of Rla, Rlb, R2a, R2b, R3, R4a, R4b, L1, L2, L3, and L4are substituted with one or more halo substituents (e.g., fluoro substituents).
[0203] In various embodiments, the compound has one of the structures set forth in Table 1
[0204] below.
[0205] Table 1. Representative compounds of Formula (I)
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223] It is understood that any embodiment of the compounds of Formula (I), as set forth above, and any specific substituent and / or variable in the compound Formula (I), as set forth above, may be independently combined with other embodiments and / or substituents and / or variables of compounds of Formula (I) to form embodiments of the disclosure not specifically set forth above. In addition, in the event that a list of substituents and / or variables is listed for any particular R group or L group in a particular embodiment and / or claim, it is understood that each individual substituent and / or variable may be deleted from the particular embodiment and / or claim and that the remaining list of substituents and / or variables will be considered to be within the scope of embodiments of the disclosure.
[0224] It is understood that in the present description, combinations of substituents and / or variables of the depicted formulae are permissible only if such contributions result in stable compounds.
[0225] For the purposes of administration, the compounds of the present disclosure (typically in the form of lipid nanoparticles in combination with a therapeutic agent) may be administered as a raw chemical or may be formulated as pharmaceutical compositions. Pharmaceutical
[0226] compositions (e.g., lipid nanoparticles) of the present disclosure comprise a compound of Formula (I) and one or more pharmaceutically acceptable carrier, diluent, or excipient. The compound of Formula (I) is present in the composition in an amount which is effective to form a lipid nanoparticle and deliver the therapeutic agent, e.g., for treating a particular disease or condition of interest. Appropriate concentrations and dosages can be readily determined by one skilled in the art.
[0227] An embodiment provides a composition (e.g., lipid nanoparticles) comprising a compound of Formula (I) and a therapeutic agent. In some embodiments, the composition (e.g., lipid nanoparticles) further comprises one or more excipient selected from neutral lipids, steroids, and polymer conjugated lipids.
[0228] In some embodiments, the therapeutic agent comprises a nucleic acid. In certain embodiments, the nucleic acid is selected from antisense and messenger RNA.
[0229] In certain embodiments, the composition comprises one or more neutral lipids selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM. In some embodiments, the neutral lipid is DSPC.
[0230] In some embodiments, the molar ratio of the compound to the neutral lipid ranges from about 2:1 to about 8:1. In certain embodiments, the steroid is cholesterol. In some embodiments, the molar ratio of the compound to cholesterol ranges from about 2: 1 to 1: 1. In some embodiments, the ratio is from 5: 1 to 1: 1 or from 2:1 to 1:1.
[0231] In certain embodiments, the polymer conjugated lipid is a pegylated lipid. In various embodiments, the polymer conjugated lipid is a pegylated lipid. For example, some embodiments include a pegylated diacylglycerol (PEG-DAG) such as
[0232] l-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), a pegylated phosphatidylethanoloamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) such as 4-0-(2',3'-di(tetradecanoyloxy)propyl-l-0-(co-methoxy(polyethoxy)ethyl)butanedioate (PEG-S-DMG), a pegylated ceramide (PEG-cer), or a PEG dialkoxypropylcarbamate such as co-methoxy(polyethoxy)ethyl-N-(2,3-di(tetradecanoxy)propyl)carbamate or 2,3-di(tetradecanoxy)propyl-N-(co-methoxy(polyethoxy)ethyl)carbamate.
[0233] In some embodiments, the molar ratio of the compound to the pegylated lipid ranges from about 100:1 to about 10:1 or from about 100:1 to about 25:1. In some embodiments, the molar ratio of the compound to pegylated lipid ranges from about 100: 1 to about 20: 1 or from about 100:1 to about 10:1.
[0234] In some embodiments, the pegylated lipid is PEG-DMG. In certain embodiments, the pegylated lipid has the following Formula (II):
[0235]
[0236] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:
[0237] R5and R6are each independently a straight or branched, alkyl, alkenyl or alkynyl from 10 to 30 carbon atoms, wherein the alkyl, alkenyl or alkynyl is optionally interrupted by one or more ester bonds; and
[0238] w has a value ranging from 30 to 60.
[0239] In certain embodiments, R5and R6are each independently straight alkyl chain containing from 12 to 16 carbon atoms. In some embodiments, w is 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55. In certain embodiments, w has a value ranging from 40 to 50. In some embodiments, w ranges from 42 to 48. In some embodiments, w is 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0240] In some embodiments, the lipid nanoparticle or composition comprises a plurality of pegylated lipids of Formula (II) and the average w for the plurality ranges from 40 to 50. In some embodiments, the average w is 43, 44, 45, 46, 47, or 48.
[0241] Synthesis of pegylated lipids can be found in US Patent No. 9,738,593, the disclosure of which is hereby incorporated by reference.
[0242] In some embodiments, the lipid nanoparticle or composition comprises 45-50 mol % of a compound of Formula (I), 5-15 mol% DSPC, 35-45 mol% cholesterol, and 1.5-2.5 mol% of a pegylated lipid (e.g., a compound of Formula (II)) based on the total moles of each of the components. In some embodiments, the lipid nanoparticle or composition comprises 47.5 mol% of a compound of Formula (I), 10 mol% DSPC, 40.7 mol% cholesterol, and 1.8 mol% of a compound of Formula (II).
[0243] Administration of the compositions of the disclosure can be carried out via any of the accepted modes of administration of agents for serving similar utilities. For example, the pharmaceutical compositions of the disclosure may be formulated into preparations into a liquid solution such as solutions, suspensions, injections, etc. Atypical route of administering pharmaceutical compositions of the present disclosure includes parenteral injection. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intradermal, intrastemal injection or infusion techniques. In some embodiments, the administering is performed via an intravenous or intramuscular injection. Pharmaceutical compositions of the disclosure are formulated to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will beadministered to a subject or patient take the form of one or more dosage units, where for example, a single injection may be a single dosage unit, and a container (e.g., a vial) of LNPs of the disclosure may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition or LNPs to be administered will, in any event, contain a therapeutically effective amount of a therapeutic agent of the disclosure (e.g., antisense RNA, mRNA, etc ), or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this disclosure.
[0244] A pharmaceutical composition of the disclosure may be in the form of a liquid solution. In some embodiments, the pharmaceutical composition comprises carrier(s) that are liquid, with the compositions being, for example, an injectable liquid.
[0245] The pharmaceutical composition may be in the form of a liquid, for example, a solution, emulsion, or suspension. The liquid may be formulated as a liquid for delivery by injection, as an example. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer, and isotonic agent may be included.
[0246] The liquid pharmaceutical compositions of the disclosure, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer’s solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose; agents to act as cryoprotectants such as sucrose or trehalose. The parenteral preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.
[0247] A liquid pharmaceutical composition of the disclosure intended for parenteral should contain an amount of an LNP of the disclosure such that a suitable dosage will be obtained.
[0248] The pharmaceutical compositions of the disclosure may be prepared by methodology well known in the pharmaceutical art. For example, a pharmaceutical composition intended to be administered by injection can be prepared by combining the lipid nanoparticles of the disclosure with sterile, distilled water, or other carriers to form a solution. A surfactant may be added tofacilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the compound of the disclosure to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
[0249] The compositions of the disclosure are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including (1) the activity of the specific therapeutic agent employed; (2) the metabolic stability and length of action of the therapeutic agent; (3) the age, body weight, general health, sex, and diet of the patient; (4) the mode and time of administration; (5) the rate of excretion; (6) the drug combination; (7) the severity of the particular disorder or condition; and (8) the subject undergoing therapy.
[0250] Compositions of the disclosure may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents. Such combination therapy includes administration of a single pharmaceutical dosage formulation of a composition of the disclosure and one or more additional active agents, as well as administration of the composition of the disclosure and each active agent in its own separate pharmaceutical dosage formulation. For example, a composition of the disclosure and the other active agent can be administered to the patient together in a single liquid dosage composition such as an injection, or each agent administered in separate dosage formulations. Where separate dosage formulations are used, the compositions of the disclosure and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.
[0251] Preparation methods for the above compounds and compositions are described herein below and / or known in the art.
[0252] It will be appreciated by those skilled in the art that in the process described herein the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, t-butyldimethylsilyl, / -butyldiphenylsilyl or trimethyl silyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include / -butoxy carbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylalkyl), / ?-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T. W. and P. G. M. Wutz, Protective Groups in Organic Synthesis (1999), 3rdEd., Wiley. As one of skill inthe art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
[0253] Furthermore, all compounds of the disclosure which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art. Salts of the compounds of the disclosure can be converted to their free base or acid form by standard techniques (e.g., pH adjustment).
[0254] The following examples show methods of preparing compounds of this disclosure, / .<., compounds of Formula (I):
[0255]
[0256] or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein Rla, Rlb, R2a, R2b, R3, R4a, R4b, L1, L2, L3, and L4are as defined herein.
[0257] It is understood that one skilled in the art may be able to make these compounds by similar methods or by combining other methods known to one skilled in the art. It is also understood that one skilled in the art would be able to make, in a similar manner as described below, other compounds of Formula (I) not specifically illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, e.g., Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this disclosure. Purification (e.g., silica gel chromatography, filtration, extraction, efc.) after each described reaction step is performed as needed.
[0258] EXAMPLE 1
[0259] IMMUNOGLOBULIN G (IGG) MRNA IN VIVO EVALUATION USING
[0260] LIPID NANOPARTICLE COMPOSITIONS
[0261] A lipid of Formula (I), DSPC, cholesterol and PEG-lipid of Formula (II) are solubilized in ethanol at a molar ratio of 47.5:10:40.7:1.8. Lipid nanoparticles (LNP) are prepared at a total lipid to mRNA weight ratio of approximately 10:1 to 40: 1. Briefly, the mRNA is diluted to 0.2 mg / mL in 10 to 50 mM citrate buffer, pH 4 to 6 or 10 to 25 mM acetate buffer, pH 4 to 6.
[0262] Syringe pumps are used to mix the ethanolic lipid solution with the mRNA aqueous solution at a ratio of about 1:5 to 1:3 (vol / vol) with total flow rates above 15 mL / min. The ethanol is then removed, and the external buffer is replaced with PBS by dialysis. Finally, the lipid nanoparticles are filtered through a 0.2 pm pore sterile filter.
[0263] Studies are performed in 6-8-week-old CD-l / ICR mice (Charles River or Inotiv) according to guidelines established by an institutional animal care committee (ACC) and the Canadian Council on Animal Care (CCAC). Varying doses of mRNA-lipid nanoparticle are systemically administered by tail vein injection and animals euthanized at a specific time point (e.g., 24 hours) post-administration. The whole blood is collected, and the serum subsequentially separated by centrifuging the tubes of the whole blood at 2000 * g for 10 minutes at 4 °C and stored at -80 °C until use for analysis.
[0264] For immunoglobulin G (IgG) ELISA (Life Diagnostics Human IgG ELISA kit), the serum samples are diluted at 100 to 20,000 folds with 1 x diluent solution. 100 pL of diluted serum is dispensed into anti-human IgG coated 96-well plate in duplicate alongside human IgG standards and incubated in a plate shaker at 150 rpm at 25 °C for 45 minutes. The wells are washed 5 times with lx wash solution using a plate washer (400 pL / well). 100 pL of HRP conjugate is added into each well and incubated in a plate shaker at the same condition above. The wells are washed 5 times again with 1 x wash solution using a plate washer (400 pL / well).
[0265] 100 pL of TMB reagent is added into each well and incubated in a plate shaker at the same condition above. The reaction is stopped by adding 100 pL of Stop solution to each well. The absorbance is read at 450 nm (A450) with a microplate reader. The amount of human IgG in mouse serum is determined by plotting A450 values for the assay standard against human IgG concentration.
[0266] EXAMPLE 2
[0267] DETERMINATION OF PKA OF FORMULATED LIPIDS
[0268] As described elsewhere, the pKa of formulated lipids is correlated with the effectiveness of LNPs for delivery of nucleic acids (see Jayaraman et al, Angewandte Chemie, InternationalEdition (2012), 51(34), 8529-8533; Semple et al, Nature Biotechnology 28, 172-176 (2010)). In some embodiments, the preferred range of pKa is ~5 to ~7. The pKaof each lipid may be determined in lipid nanoparticles using an assay based on fluorescence of 2-(p-toluidino)-6-napthalene sulfonic acid (TNS). Lipid nanoparticles comprising compound of Formula (I) / DSPC / cholesterol / PEG-lipid (47.5:10:40.7:1.8 mol%) in PBS at a concentration of 0.4 mM total lipid are prepared using the in-line process as described in Example 1. TNS is prepared as a 100 pM stock solution in distilled water. Vesicles are diluted to 24 pM lipid in 2 mL of buffered solutions containing 10 mM HEPES, 10 mM MES, 10 mM ammonium acetate, and 130 mM NaCl, where the pH ranged from 2.5 to 11. An aliquot of the TNS solution is added to give a final concentration of 1 pM and following vortex mixing fluorescence intensity is measured at room temperature in a SLM Aminco Series 2 Luminescence Spectrophotometer using excitation and emission wavelengths of 321 nm and 445 nm. A sigmoidal best fit analysis is applied to the fluorescence data and the pKais measured as the pH giving rise to half-maximal fluorescence intensity.
[0269] EXAMPLE 3
[0270] DETERMINATION OF EFFICACY OF LIPID NANOPARTICLE FORMULATIONS
[0271] CONTAINING VARIOUS CATIONIC LIPIDS USING IGG MRNA EXPRESSION RODENT MODEL
[0272] Representative compounds of the disclosure were formulated using the following molar ratio: 47.5% cationic lipid / 10% DSPC / 40.7% Cholesterol / 1.8% PEG lipid. The activity was determined by measuring the amount of human IgG in mouse serum as described in Example 1. The activity was compared at a dose of 1.0 or 0.3 mg mRNA / kg and expressed as pg IgG / mL serum measured 24 hours after administration, as described in Example 1. Compound numbers in Table 2 correspond to the compound numbers of Table 1.
[0273] Table 2. Novel Cationic Lipids and Associated Activity
[0274]
[0275]
[0276] SYNTHETIC EXAMPLE 1
[0277] SYNTHESIS OF N-(9-(BIS(2-HEXYLDECYL)AMINO)NONYL)-N-(3-(DIMETHYLAMINO)PROPYL)-2- HEXYLDECANAMIDE (COMPOUND 1-1 )
[0278]
[0279] Synthesis of 9-((3-(dimethylamino)propyl)amino)-A^V-bis(2-hexyldecyl)nonanamide
[0280]
[0281] 9-((3-(Dimethylamino)propyl)amino)-A, A-bis(2-hexyldecyl)nonanamide was prepared from 9-bromo-7V,7V-bis(2-hexyldecyl)nonanamide (365 pmol, 250 mg), 3 -(dimethylamino)- 1-propanamine (730 pmol, 75 mg, 92 pL), and DIPEA (730 pmol, 94 mg, 127 pL) in ACN (1.46 mL), by following procedure outlined for 6-(decylamino)-A, A-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 9-((3-(dimethylamino)propyl)amino)-A, A-bis(2-hexyldecyl)nonanamide (124 mg, 48%). ESIMS: m / z calculated for C46H95N3O = 705.75, found [M+H]+= 707.12.
[0282] Synthesis of A^1-(3-(dimethylamino)propyl)-A9^V9-bis(2-hexyldecyl)nonane-l,9-diamine
[0283]
[0284] 7V1-(3-(Dimethylamino)propyl)-7V9,7V9-bis(2-hexyldecyl)nonane-l,9-diamine was prepared from 9-((3-(dimethylamino)propyl)amino)-7V,7V-bis(2-hexyldecyl)nonanamide (175 pmol, 124 mg), and LAH (300 pmol, 11 mg) in THF (3.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-^-(Dimethylamino)propyl)-A9, A9-bis(2-hexyldecyl)nonane-l,9-diamine was 84 mg (69%). ESIMS: m / z calculated for C46H97N3 = 691.77, found [M+H]+= 693.04.
[0285] Synthesis of 7V-(9-(bis(2-hexyldecyl)amino)nonyl)-7V-(3-(dimethylamino)propyl)-2-hexyldecanamide
[0286]
[0287] 7V-(9-(bis(2-hexyldecyl)amino)nonyl)-7V-(3-(dimethylamino)propyl)-2-hexyldecanamide was prepared from 2-hexyldecanoic acid (210 pmol, 54 mg, 62 pL), oxalyl chloride (1.75 mmol, 222 mg, 148 pL), triethylamine (5.05 mmol, 511 mg, 0.7 mL), 7V1-(3-(dimethylamino)propyl)-7V9,7V9-bis(2-hexyldecyl)nonane-l,9-diamine (175 pmol, 121 mg) and DMAP (75 pmol, 10 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide.
[0288] Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(9-(bis(2-hexyldecyl)amino)nonyl)-7V-(3-(dimethylamino)propyl)-2-hexyldecanamide was 35 mg (21%).
[0289] 'HNMR (400 MHz, CDCh) 63.77 - 3.62 (m, 1H), 3.42 - 3.16 (m, 4H), 2.60 - 2.43 (m, 1H), 2.35 -2.13 (m, 10H), 2.13 - 1.97 (dd, 4H), 1.78 - 1.03 (m, 103H), 0.94 - 0.78 (m, 18H). ESI-MS: m / z calculated for C62H127N3O = 930.00, found [M+H]+= 931.29.
[0290] SYNTHETIC EXAMPLE 2
[0291] SYNTHESIS OF N-(4-(BIS(2-OCTYLDODECYL)AMINO)BUTYL)-N-DECYL-4- (DIMETHYLAMINO)BUTANAMIDE (COMPOUND 1-2)
[0292]
[0293] Synthesis of bis(2-octyldodecyl)amine
[0294]
[0295] Bis(2-octyldodecyl)amine was prepared from 9-(bromomethyl)nonadecane (5.28 mmol, 1.90 g), 2-octyldodecan-l -amine (6.21 mmol, 1.85 g) and DIPEA (18.60 mmol, 2.41 g, 3.35 mL) by following the procedure for bis(2-hexyldecyl)amine. The yield of bis(2-octyldodecyl)amine was 1.43 g (47%). ESI-MS: m / z calculated for C4oH83N = 577.65, found [M+H]+= 578.85.
[0296] Synthesis of 4-(bis(2-octyldodecyl)amino)-4-oxobutanoic acid
[0297]
[0298] 4-(Bis(2-octyldodecyl)amino)-4-oxobutanoic acid was prepared from dihydrofuran-2,5-dione (2.15 mmol, 215 mg) and bis(2-octyldodecyl)amine (2.23 mmol, 1.29 g) by following the procedure outlined for 4-(bis(2-hexyldecyl)amino)-4-oxobutanoic acid. The yield of 4-(bis(2-octyldodecyl)amino)-4-oxobutanoic acid was 1.45 g (99%).
[0299] Synthesis of N1-decyl-N4,N4-bis(2-octyldodecyl)succinamide
[0300]
[0301] 7V1-Decyl-7V4,7V4-bis(2-octyldodecyl)succinamide was prepared from 4-(bis(2-octyldodecyl)amino)-4-oxobutanoic acid (1.86 mmol, 1.86 g), DIPEA (3.72 mmol, 480 mg, 649 pL), decyl amine (2.23 mmol, 918 mg) and HATU (2.42 mmol, 918 mg) by following the procedure outlined for 7V1-decyl-7V4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 50% EtOAc in Hexanes) gave 7V1-Decyl-A4, A4-bis(2-octyldodecyl)succinamide (1.1 g, 72%). ESI-MS: m / z calculated for C54H108N2O2 = 816.84, found [M+H]+= 817.97.
[0302] Synthesis of N1-decyl-N4, N4-bis(2-octyldodecyl)butane-l,4-diamine
[0303]
[0304] N1-decyl-N4, N4-bis(2-octyldodecyl)butane-l,4-diamine was prepared from A ecyl- A4,7V4-bis(2-octyldodecyl)succinamide (1.22 mmol, 1.00 g), and LAH (2.00 mmol, 76 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-decyl-N4, N4-bis(2-octyldodecyl)butane-l,4-diamine was 810 mg (70%). ESI-MS: m / z calculated for C54H112N2 = 788.88, found [M+H]+= 790.01.
[0305] Synthesis of 7V-(4-(bis(2-octyldodecyl)amino)butyl)-A-decyl-4-(dimethylamino)butanamide
[0306]
[0307] A-(4-(Bis(2-octyldodecyl)amino)butyl)-A-decyl-4-(dimethylamino)butanamide was prepared from N1-decyl-N4, N4-bis(2-octyldodecyl)butane-l,4-diamine (189 pmol, 149 mg), DIPEA (378 pmol, 49 mg, 66 pL), 3 -carboxy- l-(dimethylammonio)propane chloride (208 pmol, 35 mg) and HATU (246 pmol, 93 mg) by following the procedure outlined for / ' / '-decyl- / ' / 4, / ' / 4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of A-(4-(bis(2-octyldodecyl)amino)butyl)-N-decyl-4-(dimethylamino)butanamide was 90 mg (53%).
[0308] 'H NMR (400 MHz, CDCh) 63.33 - 3.16 (m, 4H), 2.36 - 2.23 (m, 6H), 2.22 (s, 6H), 2.10 - 2.03 (m, 4H), 1.87 - 1.75 (m, 2H), 1.72 - 1.46 (m, 8H), 1.40 - 1.09 (m, 85H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C60H123N3O = 901.97, found [M+H]+= 903.26.
[0309] SYNTHETIC EXAMPLE 3
[0310] SYNTHESIS OF N-(4-(BIS(2-HEXYLDECYL)AMINO)BUTYL)-N-DECYL-4- (DIMETHYLAMINO)BUTANAMIDE (COMPOUND 1-3)
[0311]
[0312] Synthesis of 4-(bis(2-hexyldecyl)amino)-4-oxobutanoic acid
[0313]
[0314] To a solution of dihydrofuran-2,5-dione (2.15 mmol, 215 mg) in THF (8.0 mL) was added bis(2-hexyldecyl)amine (2.26 mmol, 1.05 g) solution in 2.0 mL THF and the mixture was stirred at room temperature for 1 h. After that, 1 M HC1 (5.0 ml) was added to the mixture and stirring continued for about 5 minutes. The mixture was then extracted with DCM and the combined organic phase was dried over anhydrous Na2SC>4 and evaporated under reduced pressure to obtain crude 4-(bis(2-hexyldecyl)amino)-4-oxobutanoic acid (1.20 g, 99%).
[0315] Synthesis of A4-decyl-A4^V4-bis(2-hexyldecyl)succinamide
[0316]
[0317] To 4-(bis(2-hexyldecyl)amino)-4-oxobutanoic acid (1.77 mmol, 1.05 g), DIPEA (3.72 mmol, 480 mg, 649 pL) and decyl amine (2.23 mmol, 351 mg, 456 pL) in DCM (10.0 mL), HATU (2.42 mmol, 918 mg) was added in one portion. The reaction mixture was stirred for 30 minutes and then washed with saturated aqueous NaHCCh. The organic layer was separated, dried over anhydrous Na2SC>4 and concentrated. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide (1.0g, 76%). ESI-MS: m / z calculated for C46H92N2O2 = 704.72, found [M+H]+= 705.85.
[0318] Synthesis of N1-decyl-N4, N4-bis(2-hexyldecyl)butane-l,4-diamine
[0319]
[0320] N1-decyl-N4, N4-bis(2-hexyldecyl)butane-l,4-diamine was prepared from ^-decyl-A4,?4-bis(2-hexyldecyl)succinamide (1.42 mmol, 1.00 g), and LAH (2.00 mmol, 76 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-decyl-N4, N4-bis(2-hexyldecyl)butane-l,4-diamine was 820 mg (84%). ESI-MS: m / z calculated for C46H96N2 = 676.76, found [M+H]+= 677.95.
[0321] Synthesis of 7V-(4-(bis(2-hexyldecyl)amino)butyl)-A-decyl-4-(dimethylamino)butanamide
[0322]
[0323] A-(4-(bis(2-hexyldecyl)amino)butyl)-A-decyl-4-(dimethylamino)butanamide was prepared from N1-decyl-N4, N4-bis(2-hexyldecyl)butane-l,4-diamine (204 pmol, 138 mg), DIPEA (224 pmol, 53 mg, 71.2 pL), 3 -carboxy- l-(dimethylammonio)propane chloride (224 pmol, 38 mg) and HATU (265 pmol, 101 mg) by following the procedure outlined for ^-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of A-(4-(bis(2-hexyldecyl)amino)butyl)-A-decyl-4-(dimethylamino)butanamide was 65 mg (40%).
[0324] 'H NMR (400 MHz, CDCh) 63.33 - 3.16 (m, 4H), 2.35 - 2.23 (m, 6H), 2.22 (s, 6H), 2.10 - 2.02 (m, 4H), 1.88 - 1.74 (m, 2H), 1.69 - 1.43 (m, 6H), 1.43 - 1.07 (m, 69H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C52H107N3O = 789.84, found [M+H]+= 791.06.
[0325] SYNTHETIC EXAMPLE 4
[0326] SYNTHESIS OF N-(6-(BIS(2-HEXYLDECYL)AMINO)HEXYL)-N-(2- (DIMETHYLAMINO)ETHYL)NONANAMIDE (COMPOUND 1-4)
[0327]
[0328] Synthesis of 6-bronio-\.\-bis(2-hexyldecyl)hexananiide
[0329]
[0330] 6-Bromo-A, A-bis(2-hexyldecyl)hexanamide was prepared from 6-bromohexanoic acid (3.49 mmol, 0.68 g), oxalyl chloride (16.44 mmol, 2.09 g, 1.41 mL), triethylamine (18.04 mmol, 1.82 g, 2.50 mL), bis(2-hexyldecyl)amine (3.22 mmol, 1.50 g) and DMAP (151 pmol, 20 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography, with Hexanes / EtOAc gradient. The yield of 6-bromo-A, A-bis(2-hexyldecyl)hexanamide was 1.90 g (92%). ESI-MS: m / z calculated for CssFLeBrNO = 641.51, found [M+H]+= 642.73.
[0331] Synthesis of 6-((2-(dimethylamin())ethyl)amino)- \. A-bis(2-hexyldecyl)hex:inamide
[0332]
[0333] 6-((2-(Dimethylamino)ethyl)amino)-7V, A-bis(2-hexyldecyl)hexanamide was prepared from 6-bromo-7V,7V-bis(2-hexyldecyl)hexanamide (373 pmol, 240 mg), 2-(dimethylamino)-l-ethanamine (747 pmol, 66 mg, 81 pL), and potassium carbonate (448 pmol, 62 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-7V,7V-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 15% MeOH in DCM) to give 6-((2-(dimethylamino)ethyl)amino)-A,7V-bis(2-hexyldecyl)hexanamide (78 mg, 32%). ESI-MS: m / z calculated for C42H87N3O = 649.68, found [M+H]+= 650.80.
[0334] Synthesis of \1-(2-(diniethylaniino)ethyl)-\6,\6-bis(2-hexyldecyl)hexane-1.6-dianiine
[0335]
[0336] 7V1-(2-(dimethylamino)ethyl)-7V6,7V6-bis(2-hexyldecyl)hexane-l,6-diamine was prepared from 6-((2-(dimethylamino)ethyl)amino)-7V,7V-bis(2-hexyldecyl)hexanamide (100 pmol, 65 mg), and LAH (1.00 mmol, 38 mg) in THF (5.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude 7V1-(2-(dimethylamino)ethyl)-A6, A6-bis(2-hexyldecyl)hexane-l,6-diamine was 55 mg (86%). ESI-MS: m / z calculated for C42H89N3 = 635.71, found [M+H]+= 636.99.
[0337] Synthesis of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(2-(dimethylamino)ethyl)nonanamide
[0338]
[0339] 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(2-(dimethylamino)ethyl)nonanamide was prepared from nonanoyl chloride (71 pmol, 13 mg, 13 pL), triethylamine (177 pmol, 18 mg, 24 pL), 7V1-(2-(dimethylamino)ethyl)-7V6,7V6-bis(2-hexyldecyl)hexane-l,6-diamine (71 pmol, 45 mg) and DMAP (6 pmol, 0.7 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(2-(dimethylamino)ethyl)nonanamide was 35 mg (76%).
[0340] 'HNMR (400 MHz, CDCh) 63.55 - 3.43 (dd, 1H), 3.39 - 3.22 (m, 3H), 2.71 - 1.98 (m, 14H), 1.73 - 1.46 (m, 5H), 1.46 - 1.02 (m, 74H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C51H105N3O = 775.83, found [M+H]+= 777.05.
[0341] SYNTHETIC EXAMPLE 5
[0342] SYNTHESIS OF N-(3-(BIS(2-HEXYLDECYL)AMINO)PROPYL)-N-DECYL-4- (DIMETHYLAMINO)BUTANAMIDE (COMPOUND 1-5)
[0343]
[0344] Synthesis of bis(2-hexyldecyl)amine
[0345]
[0346] A mixture of 7-(bromomethyl)pentadecane (5.28 mmol, 1.61 g), 2 -hexyldecan- 1 -amine (6.21 mmol, 1.50 g), DIPEA (18.60 mmol, 2.41 g, 3.35 mL) and potassium iodide (5.28 mmol, 877 mg) in ACN (12.40 mL), was reacted in a microwave reactor at 140 °C for 30 min and then concentrated under vacuum. The residue was partitioned between water and EtOAc, dried over anhydrous sodium sulfate, filtered, and concentrated again. The crude product was purified via flash chromatography (0% to 15% MeOH in DCM) to give bis(2-hexyldecyl)amine (732 mg, 30%). ESI-MS: m / z calculated for C32H67N = 465.53, found [M+H]+= 466.68.
[0347] Synthesis of 3-br()ni()- \.\-bis(2-hexyldecyl)propananiide
[0348]
[0349] 3 -Bromopropionic acid (5.58 mmol, 845 mg) was dissolved in dry DCM (5.00 mL) to which catalytic amount of DMF was added. The reaction mixture was cooled down to 0 °C and excess oxalyl chloride (42.90 mmol, 5.45 g, 3.68 mL) was added in a single portion. After stirring at room temperature for 1 h, solvent and unreacted oxalyl chloride were removed on the rotavapor. A small amount of dry DCM was added and again removed under vacuum. Crude acyl chloride was dissolved in 2 ml of dry DCM and immediately added (a single portion) to a solution of bis(2-hexyldecyl)amine (4.29 mmol, 2.00 g), EtiN (12.90 mmol, 1.30 g, 1.80 mL) and DMAP (42.9 pmol, 5.2 mg) in dry DCM (50.00 mL), cooled down to 0 °C. After stirring overnight, reaction was quenched by adding small amount of MeOH and stirred for several minutes. After that, the solvent was removed under vacuum. The residue was partitioned between water and EtOAc and purified via flash chromatography (Hex: EtOAc = 3: 1) to give 3-bromo-A, A-bis(2-hexyldecyl)propanamide (1.70 g, 76%). ESI-MS: m / z calculated for C35H70BrNO = 599.46, found [M+H]+= 600.47.
[0350] Synthesis of 3-(decyl:iniin())- \.\-bis(2-hexyldecyl)propananiide
[0351]
[0352] 3-(Decylamino)-A, A-bis(2-hexyldecyl)propanamide was prepared from 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide (1.70 mmol, 884 mg), and decylamine (5.10 mmol, 802 mg), which were dissolved in THF (10 mL) and stirred in a sealed vial at 70 °C over night. After removal of solvent under vacuum, the residue was purified via flash chromatography (0% to 100% EtOAc in DCM) to give 3-(decylamino)-A, A-bis(2-hexyldecyl)propanamide (1.05 g, 91%). ESI-MS: m / z calculated for C45H92N2O = 676.72, found [M+H]+= 677.71.
[0353] Synthesis of AA ecyl- \A )is(2-hexyldec l)piopane-l.3-di:iniine
[0354]
[0355] 3-(Decylamino)-7V,7V-bis(2-hexyldecyl)propanamide (1.11 mmol, 750 mg) was dissolved in dry THF (20.00 mL), LAH (11.10 mmol, 420 mg) was added in one portion and the reaction mixture was refluxed overnight. After this time, reaction mixture was quenched with wet diethyl ether; anhydrous Na2SC>4 was added and mixture filtered. Solvent was removed under vacuum to yield a crude 7V1-decyl-7V3, A3-bis(2-hexyldecyl)propane-l,3-diamine (470 mg, 64 %) that was not purified further. ESI-MS: m / z calculated for C45H94N2 = 662.74, found [M+H]+= 663.71.
[0356] Synthesis of 7V-(3-(bis(2-hexyldecyl)amino)propyl)-7V-decyl-4-(dimethylamino)butanamide
[0357]
[0358] 7V-(3-(Bis(2-hexyldecyl)amino)propyl)-7V-decyl-4-(dimethylamino)butanamide was prepared from 3 -carboxy- l-(dimethylammonio)propane chloride (0.30 mmol, 50 mg), oxalyl chloride (0.90 mmol, 114 mg, 77.2 pL), triethylamine (302.0 pmol, 36 mg), TV ecyl-TV3,^3-bis(2-hexyldecyl)propane-l,3-diamine (151.0 pmol, 100 mg) and DMAP (15.1 pmol, 2 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done with Hexanes / EtOAc (spiked with 1% EtsN). The yield was 30 mg (26%).
[0359] 1H NMR (400 MHz, CDCh) 83.34 - 3.15 (m, 4H), 2.50 - 2.18 (s, 9H), 2.11 - 2.02 (d,
[0360] 4H), 2.02 - 1.90 (s, 2H), 1.72 - 1.45 (m, 8H), 1.41 - 1.06 (d, 69H), 0.92 - 0.83 (m, 15H). ESIMS: m / z calculated for C51H105N3O = 775.88, found [M+H]+= 777.01.
[0361] SYNTHETIC EXAMPLE 6
[0362] SYNTHESIS OF N-(9-(BIS(2-HEXYLDECYL)AMINO)NONYL)-N-(2- (DIMETHYLAMINO)ETHYL)NONANAMIDE (COMPOUND 1-6)
[0363]
[0364] Synthesis of 9-bromo-7V, A-bis(2-hexyldecyl)nonanamide
[0365]
[0366] 9-Bromo-7V,7V-bis(2-hexyldecyl)nonanamide was prepared from 9-bromononanoic acid (2.87 mmol, 0.68 g), oxalyl chloride (1.10 mmol, 1.39 g, 0.94 mL), triethylamine (11.54 mmol, 1.18 g, 1.60 mL), bis(2-hexyldecyl)amine (2.13 mmol, 1.00 g) and DMAP (300 pmol, 40 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography, with Hexanes / EtOAc gradient. The yield of 9-bromo-7V,7V-bis(2-hexyldecyl)nonanamide was 2.76 g (89%). ESI-MS: m / z calculated for C41H82BrNO = 683.56, found [M+H]+= 684.84.
[0367] Synthesis of 9-((2-(diinetliyl:iinino)etliyl):iinino)-\,\-bis(2-hexyldecyl)non:in:iinide
[0368]
[0369] 9-((2-(dimethylamino)ethyl)amino)-A,7V-bis(2-hexyldecyl)nonanamide was prepared from 9-bromo-7V,7V-bis(2-hexyldecyl)nonanamide (219 pmol, 150 mg), 2-(dimethylamino)-l-ethanamine (438 pmol, 39 mg, 48 pL), and potassium carbonate (263 pmol, 36 mg) in ACN (5.87 mL), by following procedure outlined for 6-(decylamino)-7V,7V-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 9-((2-(dimethylamino)ethyl)amino)-A,7V-bis(2-hexyldecyl)nonanamide (60 mg, 40%). ESI-MS: m / z calculated for C45H93N3O = 691.73, found [M+H]+= 693.02.
[0370] Synthesis of \’-(2-( Dimet hylamino)ethyl)-\'\\ -bis(2-hexyldecyl)nonane- 1.9-diamine
[0371]
[0372] 7V1-(2-(Dimethylamino)ethyl)-7V9,7V9-bis(2-hexyldecyl)nonane-l,9-diamine was prepared from 9-((2-(dimethylamino)ethyl)amino)-7V,7V-bis(2-hexyldecyl)nonanamide (72 pmol, 50 mg), and LAH (300 pmol, 11 mg) in THF (3.0 mL) by following the procedure outlined for ^-decyl- 7V3,7V3-bis(2-hexyldecyl)propane-l,3-diamine. The yield of the crude7V1-(2- (Dimethylamino)ethyl)-A9, A9-bis(2-hexyldecyl)nonane-l,9-diamine was 45 mg (92%). ESI-MS: m / z calculated for C45H95N3 = 677.75, found [M+H]+= 679.11.
[0373] Synthesis of 7V-(9-(bis(2-hexyldecyl)amino)nonyl)-7V-(2-(dimethylamino)ethyl)nonanamide
[0374]
[0375] 7V-(9-(Bis(2-hexyldecyl)amino)nonyl)-7V-(2-(dimethylamino)ethyl)nonanamide was prepared from nonanoyl chloride (89 pmol, 16 mg, 16 pL), tri ethylamine (221 pmol, 22 mg, 31 pL), 7V1-(2-(Dimethylamino)ethyl)-7V9,7V9-bis(2-hexyldecyl)nonane-l,9-diamine (74 pmol, 50 mg) and DMAP (15 pmol, 2 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(9-(bis(2-hexyldecyl)amino)nonyl)-7V-(2-(dimethylamino)ethyl)nonanamide was 55 mg (91%).
[0376] 'HNMR (400 MHz, CDCh) 83.50 - 3.14 (m, 4H), 2.65 - 2.37 (m, 2H), 2.37 - 2.18 (m, 10H), 2.14 - 1.98 (m, 4H), 1.76 - 1.06 (m, 77H), 1.01 - 0.65 (m, 15H). ESI-MS: m / z calculated for C54H111N3O = 817.87, found [M+H]+= 819.24.
[0377] SYNTHETIC EXAMPLE 7
[0378] SYNTHESIS OF N-(4-(BIS(2-OCTYLDODECYL)AMINO)BUTYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-7)
[0379]
[0380] Synthesis of \1-(3-(diniethylaniin())pr()pyl)-\4,\4-bis(2-octyldodecyl)succinaniide
[0381]
[0382] A1-(3-(Dimethylamino)propyl)-A4, A4-bis(2-octyldodecyl)succinamide was prepared from 4-(bis(2-octyldodecyl)amino)-4-oxobutanoic acid (321 pmol, 218 mg), 3 -(dimethylamino)- 1-propanamine (399 pmol, 41 mg, 50 pL), DIPEA (498 pmol, 64 mg, 87 pL) and HATU (399 pmol, 152 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (MeOH / DCM gradient) gave N1-(3-(dimethylamino)propyl)-A4, A4-bis(2-octyldodecyl)succinamide (220 mg, 87%). ESI-MS: m / z calculated for C49H99N3O2 = 761.77, found [M+H]+= 762.98.
[0383] Synthesis of A^1-(3-(dimethylamino)propyl)-Az4^V4-bis(2-octyldodecyl)butane-l,4-diamine
[0384]
[0385] 7V1-(3-(Dimethylamino)propyl)-7V4,7V4-bis(2-octyldodecyl)butane-l,4-diamine was prepared from7V1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-octyldodecyl)succinamide (171 pmol, 130 mg), and LAH (1.71 mmol, 65 mg) in THF (10 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude7V1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-octyldodecyl)butane-l,4-diamine was 90 mg (72%). ESIMS: m / z calculated for C49H103N3 = 733.82, found [M+H]+= 735.03.
[0386] Synthesis of 7V-(4-(bis(2-octyldodecyl)amino)butyl)-7V-(3- (dimethylamino)propyl)nonanamide
[0387]
[0388] 7V-(4-(bis(2-octyldodecyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (217 pmol, 38 mg, 39 pL), tri ethylamine (725 pmol, 73 mg, 101 pL), 7V1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-octyldodecyl)butane-l,4-diamine (116 pmol, 85 mg) and DMAP (14 pmol, 2 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(4-(bis(2-octyldodecyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was 55 mg (35%).
[0389] 'HNMR (400 MHz, CDCh) 83.38 - 3.18 (m, 4H), 2.34 - 2.20 (m, 10H), 2.11 - 2.02 (m, 4H), 1.89 - 1.44 (m, 7H), 1.44 - 1.10 (m, 81H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C58H119N3O = 873.94, found [M+H]+= 875.15.
[0390] SYNTHETIC EXAMPLE 8
[0391] SYNTHESIS OF N-(5-(BIS(2-OCTYLDODECYL)AMINO)PENTYL)-N-(2- (DIMETHYLAMINO)ETHYL)NONANAMIDE (COMPOUND 1-8)
[0392]
[0393] Synthesis of 5-br()nio-\.\-bis(2-octyldodecyl)pentananiide
[0394]
[0395] 5-Bromo-7V,7V-bis(2-octyldodecyl)pentanamide was prepared from bis(2-octyldodecyl)amine (6.92 mmol, 4.00 g), 5-bromovaleric acid (8.3 mmol, 1.50 g), DIPEA (20.8 mmol, 2.69 g, 3.63 mL) and HATU (8.99 mmol, 3.53 g) by following the procedure outlined for N1-decyl-N4,N4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (Hexanes / EtOAc gradient) gave 5-bromo-7V,7V-bis(2-octyldodecyl)pentanamide (4.01 g, 78%). ESI-MS: m / z calculated for C45H90BrNO = 739.62, found [M+H]+= 740.83.
[0396] Synthesis of 5-((2-(dimethylamino)ethyl)amino)-A^V-bis(2-octyldodecyl)pentanamide
[0397]
[0398] 5-((2-(Dimethylamino)ethyl)amino)-A, A-bis(2-octyldodecyl)pentanamide was prepared from 5-bromo-7V,7V-bis(2-octyldodecyl)pentanamide (405 pmol, 300 mg), 2-(dimethylamino)ethanamine (810 pmol, 71 mg, 81 pL), and potassium carbonate (486 pmol, 67 mg) in ACN (4.93 mL), by following procedure outlined for 6-(decylamino)-A,7V-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 25% MeOH in DCM) to give 5-((2-(dimethylamino)ethyl)amino)-A,7V-bis(2-octyldodecyl)pentanamide (150 mg, 50%). ESI-MS: m / z calculated for C49H101N3O = 747.79, found [M+H]+= 749.00.
[0399] Synthesis of \1-(2-(diniethylaniino)ethyl)-\5,\'-bis(2-octyldodecyl)pentane-1.5-dianiine
[0400]
[0401] 7V1-(2-(Dimethylamino)ethyl)-7V5,7V5-bis(2-octyldodecyl)pentane-l,5-diamine was prepared from 5-((2-(dimethylamino)ethyl)amino)-7V,7V-bis(2-octyldodecyl)pentanamide (112 pmol, 84 mg), and LAH (1.12 mmol, 43 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude 7V1-(2-(dimethylamino)ethyl)-7V5,7V5-bis(2-octyldodecyl)pentane-l,5-diamine was 50 mg (61%). ESIMS: m / z calculated for C49H103N3 = 733.82, found [M+H]+= 735.03.
[0402] Synthesis of 7V-(5-(bis(2-octyldodecyl)amino)pentyl)-7V-(2- (dimethylamino)ethyl)nonanamide
[0403]
[0404] 7V-(5-(Bis(2-octyldodecyl)amino)pentyl)-7V-(2-(dimethylamino)ethyl)nonanamide was prepared from nonanoyl chloride (92 pmol, 16 mg, 17 pL), tri ethylamine (184 pmol, 17 mg, 26 pL), 7V1-(2-(dimethylamino)ethyl)-7V5,7V5-bis(2-octyldodecyl)pentane-l,5-diamine (61 pmol, 45 mg) and DMAP (0.6 pmol, 0.7 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(5-(bis(2-octyldodecyl)amino)pentyl)-7V-(2-(dimethylamino)ethyl)nonanamide was 52 mg (97%).
[0405] 'HNMR (400 MHz, CDCh) 83.56 - 3.16 (m, 4H), 2.62 - 2.16 (m, 12H), 2.11 -2.05 (m, 3H), 1.79 - 1.03 (m, 87H), 0.95 - 0.83 (m, 15H). ESI-MS: m / z calculated for C58H119N3O = 873.94, found [M+H]+= 875.15.
[0406] SYNTHETIC EXAMPLE 9
[0407] SYNTHESIS OF N-(4-(BIS(2-HEXYLDECYL)AMINO)BUTYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-9)
[0408]
[0409] Synthesis of \1-(3-(diniethylaniino)propyl)-\4,\4-bis(2-hexyldecyl)succaniniide
[0410]
[0411] 7V1-(3-(Dimethylamino)propyl)-7V4,7V4-bis(2-hexyldecyl)succinamide was prepared from 4-(bis(2-hexyldecyl)amino)-4-oxobutanoic acid (322 pmol, 188 mg), 3 -(dimethylamino)- 1-propanamine (399 pmol, 41 mg, 50 pL), DIPEA (498 pmol, 64 mg, 87 pL) and HATU (399 pmol, 152 mg) by following the procedure outlined for N1-decyl-N4,N4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (MeOH / DCM gradient) gave N1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-hexyldecyl)succinamide (140 mg, 65%). ESI-MS: m / z calculated for C41H83N3O2 = 649.65, found [M+H]+= 650.86.
[0412] Synthesis of A^1-(3-(dimethylamino)propyl)-Az4^V4-bis(2-hexyldecyl)butane-l,4-diamine
[0413]
[0414] 7V1-(3-(Dimethylamino)propyl)-7V4,7V4-bis(2-hexyldecyl)butane-l,4-diamine was prepared from 7V1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-hexyldecyl)succinamide (123 pmol, 80 mg), and LAH (2.46 mmol, 93 mg) in THF (3.70 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-^-(dimethylamino)propyl)-7V4,7V4-bis(2-hexyldecyl)butane-l,4-diamine was 75 mg (98%). ESI-MS: m / z calculated for C41H87N3 = 621.69, found [M+H]+= 622.83.
[0415] Synthesis of 7V-(4-(bis(2-hexyldecyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide
[0416]
[0417] 7V-(4-(bis(2-hexyldecyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (172 pmol, 30 mg, 31 pL), triethylamine (369 pmol, 37 mg, 51 pL), 7V1-(3-(bis(2-hexyldecyl)amino)propyl)-7V3,7V3-dimethylpropane-l,3-diamine (123 pmol, 77 mg) and DMAP (14 pmol, 2 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(4-(bis(2-hexyldecyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was 67 mg (71%).
[0418] 'H NMR (400 MHz, CDCh) 83.31 - 3.16 (m, 6H), 2.61 - 2.54 (m, 3H), 2.44 - 2.23 (m, 7H), 1.93 - 1.80 (m, 2H), 1.79 - 1.44 (m, 20H), 1.38 - 1.19 (m, 54H), 0.95 - 0.83 (m, 15H). ESI-MS: m / z calculated for C50H103N3O = 761.81, found [M+H]+= 762.99.
[0419] SYNTHETIC EXAMPLE 10
[0420] SYNTHESIS OF N-(5-(BIS(2-OCTYLDODECYL)AMINO)-5-OXOPENTYL)-N-(2- (DIMETHYLAMINO)ETHYL)NONANAMIDE (COMPOUND I- 10)
[0421]
[0422] Synthesis of 7V-(5-(bis(2-octyldodecyl)amino)-5-oxopentyl)-7V-(2- (dimethylamino)ethyl)nonanamide
[0423]
[0424] 7V-(5-(Bis(2-octyldodecyl)amino)-5-oxopentyl)-7V-(2-(dimethylamino)ethyl)nonanamide was prepared from nonanoyl chloride (80 pmol, 14 mg, 15 pL), triethylamine (334 pmol, 34 mg, 47 pL), 5-((2-(dimethylamino)ethyl)amino)-7V,7V-bis(2-octyldodecyl)pentanamide (67 pmol, 50 mg) and DMAP (0.7 pmol, 0.8 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatographywith Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of N-(5-(bis(2-octyldodecyl)amino)-5-oxopentyl)-N-(2-(dimethylamino)ethyl)nonanamide was 48 mg (81%).
[0425] ¹H NMR (400 MHz, CDCl₃) δ 3.55 - 3.47 (m, 1H), 3.43 - 3.20 (m, 5H), 3.14 - 3.05 (m, 2H), 2.46 -2.37 (m, 3H), 2.36 -2.24 (m, 7H), 1.73 - 1.53 (m, 8H), 1.49 - 1.10 (m, 77H), 0.92 -0.82 (m, 15H).. ESI-MS: m / z calculated for C58H117N3O2 = 887.91, found [M+H]+= 889.12.
[0426] SYNTHETIC EXAMPLE 11
[0427] SYNTHESIS OF N-(3-(BIS(2-HEXYLDECYL)AMINO)PROPYL)-N-(2- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-11)
[0428]
[0429] Synthesis of 3-((3-(dimethylamino)propyl)amino)-A^V-bis(2-hexyldecyl)propanamide
[0430]
[0431] 3-((3-(Dimethylamino)propyl)amino)-N,N-bis(2-hexyldecyl)propanamide was prepared from 3-bromo-N,N-bis(2-hexyldecyl)propanamide (334 pmol, 200 mg) and 2-(dimethylamino)propanamine (1.15 mmol, 118 mg) by following procedure outlined for 3-((2-(dimethylamino)ethyl)amino)-7V,7V-bis(2-hexyldecyl)propanamide. Purification via flash chromatography (0% to 50% MeOH in DCM, spiked with 1% EtsN) gave 180 mg (86%) of 3-((3-(dimethylamino)propyl)amino)-7V,7V-bis(2-hexyldecyl)propanamide. ESI-MS: m / z calculated for C40H83N3O = 621.65, found [M+H]+= 622.85.
[0432] Synthesis of N1-(3-(bis(2-hexyldecyl)amino)propyl)-N3,N3-dimethylpropane-1,3-diamine
[0433]
[0434] N1-(3-(bis(2-hexyldecyl)amino)propyl)-N3,N3-dimethylpropane-1,3-diamine was prepared from 3-((3-(dimethylamino)propyl)amino)-N,N-bis(2-hexyldecyl)propanamide (305 μmol, 190 mg), and LAH (3.05 mmol, 116 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(3-(bis(2-hexyldecyl)amino)propyl)-N3,N3-dimethylpropane-1,3-diamine was 169 mg (91%). ESIMS: m / z calculated for C40H85N3 = 607.67, found [M+H]+= 608.88.
[0435] Synthesis of 7V-(3-(bis(2-hexyldecyl)amino)propyl)-7V-(2- (dimethylamino)propyl)nonanamide
[0436]
[0437] N-(3-(Bis(2-hexyldecyl)amino)propyl)-N-(2-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (458 μmol, 81 mg, 83 μL), triethylamine (1.44 mmol, 145 mg, 0.20 mL), N1-(3-(bis(2-hexyldecyl)amino)propyl)-N3,N3-dimethylpropane-1,3-diamine (305 μmol, 186 mg) and DMAP (30 μmol, 4 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of N-(3-(bis(2-hexyldecyl)amino)propyl)-N-(2-(dimethylamino)propyl)nonanamide was 150 mg (66%).
[0438] 1H NMR (400 MHz, CDCl₃) δ 3.38 - 3.21 (m, 4H), 2.52 -2.13 (m, 12H), 2.13 -2.05 (m, 4H), 1.96 - 1.53 (m, 6H), 1.53 - 1.03 (m, 60H), 1.03 - 0.60 (m, 15H). ESI-MS: m / z calculated for C49H101N3O = 747.79, found [M+H]+= 749.01.
[0439] SYNTHETIC EXAMPLE 12
[0440] SYNTHESIS OF N-(3-(BIS(2-HEXYLDECYL)AMINO)PROPYL)-N-(2- (DIMETHYLAMINO)ETHYL)NONANAMIDE (COMPOUND 1-12)
[0441]
[0442] Synthesis of 3-((2-(dimethylamino)ethyl)amino)-N,N-bis(2-hexyldecyl)propanamide
[0443]
[0444] 3-((2-(Dimethylamino)ethyl)amino)-N,N-bis(2-hexyldecyl)propanamide was prepared from 3-bromo-N,N-bis(2-hexyldecyl)propanamide (334 μmol, 200 mg) and 2-(dimethylamino)ethanamine (1.54 mmol, 136 mg) which were dissolved in THF (10.00 mL) and heated for 2 days at 70 °C in a sealed vial. After removal of solvent under reduced pressure, purification via flash chromatography (0% to 50% MeOH in DCM) gave 190 mg (93%) of 3-((2-(Dimethylamino)ethyl)amino)-N,N-bis(2-hexyldecyl)propanamide. ESI-MS: m / z calculated for C39H81N3O = 607.64, found [M+H]+= 608.94.
[0445] Synthesis of N1-(2-(dimethylamino)ethyl)-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine
[0446]
[0447] N1-(2-(dimethylamino)ethyl)-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine was prepared from 3-((2-(dimethylamino)ethyl)amino)-N,N-bis(2-hexyldecyl)propanamide (329 μmol, 200 mg), and LAH (5.30 mmol, 201 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(2-(dimethylamino)ethyl)-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine was 181 mg (93%). ESIMS: m / z calculated for C39H83N3 = 593.66, found [M+H]+= 594.87.
[0448] Synthesis of 7V-(3-(bis(2-hexyldecyl)amino)propyl)-7V-(2-(dimethylamino)ethyl)nonanamide
[0449]
[0450]
[0451] N-(3-(Bis(2-hexyldecyl)amino)propyl)-N-(2-(dimethylamino)ethyl)nonanamide was prepared from nonanoyl chloride (458 μmol, 81 mg, 83 μL), triethylamine (1.44 mmol, 145 mg, 0.20 mL), N1-(2-(dimethylamino)ethyl)-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine (305 μmol, 181 mg) and DMAP (30 μmol, 4 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of N-(3-(bis(2-hexyldecyl)amino)propyl)-N-(2-(dimethylamino)ethyl)nonanamide was 150 mg (67%).
[0452] ¹H NMR (400 MHz, CDCl₃) δ 3.58 - 3.40 (m, 1H), 3.40 - 3.22 (m, 3H), 2.63 - 2.46 (m, 1H), 2.46 -2.37 (m, 1H), 2.37 - 2.19 (m, 10H), 2.14 - 1.97 (m, 4H), 1.70 - 1.57 (m, 4H), 1.44 -1.11 (m, 62H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C48H99N3O = 733.78, found [M+H]+= 735.01.
[0453] SYNTHETIC EXAMPLE 13
[0454] SYNTHESIS OF N-(8-(BIS(2-OCTYLDODECYL)AMINO)OCTYL)-N-(2- (DIMETHYLAMINO)ETHYL)NONANAMIDE (COMPOUND 1-13)
[0455]
[0456] Synthesis of 8-((2-(dimethylamino)ethyl)amino)-N,N-bis(2-octyldodecyl)octanamide
[0457]
[0458] NH
[0459]
[0460] 8-((2-(Dimethylamino)ethyl)amino)-N,N-bis(2-octyldodecyl)octanamide was prepared from 8-bromo-N,N-bis(2-octyldodecyl)octanamide (0.32 mmol, 248 mg), 2-(dimethylamino)-1-ethanamine (4.58 mmol, 403 mg, 0.50 mL), and potassium carbonate (0.35 mmol, 48 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-N,N-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 8-((2-(dimethylamino)ethyl)amino)-A, A-bis(2-octyldodecyl)octanamide (130 mg, 51%). ESI-MS: m / z calculated for C52H107N3O = 789.84, found [M+H]+= 791.27.
[0461] Synthesis of N1-(2-(dimethylamino)ethyl)-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine
[0462]
[0463] N1-(2-(Dimethylamino)ethyl)-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine was prepared from 8-((2-(dimethylamino)ethyl)amino)-N,N-bis(2-octyldodecyl)octanamide (163 μmol, 130 mg), and LAH (1.00 mmol, 38 mg) in THF (5.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(2-(dimethylamino)ethyl)-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine was 110 mg (88%). ESIMS: m / z calculated for C52H109N3 = 775.86, found [M+H]+= 777.07.
[0464] Synthesis of 7V-(8-(bis(2-octyldodecyl)amino)octyl)-7V-(2-(dimethylamino)ethyl)nonanamide
[0465]
[0466] N-(8-(bis(2-octyldodecyl)amino)octyl)-N-(2-(dimethylamino)ethyl)nonanamide was prepared from nonanoyl chloride (0.17 mmol, 31 mg, 31 μL), triethylamine (3.61 mmol, 365 mg, 0.5 mL), N1-(2-(dimethylamino)ethyl)-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine (0.14 mmol, 110 mg) and DMAP (75 μmol, 10 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of N-(8-(bis(2-octyldodecyl)amino)octyl)-N-(2-(dimethylamino)ethyl)nonanamide was 47 mg (37%).
[0467] ¹H NMR (400 MHz, CDCl₃) δ 3.52 - 3.16 (m, 4H), 2.47 - 2.19 (m, 11H), 2.15 - 1.99 (m, 3H), 1.70 - 1.06 (m, 93H), 0.91 - 0.78 (m, 15H). ESI-MS: m / z calculated for C61H125N3O = 915.98, found [M+H]+= 917.32.
[0468] SYNTHETIC EXAMPLE 14
[0469] SYNTHESIS OF N-(6-(BIS(2-HEXYLDECYL)AMINO)HEXYL)-N-DECYL-3- (DIMETHYLAMINO)PROPANAMIDE (COMPOUND 1-14)
[0470]
[0471] Synthesis of 6-bronio-\.\-bis(2-hexyldecyl)hexananiide
[0472]
[0473] 6-Bromo-N,N-bis(2-hexyldecyl)hexanamide was prepared from 6-bromohexanoic acid (5.00 mmol, 1.00 g), oxalyl chloride (23.31 mmol, 2.95 g, 2.00 mL), triethylamine (8.91 mmol, 1.06 g), bis(2-hexyldecyl)amine (4.29 mmol, 2.00 g) and DMAP (151.2 μmol, 20 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield was 2.18 g (79%). ESI-MS: m / z calculated for C38H76BrNO = 641.51, found [M+H]+= 642.64.
[0474] Synthesis of 6-(decylamino)-\.\-bis(2-hexyldecyl)hex:in:imide
[0475]
[0476] A mixture of 6-bromo-N,N-bis(2-hexyldecyl)hexanamide (2.3 mmol, 1.50 g), decylamine (7.50 mmol, 1.18 g), and potassium carbonate (2.30 mmol, 322 mg) in ACN (20.00 mL), was reacted in a sealed vial at 70 °C overnight and then concentrated under vacuum. The residue was partitioned between water and EtOAc, dried over anhydrous sodium sulfate, filtered, and concentrated again. The crude product was purified via flash chromatography (0 to 100% EtOAc in hexanes, spiked with 1% Et₃N) to give 6-(decylamino)-N,N-bis(2-hexyldecyl)hexanamide (1.21 g, 73%). ESI-MS: m / z calculated for C48H98N2O = 718.77, found [M+H]+= 719.90.
[0477] Synthesis of N1-decyl-N6, N6-bis(2-hexyldecyl)hexane-l,6-diamine
[0478]
[0479]
[0480] N1-decyl-N6, N6-bis(2-hexyldecyl)hexane-l,6-diamine was prepared from 6-(decylamino)-7V,7V-bis(2-hexyldecyl)hexanamide (1.68 mmol, 1.20 g), and LAH (2.00 mmol, 76 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-decyl-N6, N6-bis(2-hexyldecyl)hexane-l,6-diamine was 876 mg (74%). ESI-MS: m / z calculated for C48H100N2 = 704.79, found [M+H]+= 705.92.
[0481] Synthesis of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-3-bromo-7V-decylpropanamide
[0482]
[0483] 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-3-bromo-7V-decylpropanamide was prepared from 3 -bromopropionic acid (527 pmol, 81 mg), oxalyl chloride (2.33 mmol, 295 mg, 200 pL), triethylamine (7.18 mmol, 730 mg), bis(2-hexyldecyl)amine (440 pmol, 310 mg) and DMAP(15.1 pmol, 2 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield was 277 mg (75%). ESI-MS: m / z calculated for CsiHio3BrN20 = 838.73, found [M+H]+= 839.85.
[0484] Synthesis of / V-(6-(bis(2-hexyldecyl)amino)hexyl)- / V-decyl-3-(dimethylamino)propanamide
[0485]
[0486] A-(6-(bis(2-hexyldecyl)amino)hexyl)-3-bromo-A-decylpropanamide (298 pmol, 250 mg) was dissolved in 10 mL of 2M THF solution of dimethyl amine and stirred at room temperature over 2 days. After that, reaction mixture was concentrated and purified via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient to give A-(6-(bis(2-hexyldecyl)amino)hexyl)-A-decyl-3-(dimethylamino)propanamide (198 mg, 83%).
[0487] 1H NMR (400 MHz, CDCl3) δ3.32 – 3.16 (m, 4H), 2.80 - 2.62 (m, 2H), 2.57 - 2.45 (m, 2H), 2.38 -2.16 (m, 8H), 2.10 -2.02 (m, 4H), 1.68 - 1.45 (m, 4H), 1.42 - 1.06 (m, 70H), 0.92 -0.81 (m, 15H). ESI-MS: m / z calculated for C53H109N3O = 803.86, found [M+H]+= 804.99.
[0488] SYNTHETIC EXAMPLE 15
[0489] SYNTHESIS OF N-(6-(BIS(2-HEXYLDECYL)AMINO)HEXYL)-N-DECYL-6- (DIMETHYLAMINO)HEXANAMIDE (COMPOUND 1-15)
[0490]
[0491] Synthesis of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-6-bromo-7V-decylhexanamide
[0492]
[0493] A-(6-(bis(2-hexyldecyl)amino)hexyl)-6-bromo-A-decylhexanamide was prepared from 6-bromohexanoic acid (0.34 mmol, 65 mg), oxalyl chloride (1.79 mmol, 222 mg, 150 pL), triethylamine (5.05 mmol, 511 mg), N1-decyl-N6, N6-bis(2-hexyldecyl)hexane-l,6-diamine (284 pmol, 200 mg) and DMAP (15.1 pmol, 2 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography, with Hexanes / EtOAc (spiked with 1% EtsN). The yield was 250 mg (99%). ESI-MS: m / z calculated for C54H111N3O = 880.77, found [M+H]+= 883.1.
[0494] Synthesis of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-decyl-6-(dimethylamino)hexanamide
[0495]
[0496] 7V-(6-(Bis(2-hexyldecyl)amino)hexyl)-7V-decyl-6-(dimethylamino)hexanamide was prepared from7V-(6-(bis(2-hexyldecyl)amino)hexyl)-6-bromo-7V-decylhexanamide (281 pmol, 250 mg) and dimethyl amine (2M in THF, 10.00 mL) by following the procedure outlined for N-(6-(bis(2-hexyldecyl)amino)hexyl)-3-bromo-N-decylpropanamide. Purification via flash chromatography (0% to 50% EtOAc in Hexanes spiked with 1% EtsN) gave 195 mg (82%) of N-(6-(Bis(2-hexyldecyl)amino)hexyl)-7V-decyl-6-(dimethylamino)hexanamide.
[0497] 1HNMR (400 MHz, CDCh) 63.33 - 3.11 (m, 4H), 2.46 -2.17 (m, 13H), 2.13 -2.00 (m, 5H), 1.76 - 1.06 (m, 89H), 0.99 - 0.78 (m, 15H). ESI-MS: m / z calculated for C56H115N3O = 845.90, found [M+H]+= 847.20.
[0498] SYNTHETIC EXAMPLE 16
[0499] SYNTHESIS OF N-(8-(BIS(2-HEXYLDECYL)AMINO)OCTYL)-N-DECYL-6- (DIMETHYLAMINO)HEXANAMIDE (COMPOUND 1-16)
[0500]
[0501] Synthesis of 7V-(8-(bis(2-hexyldecyl)amino)octyl)-6-bromo-7V-decylhexanamide
[0502]
[0503] 7V-(8-(bis(2-hexyldecyl)amino)octyl)-6-bromo-7V-decylhexanamide was prepared from 6-bromohexanoic acid (0.52 mmol, 102 mg), oxalyl chloride (1.98 mmol, 252 mg, 170 pL), triethylamine (3.6 mmol, 365 mg, 0.50 mL), 7V1-decyl-7V8,7V8-bis(2-octyldodecyl)octane-l,6-diamine (0.46 mmol, 340 mg) and DMAP (151 pmol, 20 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of7V-(8-(bis(2-hexyldecyl)amino)octyl)-6-bromo-7V-decylhexanamide was 350 mg (83%). ESI-MS: m / z calculated for C56H113CIN2O = 908.80, found [M+H]+= 910.01.
[0504] Synthesis of 7V-(8-(bis(2-hexyldecyl)amino)octyl)-7V-decyl-6-(dimethylamino)hexanamide
[0505]
[0506] 7V-(8-(Bis(2-hexyldecyl)amino)octyl)-7V-decyl-6-(dimethylamino)hexanamide was prepared from7V-(8-(bis(2-hexyldecyl)amino)octyl)-6-bromo-7V-decylhexanamide (381 pmol, 350 mg) and dimethyl amine (2M in THF, 10.00 mL) by following the procedure outlined for N-(6-(bis(2-hexyldecyl)amino)hexyl)-3-bromo-N-decylpropanamide. Purification via flash chromatography (0% to 50% EtOAc in Hexanes spiked with 1% EtsN) gave 197 mg (59%) of N-(8-(bis(2-hexyldecyl)amino)octyl)-7V-decyl-6-(dimethylamino)hexanamide.
[0507] 1HNMR (400 MHz, CDCh) 63.31 - 3.13 (m, 4H), 2.33 - 2.21 (m, 12H), 2.09 - 2.04 (m, 4H), 1.75 - 1.59 (m, 3H), 1.58 - 1.43 (m, 8H), 1.41 - 1.10 (m, 84H), 0.91 - 0.83 (m, 15H). ESIMS: m / z calculated for C58H119N3O = 873.94, found [M+H]+= 875.23.
[0508] SYNTHETIC EXAMPLE 17
[0509] SYNTHESIS OF N-(8-(BIS(2-HEXYLDECYL)AMINO)OCTYL)-N-(3- (DIMETHYLAMINO)PROPYL)STEARAMIDE (COMPOUND 1-17)
[0510]
[0511] Synthesis of 7V-(8-(bis(2-hexyldecyl)amino)octyl)-7V-(3-(dimethylamino)propyl)stearamide
[0512]
[0513] 7V-(8-(Bis(2-hexyldecyl)amino)octyl)-7V-(3-(dimethylamino)propyl)stearamide was prepared from stearic acid (0.32 mmol, 91 mg), oxalyl chloride (1.75 mmol, 222 mg, 150 pL), triethylamine (5.05 mmol, 511 mg, 0.7 mL), N1-(3-(dimethylamino)propyl)-N8,N8-bis(2-hexyldecyl)octane-1,8-diamine (0.26 mmol, 180 mg) and DMAP (151 pmol, 20 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of A-(8-(bis(2-hexyldecyl)amino)octyl)-A-(3-(dimethylamino)propyl)stearamide was 200 mg (82%).
[0514] 'HNMR (400 MHz, CDCh) 63.51 - 3.13 (m, 4H), 2.52 -2.17 (m, 12H), 2.17 - 1.92 (m, 6H), 1.79 - 1.05 (m, 98H), 0.96 - 0.67 (m, 15H). ESI-MS: m / z calculated for C63H129N3O = 944.01, found [M+H]+= 945.34.
[0515] SYNTHETIC EXAMPLE 18
[0516] SYNTHESIS OF N-(6-(BIS(2-HEXYLDECYL)AMINO)HEXYL)-N-(3- (DIMETHYLAMINO)PROPYL)TRIDECANAMIDE (COMPOUND 1-18)
[0517]
[0518] Synthesis of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(3- (dimethylamino)propyl)tridecanamide
[0519]
[0520] 7V-(6-(Bis(2-hexyldecyl)amino)hexyl)-7V-(3-(dimethylamino)propyl)tridecanamide was prepared from tridecanoic acid (0.22 mmol, 47 mg), oxalyl chloride (1.17 mmol, 148 mg, 100 pL), triethylamine (5.05 mmol, 511 mg, 0.70 mL), 6-bromo-7V,7V-bis(2-hexyldecyl)hexanamide (0.18 mmol, 119 mg) and DMAP (30 pmol, 4 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flashchromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(3-(dimethylamino)propyl)tridecanamide was 119 mg (78%).
[0521] 'HNMR (400 MHz, CDCh) 63.37 - 3.17 (m, 4H), 2.36 - 2.19 (m, 11H), 2.10 - 2.03
[0522] (dd, 3H), 1.80 - 1.03 (m, 84H), 1.03 - 0.73 (m, 15H). ESI-MS: m / z calculated for C56H115N3O = 845.90, found [M+H]+= 847.31.
[0523] SYNTHETIC EXAMPLE 19
[0524] SYNTHESIS OF N-(6-(BIS(2-HEXYLDECYL)AMINO)HEXYL)-N-DECYL-4- (DIMETHYLAMINO)BUTANAMIDE (COMPOUND 1-19)
[0525]
[0526] Synthesis of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-decyl-4-(dimethylamino)butanamide
[0527]
[0528] 7V-(6-(Bis(2-hexyldecyl)amino)hexyl)-7V-decyl-4-(dimethylamino)butanamide was prepared from 3 -carboxy- l-(dimethylammonio)propane chloride (0.33 mmol, 55 mg), oxalylchloride (1.79 mmol, 222 mg, 84.0 pL), triethylamine (5.05 mmol, 511 mg), N1-decyl-N6,N6-bis(2-hexyldecyl)hexane-1,6-diamine (284.3 μmol, 200 mg) and DMAP (15.1 mol, 2 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield was 100 mg (43%).
[0529] 'HNMR (400 MHz, CDCh) 83.40 - 3.16 (m, 4H), 2.39 - 2.20 (m, 12H), 2.10 - 2.03 (m, 4H), 1.91 - 1.74 (m, 4H), 1.72 - 1.07 (m, 90H), 0.93 - 0.81 (m, 15H). ESI-MS: m / z calculated for C54H111N3O = 817.87, found [M+H]+= 819.10.
[0530] SYNTHETIC EXAMPLE 20
[0531] SYNTHESIS OF N-(8-(BIS(2-OCTYLDODECYL)AMINO)OCTYL)-N-DECYL-4- (DIMETHYLAMINO)BUTANAMIDE (COMPOUND 1-20)
[0532]
[0533] Synthesis of 8-br()ni()- \.\-bis(2-hexyldecyl)octananiide
[0534]
[0535] 8-Bromo-A, A-bis(2-hexyldecyl)octanamide was prepared from 8-bromooctanoic acid (5.11 mmol, 1.14 g), oxalyl chloride (23.32 mmol, 2.96 g, 2.00 mL), triethylamine (23.08 mmol,2.34 g, 5.20 mL), bis(2-hexyldecyl)amine (4.29 mmol, 2.00 g) and DMAP (151. nmol, 20 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide.
[0536] Purification of the crude product was done via flash chromatography, with Hexanes / EtOAc gradient. The yield of 8-Bromo-A, A-bis(2-hexyldecyl)octanamide was 2.53 g (88%). ESI-MS: m / z calculated for C4oHsoBrNO = 670.55, found [M+H]+= 671.90.
[0537] Synthesis of 8-(decylamino)-N,N-bis(2-hexyldecyl)octanamide
[0538]
[0539] 8-(Decylamino)-A, A-bis(2-octyldodecyl)octanamide was prepared from 8-bromo-A, A-bis(2-hexyldecyl)octanamide (1.19 mmol, 800 mg), decyl amine (2.38 mmol, 374 mg), and potassium carbonate (1.20 mmol, 148 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-A, A-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 15% MeOH in DCM) to give 8-(decylamino)-A, A-bis(2-hexyldecyl)octanamide (649 mg, 73%). ESI-MS: m / z calculated for C50H102N2O = 747.81, found [M+H]+= 749.02.
[0540] Synthesis of N1-decyl-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine
[0541]
[0542]
[0543] N1-Decyl-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine was prepared from 8-(decylamino)-7V,7V-bis(2-hexyldecyl)octanamide (0.67 mmol, 500 mg), and LAH (6.70 mmol, 253 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-decyl-N8, N8-bis(2-octyldodecyl)octane-1,8-diamine was 370 mg (77%). ESI-MS: m / z calculated for C50H104N2 = 732.82, found [M+H]+= 734.00.
[0544] Synthesis of 7V-(8-(bis(2-octyldodecyl)amino)octyl)-7V-decyl-4-(dimethylamino)butanamide
[0545]
[0546] 7V-(8-(Bis(2-octyldodecyl)amino)octyl)-7V-decyl-4-(dimethylamino)butanamide was prepared from 3 -carboxy- l-(dimethylammonio)propane chloride (0.33 mmol, 55 mg), oxalylchloride (0.98 mmol, 124 mg, 84.0 pL), triethylamine (5.77 mmol, 584 mg, 0.80 mL), N1-decyl-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine (0.27 mmol, 200 mg) and DMAP (151 μmol, 20 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide.
[0547] Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of A-(8-(bis(2-octyldodecyl)amino)octyl)-A-decyl-4-(dimethylamino)butanamide was 73 mg (32%).
[0548] 1H NMR (400 MHz, CDCl3) δ3.32 – 3.16 (m, 4H), 2.40 - 2.20 (m, 12H), 2.10 - 2.03 (m, 4H), 1.91 - 1.76 (m, 2H), 1.65 - 1.45 (m, 7H), 1.43 - 1.12 (m, 81H), 0.95 - 0.83 (m, 15H). ESIMS: m / z calculated for C56H115N3O = 845.90, found [M+H]+= 847.12.
[0549] SYNTHETIC EXAMPLE 21
[0550] SYNTHESIS OF N-(6-(BIS(2-HEXYLDECYL)AMINO)HEXYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-21)
[0551]
[0552] Synthesis of 6-((3-(dimethylamino)propyl)amino)-N,N-bis(2-hexyldecyl)hexanamide
[0553]
[0554] 6-((3-(Dimethylamino)propyl)amino)-N, N-bis(2-hexyldecyl)hexanamide was prepared from 6-bromo-7V,7V-bis(2-hexyldecyl)hexanamide (1.01 mmol, 650 mg), 3 -(dimethylamino)- 1-propanamine (3.97 mmol, 406 mg, 0.5 mL), and potassium carbonate (904 pmol, 125 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-A, A-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 6-((3-(dimethylamino)propyl)amino)-A, A-bis(2-hexyldecyl)hexanamide (423 mg, 63%). ESI-MS: m / z calculated for C43H89N3O = 663.70, found [M+H]+= 664.99.
[0555] Synthesis of N1-(3-(dimethylamino)propyl)-N6,N6-bis(2-hexyldecyl)hexane-1,6-diamine
[0556]
[0557] N1-(3-(dimethylamino)propyl)-N6, N6-bis(2-hexyldecyl)hexane-1,6-diamine was prepared from 6-((3-(dimethylamino)propyl)amino)-A, A-bis(2-hexyldecyl)hexanamide (636 pmol, 423 mg), and LAH (5.00 mmol, 190 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3, N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(3-(dimethylamino)propyl)-N6, N6-bis(2-hexyldecyl)hexane-1,6-diamine was 364 mg (88%). ESI-MS: m / z calculated for C43H91N3 = 659.72, found [M+H]+= 660.97.
[0558] Synthesis of N-(6-(bis(2-hexyldecyl)amino)hexyl)-N-(3-(dimethylamino)propyl)nonanamide
[0559]
[0560] 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (0.22 mmol, 36 mg, 36 pL), triethylamine (5.05 mmol, 511 mg, 0.70 mL), N1-(3-(dimethylamino)propyl)-N6,N6-bis(2-hexyldecyl)hexane-1,6-diamine (0.18 mmol, 119 mg) and DMAP (60 pmol, 7 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(6-(bis(2-hexyldecyl)amino)hexyl)-7V-(3-(dimethylamino)propyl)nonanamide was 105 mg (74%).
[0561] 1H NMR (400 MHz, CDCl3) δ3.37 – 3.16 (m, 4H), 2.34 - 2.18 (m, 12H), 2.09 - 2.02 (m, 4H), 1.91 - 1.04 (m, 86H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C52H107N3O = 789.84, found [M+H]+= 791.17.
[0562] SYNTHETIC EXAMPLE 22
[0563] SYNTHESIS OF N-(8-(BIS(2-HEXYLDECYL)AMINO)OCTYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-22)
[0564]
[0565] Synthesis of 8-bronio-\.\-bis(2-hexyldecyl)octananiide
[0566]
[0567] 8-Bromo-A, A-bis(2-hexyldecyl)octanamide was prepared from 8-bromooctanoic acid (5.11 mmol, 1.14 g), oxalyl chloride (23.32 mmol, 2.96 g, 2.00 mL), triethylamine (23.09 mmol, 2.37 g, 3.20 mL), bis(2-hexyldecyl)amine (4.26 mmol, 2.00 g) and DMAP (300 pmol, 40 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography, with Hexanes / EtOAc gradient. The yield of 8-bromo-A, A-bis(2-hexyldecyl)octanamide was 2.53 g (88%). ESI-MS: m / z calculated for C4oHsoBrNO = 669.54, found [M+H]+= 670.74.
[0568] Synthesis of 8-((3-(dimethylamino)propyl)amino)-N,N-bis(2-hexyldecyl)octanamide
[0569]
[0570] 8-((3-(Dimethylamino)propyl)amino)-7V, A-bis(2-hexyldecyl)octanamide was prepared from 8-bromo-7V,7V-bis(2-hexyldecyl)octanamide (1.19 mmol, 800 mg), 3 -(dimethylamino)- 1-propanamine (3.97 mmol, 406 mg, 0.50 mL), and potassium carbonate (1.20 mmol, 148 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-7V,7V-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 8-((3-(dimethylamino)propyl)amino)-A,7V-bis(2-hexyldecyl)octanamide
[0571] (362 mg, 44%). ESI-MS: m / z calculated for C45H93N3O = 691.73, found [M+H]+= 693.01.
[0572] Synthesis of N1-(3-(dimethylamino)propyl)-N8,N8-bis(2-hexyldecyl)octane-1,8-diamine
[0573]
[0574] N1-(3-(Dimethylamino)propyl)-N8,N8-bis(2-hexyldecyl)octane-1,8-diamine was prepared from 8-((3-(dimethylamino)propyl)amino)-7V,7V-bis(2-hexyldecyl)octanamide (523 pmol, 362 mg), and LAH (1.00 mmol, 38 mg) in THF (5.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(3-(dimethylamino)propyl)-N8, N8-bis(2-hexyldecyl)octane-1,8-diamine was 302 mg (85%). ESI-MS: m / z calculated for C45H95N3 = 677.75, found [M+H]+= 679.12.
[0575] Synthesis of 7V-(8-(bis(2-hexyldecyl)amino)octyl)-7V-(3-(dimethylamino)propyl)nonanamide
[0576]
[0577] 7V-(8-(Bis(2-hexyldecyl)amino)octyl)-7V-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (0.23 mmol, 41 mg, 42 pL), triethylamine (5.05 mmol, 511 mg, 0.7 mL), N1-(3-(dimethylamino)propyl)-N8,N8-bis(2-hexyldecyl)octane-1,8-diamine (0.22 mmol, 152 mg) and DMAP (151 pmol, 20 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(8-(bis(2-hexyldecyl)amino)octyl)-7V-(3-(dimethylamino)propyl)nonanamide was 120 mg (67%).
[0578] 1H NMR (400 MHz, CDCl3) δ3.37 – 3.16 (m, 4H), 2.34 - 2.18 (m, 12H), 2.10 - 2.03 (m, 4H), 1.76 - 1.58 (m, 7H), 1.55 - 1.06 (m, 80H), 0.92 - 0.83 (m, 15H). ESI-MS: m / z calculated for C54H111N3O = 817.87, found [M+H]+= 819.25.
[0579] SYNTHETIC EXAMPLE 23
[0580] SYNTHESIS OF N-(8-(BIS(2-OCTYLDODECYL)AMINO)OCTYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-23)
[0581]
[0582] Synthesis of 8-bromo-N,N-bis(2-octyldodecyl)octanamide
[0583]
[0584] 8-Bromo-A, A-bis(2-octyldodecyl)octanamide was prepared from 8-bromooctanoic acid (5.11 mmol, 1.14 g), oxalyl chloride (23.32 mmol, 2.96 g, 2.00 mL), triethylamine (23.09 mmol, 2.37 g, 3.20 mL), bis(2-octyldodecyl)amine (4.37 mmol, 2.53 g) and DMAP (300 pmol, 40 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide.
[0585] Purification of the crude product was done via flash chromatography, with Hexanes / EtOAc gradient. The yield of 8-bromo-A, A-bis(2-octyldodecyl)octanamide was 2.91 g (85%). ESI-MS: m / z calculated for C4sH96BrNO = 781.67, found [M+H]+= 782.90.
[0586] Synthesis of 8-((3-(dimethylamino)propyl)amino)-N,N-bis(2-octyldodecyl)octanamide
[0587]
[0588] 8-((3-(Dimethylamino)propyl)amino)-A, A-bis(2-octyldodecyl)octanamide was prepared from 8-bromo-7V,7V-bis(2-octyldodecyl)octanamide (0.64 mmol, 500 mg), 3 -(dimethylamino)- 1-propanamine (2.38 mmol, 244 mg, 0.30 mL), and potassium carbonate (1.20 mmol, 148 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-7V,7V-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 8-((3-(dimethylamino)propyl)amino)-A,7V-bis(2-octyldodecyl)octanamide (250 mg, 49%). ESI-MS: m / z calculated for C53H109N3O = 803.86, found [M+H]+= 805.12.
[0589] Synthesis of N1-(3-(dimethylamino)propyl)-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine
[0590]
[0591] 7V1-(3-(Dimethylamino)propyl)-7V8,7V8-bis(2-octyldodecyl)octane-l,8-diamine was prepared from 8-((3-(dimethylamino)propyl)amino)-7V,7V-bis(2-octyldodecyl)octanamide (314 pmol, 250 mg), and LAH (3.95 mmol, 150 mg) in THF (5.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(3-(dimethylamino)propyl)-N8, N8-bis(2-octyldodecyl)octane-1,8-diamine was 184 mg (74%). ESIMS: m / z calculated for C53H111N3 = 789.88, found [M+H]+= 791.20.
[0592] Synthesis of N-(8-(bis(2-octyldodecyl)amino)octyl)-N-(3-(dimethylamino)propyl)nonanamide
[0593]
[0594]
[0595] N-(8-(bis(2-octyldodecyl)amino)octyl)-N-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (0.28 mmol, 50 mg, 50 μL), triethylamine (5.05 mmol, 511 mg, 0.7 mL), N1-(3-(dimethylamino)propyl)-N8,N8-bis(2-octyldodecyl)octane-1,8-diamine (0.23 mmol, 184 mg) and DMAP (151 μmol, 20 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% Et₃N) gradient. The yield of N-(8-(bis(2-octyldodecyl)amino)octyl)-N-(3-(dimethylamino)propyl)nonanamide was 116 mg (52%).
[0596] 1H NMR (400 MHz, CDCl3) δ3.37 – 3.16 (m, 4H), 2.34 - 2.11 (m, 12H), 2.09 - 2.02 (m, 4H), 1.85 - 1.04 (m, 99H), 0.94 - 0.76 (m, 15H). ESI-MS: m / z calculated for C62H127N3O = 930.00, found [M+H]+= 931.30.
[0597] SYNTHETIC EXAMPLE 24
[0598] SYNTHESIS OF N-(6-(BIS(2-OCTYLDODECYL)AMINO)HEXYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-24)
[0599]
[0600] Synthesis of 6-bromo-N,N-bis(2-octyldodecyl)hexanamide
[0601]
[0602]
[0603] 6-Bromo-7V,7V-bis(2-octyldodecyl)hexanamide was prepared from bis(2-octyldodecyl)amine (6.92 mmol, 4.00 g), 6-bromohexanoic acid (8.2 mmol, 1.59 g), oxalyl chloride (36.3 mmol, 4.60 g, 3.11 mL), triethylamine (37.50 mmol, 3.80 g, 5.20 mL), and DMAP (1.51 mmol, 200 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification via flash chromatography (Hexanes / EtOAc gradient) gave 6-bromo-7V,7V-bis(2-octyldodecyl)hexanamide (4.34 g, 83%). ESI-MS: m / z calculated for C46H92BrNO = 753.64, found [M+H]+= 754.93.
[0604] Synthesis of 6-((3-(dimethylamino)propyl)amino)-N,N-bis(2-octyldodecyl)hexanamide
[0605]
[0606] 6-((3-(Dimethylamino)propyl)amino)-7V,7V-bis(2-octyldodecyl)hexanamide was prepared from 6-bromo-7V,7V-bis(2-octyldodecyl)hexanamide (1.39 mmol, 1.05 g), 3 -(dimethylamino)- 1-propanamine (7.94 mmol, 812 mg, 1.00 mL), and potassium carbonate (1.42 mmol, 196 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-N,N-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 6-((3-(dimethylamino)propyl)amino)-N,N-bis(2-hexyldecyl)hexanamide (562 mg, 69%). ESI-MS: m / z calculated for C51H105N3O = 775.83, found [M+H]+= 777.16.
[0607] Synthesis of N1-(3-(dimethylamino)propyl)-N6,N6-bis(2-octyldodecyl)hexane-1,6-diamine
[0608]
[0609] A1-(3-(Dimethylamino)propyl)-A6, A6-bis(2-octyldodecyl)hexane-l,6-diamine was prepared from 6-((3-(Dimethylamino)propyl)amino)-A, A-bis(2-octyldodecyl)hexanamide (438 pmol, 340 mg), and LAH (3.80 mmol, 100 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3, N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude 7\d-(3-(dimethylamino)propyl)-A6, A6-bis(2-octyldodecyl)hexane-l,6-diamine was 270 mg (81%). ESIMS: m / z calculated for C51H107N3 = 761.85, found [M+H]+= 762.90.
[0610] Synthesis of N-(6-(bis(2-hexyldecyl)amino)hexyl)-N-(3-(dimethylamino)propyl)nonanamide
[0611]
[0612] N-(6-(Bis(2-hexyldecyl)amino)hexyl)-N-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (0.32 mmol, 53 mg, 54 μL), triethylamine (3.61 mmol, 36 mg, 0.50 mL), N1-(3-(Dimethylamino)propyl)-N6,N6-bis(2-octyldodecyl)hexane-1,6-diamine (0.36 mmol, 270 mg) and DMAP (60 μmol, 7 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% Et₃N) gradient. The yield of N-(6-(bis(2-hexyldecyl)amino)hexyl)-N-(3-(dimethylamino)propyl)nonanamide was 165 mg (57%).
[0613] 1H NMR (400 MHz, CDCl3) δ 3.59 - 3.06 (m, 4H), 2.45 - 2.18 (m, 12H), 2.18 - 1.98 (m, 4H), 1.89 - 1.10 (m, 94H), 1.10 - 0.75 (m, 15H). ESI-MS: m / z calculated for C60H123N3O = 901.97, found [M+H]+= 903.21.
[0614] SYNTHETIC EXAMPLE 25
[0615] SYNTHESIS OF N-(6-(BIS(2-OCTYLDODECYL)AMINO)HEXYL)-N-DECYL-4- (DIMETHYLAMINO)BUTANAMIDE (COMPOUND 1-25)
[0616]
[0617] Synthesis of 6-bromo-N,N-bis(2-octyldodecyl)hexanamide
[0618]
[0619] 6-bromo-N,N-bis(2-octyldodecyl)hexanamide was prepared from 6-bromohexanoic acid (8.15 mmol, 1.59 g), oxalyl chloride (36.26 mmol, 4.60 g, 3.11 mL), triethylamine (37.51 mmol, 3.80 g, 5.20 mL), bis(2-octyldodecyl)amine (7.09 mmol, 4.10 g) and DMAP (151 μmol, 20 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide.
[0620] Purification of the crude product was done via flash chromatography, with Hexane s / EtO Ac. The yield of 6-bromo-A, A-bis(2-octyldodecyl)hexanamide was 4.87 g (91%). ESI-MS: m / z calculated for C46H92BrNO = 753.64, found [M+H]+= 754.85.
[0621] Synthesis of 6-(decylaniin())-\.\-bis(2-octyldodecyl)hexananiide
[0622]
[0623] 6-(Decylamino)-N,N-bis(2-octyldodecyl)hexanamide was prepared from 6-bromo-N,N-bis(2-octyldodecyl)hexanamide (0.47 mmol, 355 mg), decyl amine (2.35 mmol, 370 mg), and potassium carbonate (0.47 mmol, 65 mg) in ACN (10.00 mL), by following procedure outlined for 6-(decylamino)-N,N-bis(2-hexyldecyl)hexanamide. The crude product was purified via flash chromatography (0% to 15% MeOH in DCM) to give 6-(decylamino)-N,N-bis(2-octyldodecyl)hexanamide (285 mg, 73%). ESI-MS: m / z calculated for C56H114N2O = 830.89, found [M+H]+= 832.02.
[0624] Synthesis of N1-decyl-N6,N6-bis(2-octyldodecyl)hexane-1,6-diamine
[0625]
[0626] 7V1-decyl-7V6,7V6-bis(2-octyldodecyl)hexane-l,6-diamine was prepared from 6-(decylamino)-7V,7V-bis(2-octyldodecyl)hexanamide (0.60 mmol, 500 mg), and LAH (2.63 mmol, 100 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude 7V1-decyl-A6, A6-bis(2-octyldodecyl)hexane-l,6-diamine was 370 mg (75%). ESI-MS: m / z calculated for C56H116N2 = 816.91, found [M+H]+= 818.20.
[0627] Synthesis of 7V-(6-(bis(2-octyldodecyl)amino)hexyl)-4-chloro-7V-decylbutanamide
[0628]
[0629] N-(6-(bis(2-octyldodecyl)amino)hexyl)-4-chloro-N-decylbutanamide was prepared from 4-bromobutanoic acid (0.50 mmol, 84 mg), oxalyl chloride (2.34 mmol, 298 mg, 0.20 mL), triethylamine (3.6 mmol, 365 mg, 0.50 mL), N1-decyl-N6,N6-bis(2-octyldodecyl)hexane-1,6-diamine (0.42 mmol, 340 mg) and DMAP (151 μmol, 20 mg) by following the procedure outlined for 3-bromo-N,N-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% Et₃N) gradient. The yield was 301 mg (78%). ESI-MS: m / z calculated for C60H121ClN2O = 920.92, found [M+H]+= 922.20.
[0630] Synthesis of 7V-(6-(bis(2-octyldodecyl)amino)hexyl)-7V-decyl-4-(dimethylamino)butanamide
[0631]
[0632] 7V-(6-(Bis(2-octyldodecyl)amino)hexyl)-7V-decyl-4-(dimethylamino)butanamide was prepared from7V-(6-(bis(2-octyldodecyl)amino)hexyl)-4-chloro-7V-decylbutanamide (369 pmol, 340 mg) and dimethyl amine (2M in THF, 10.00 mL) by following the procedure outlined for N-(6-(bis(2-hexyldecyl)amino)hexyl)-3-bromo-N-decylpropanamide. Purification via flash chromatography (0% to 50% EtOAc in Hexanes spiked with 1% EtsN) gave 75 mg (22%) of N-(6-(bis(2-octyldodecyl)amino)hexyl)-N-decyl-4-(dimethylamino)butanamide.
[0633] ¹H NMR (400 MHz, CDCl₃) δ 3.32 - 3.24 (m, 2H), 3.25 - 3.13 (m, 2H), 2.41 - 2.24 (m, 6H), 2.21 (s, 6H), 2.10 - 2.03 (m, 4H), 1.87 - 1.75 (m, 2H), 1.74 - 1.63 (m, 2H), 1.59 - 1.44 (m, 4H), 1.43 - 1.08 (m, 89H), 0.92 - 0.82 (m, 15H). ESI-MS: m / z calculated for C62H125N3O = 930.00, found [M+H]+= 931.30.
[0634] SYNTHETIC EXAMPLE 26
[0635] SYNTHESIS OF N-(5-(BIS(2-HEXYLDECYL)AMINO)PENTYL)-N-(3-(DIMETHYLAMINO)PROPYL)-2- HEXYLDECANAMIDE (COMPOUND 1-26)
[0636]
[0637] Synthesis of 5-(bis(2-hexyldecyl)amino)-5-oxopentanoic acid
[0638]
[0639] Bis(2-hexyldecyl)amine (4.29 mmol, 2.00 g) was dissolved in 10.00 mL of DCM and reacted overnight, at room temperature, with glutaric anhydride (5.43 mmol, 0.62 g) and DMAP (5.16 mmol, 0.63 g). The reaction mixture was concentrated and purified via flash chromatography with DCM / MeOH (spiked with 1% acetic acid) gradient to yield 1.7 g (66%) of 5 -(bi s(2-hexyldecyl)amino)-5 -oxopentanoi c acid.
[0640] Synthesis of 4-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)glutaramide
[0641]
[0642] 5-(Bis(2-hexyldecyl)amino)-5-oxopentanoic acid (2.93 mmol, 1.70 g) and CDI () were dissolved in 10.00 mL of toluene and stirred for 30 minutes. After that, N,N-dimethylpropane-1,3-diamine (14.16 mmol, 1.45 g) was added and reaction mixture heated at reflux overnight.
[0643] After cooling down, the reaction was quenched with saturated aqueous NaHCCh solution. Water phase was extracted with DCM. Combined organic phase was dried over anhydrous Na2SC>4, filtered, and concentrated under vacuum. The crude N1-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)glutaramide (1.85, 95%) was further used as is.
[0644] Synthesis of N1-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)pentane-1,5-diamine
[0645]
[0646] N1-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)pentane-1,5-diamine was prepared from N1-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)glutaramide (2.78 mmol, 1.85 g) and LAH (13.70 mmol, 520 mg) in THF (20.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)pentane-1,5-diamine was 1.24 g (70%).
[0647] Synthesis of 7V-(5-(bis(2-hexyldecyl)amino)pentyl)-7V-(3-(dimethylamino)propyl)-2-hexyldecanamide
[0648]
[0649] N-(5-(Bis(2-hexyldecyl)amino)pentyl)-N-(3-(dimethylamino)propyl)-2-hexyldecanamide was prepared from 2-hexyldecanoic acid (4.13 mmol, 1.06 g), oxalyl chloride (23.30 mmol, 2.96 g, 2.00 mL), triethylamine (6.0 mmol, 607.14 mg, 0.83 mL), N1-(3-(dimethylamino)propyl)-N5,N5-bis(2-hexyldecyl)pentane-1,5-diamine (1.95 mmol, 1.24 g) and DMAP (151 pmol, 20 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide.
[0650] Purification of the crude product was done via flash chromatography with DCM / MeOH gradient. The yield of N-(5-(bis(2-hexyldecyl)amino)pentyl)-N-(3-(dimethylamino)propyl)-2-hexyldecanamide was 370 mg (22%).
[0651] ESI-MS: m / z calculated for C58H119N3O = 873.94, found [M+H]+= 875.38.
[0652] 'HNMR (400 MHz, CDCh) 63.77 - 3.62 (m, 1H), 3.42 - 3.16 (m, 4H), 2.60 - 2.43 (m, 1H), 2.35 -2.13 (m, 10H), 2.13 - 1.97 (dd, 4H), 1.78 - 1.03 (m, 103H), 0.94 - 0.78 (m, 18H). ESI-MS: m / z calculated for C62H127N3O = 930.00, found [M+H]+= 931.29.
[0653] SYNTHETIC EXAMPLE 27
[0654] SYNTHESIS OF 4-(BIS(2-HEXYLDECYL)AMINO)-N-(3-(DIMETHYLAMINO)PROPYL)-N- NONYLBUTANAMIDE (COMPOUND 1-27)
[0655]
[0656] Synthesis of A’. A’-diinethyl-A ’-nonylpropane-l,3-diamine
[0657]
[0658] N¹,N¹-dimethyl-N³-nonylpropane-1,3-diamine was prepared from 9-bromononane (9.65 mmol, 2.00 g), 3 -(dimethylamino)- 1-propanamine (16.9 mmol, 1.73 g, 2.13 mL), and DIPEA (19.30 mmol, 2.50 g, 3.37 mL) in ACN (12.00 mL), by following procedure outlined for bis(2-hexyldecyl)amine. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give N1,N1-dimethyl-N3-nonylpropane-1,3-diamine (931 mg, 42%). ESI-MS: m / z calculated for C14H32N2 = 228.26, found [M+H]+= 229.55.
[0659] Synthesis of ethyl 4-(bis(2-hexyldecyl)amino)butanoate
[0660]
[0661] Ethyl 4-(bis(2-hexyldecyl)amino)butanoate was prepared from bis(2-hexyldecyl)amine (2.31 mmol, 1.07 g), ethyl 4-bromobutanoate (1.54 mmol, 300 mg, 220 pL), and DIPEA (3.08 mmol, 398 mg, 0.54 mL) in ACN (11.00 mL), by following procedure outlined for bis(2-hexyldecyl)amine. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give ethyl 4-(bis(2-hexyldecyl)amino)butanoate (435 mg, 49%). ESI-MS: m / z calculated for C38H77NO2 = 579.60, found [M+H]+= 580.92.
[0662] Synthesis of 4-(bis(2-hexyldecyl)amino)butanoic acid
[0663]
[0664] To ethyl 4-(bis(2-hexyldecyl)amino)butanoate (750 µmol, 435 mg) dissolved in ethanol (10.00 mL) 1M aqueous potassium hydroxide (1.80 mL) was added and the reaction mixture stirred at 60 °C overnight. The reaction mixture was concentrated, acidified by addition of 1M HCl (1.90 mL) and the concentrated to give 476 mg of crude 4-(bis(2-hexyldecyl)amino)butanoic acid. ESI-MS: m / z calculated for C36H73NO2 = 551.56, found [M+H]+= 552.79.
[0665] Synthesis of 4-(bis(2-hexyldecyl)amino)-7V-(3-(dimethylamino)propyl)-7V-nonylbutanamide
[0666]
[0667]
[0668] 4-(Bis(2-hexyldecyl)amino)-N-(3-(dimethylamino)propyl)-N-nonylbutanamide was prepared from 4-(bis(2-hexyldecyl)amino)butanoic acid (750 µmol, 414 mg), N¹,N¹-dimethyl-N³-nonylpropane-1,3-diamine (825 µmol, 188 mg), DIPEA (2.25 mmol, 291 mg, 392 pL), and HATU (981 pmol, 373 mg) by following the procedure outlined for N1-decyl-N4,N4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 4-(bis(2-hexyldecyl)amino)-7V-(3-(dimethylamino)propyl)-7V-nonylbutanamide was 266 mg (47%).
[0669] ¹H NMR (400 MHz, CDCl₃) δ 3.38 - 3.17 (m, 4H), 2.36 - 2.19 (m, 11H), 2.13 - 2.06 (m, 4H), 1.86 - 1.05 (m, 70H), 0.96 - 0.79 (m, 15H). ESI-MS: m / z calculated for C50H103N3O =
[0670] 761.81, found [M+H]+= 763.10.
[0671] SYNTHETIC EXAMPLE 28
[0672] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(4-(DIMETHYLAMINO)-N-DECYLBUTANAMIDO)BUTANOATE (COMPOUND 1-42)
[0673]
[0674] Synthesis of 3-(bis(2-hexyldecyl)amino)propan-l-ol
[0675]
[0676] 3-(Bis(2-hexyldecyl)amino)propan-l-ol was prepared from 7-(bromomethyl)pentadecane (9.80 mmol, 2.99 g), 3 -amino- 1 -propanol (5.39 mmol, 405 mg, 0.42 mL), and DIPEA (19.60 mmol, 2.53 g, 3.42 mL) in ACN (12.00 mL), by following procedure outlined for bis(2-hexyldecyl)amine. The crude product was purified via flash chromatography (0% to 50% MeOH in DCM) to give 3-(bis(2-hexyldecyl)amino)propan-l-ol (346 mg, 13%). ESI-MS: m / z calculated for C35H73NO = 523.57, found [M+H]+= 524.80.
[0677] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-chlorobutanoate
[0678]
[0679] 3-(Bis(2-hexyldecyl)amino)propyl 4-chlorobutanoate was prepared from 3-(bis(2-hexyldecyl)amino)propan-l-ol (2.29 mmol, 1.20 g), 4-chlorobutyryl chloride (2.63 mmol, 371 mg, 295 pL) and triethylamine (6.87 mmol, 695 mg, 0.96 mL) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. The crude product was purified via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient to give 3-(bis(2-hexyldecyl)amino)propyl 4-chlorobutanoate (1.29 mg, 90%). ESI-MS: m / z calculated for C39H78CINO2 = 627.57, found [M+H]+= 628.80.
[0680] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-(decylamino)butanoate
[0681]
[0682] 3-(Bis(2-hexyldecyl)amino)propyl 4-(decylamino)butanoate was prepared from 3-(bis(2-hexyldecyl)amino)propyl 4-chlorobutanoate (827 pmol, 520 mg), decylamine (2.48 mmol, 390 mg, 0.50 mL), and DIPEA (2.48 mmol, 321 mg, 0.43 mL) in ACN (15.00 mL), by following procedure outlined for bis(2-hexyldecyl)amine. The crude product was purified via flash chromatography (with Hexanes / EtOAc gradient, spiked with 1% EtsN) to give 3-(bis(2-hexyldecyl)amino)propyl 4-(decylamino)butanoate (149 mg, 24%). ESI-MS: m / z calculated for C49H100N2O2 = 748.78, found [M+H]+= 750.05.
[0683] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-(4-(dimethylamino)-7V-decylbutanamido)butanoate
[0684]
[0685] 3-(Bis(2-hexyldecyl)amino)propyl 4-(4-(dimethylamino)-A-decylbutanamido)butanoate was prepared from 3-(bis(2-hexyldecyl)amino)propyl 4-(decylamino)butanoate (199 pmol, 149 mg), 3 -carboxy- l-(dimethylammonio)propane chloride (376 pmol, 63 mg), DIPEA (597 pmol, 77 mg, 104 pL), and HATU (288 pmol, 110 mg) by following the procedure outlined for N1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. 3-(Bis(2-hexyldecyl)amino)propyl 4-(4-(dimethylamino)-A-decylbutanamido)butanoate was 37 mg (21%).
[0686] 1H NMR (400 MHz, CDCh) 84.14 - 4.07 (m, 2H), 2.59 - 2.24 (m, 14H), 2.11 - 2.05 (m, 5H), 1.91 - 1.79 (m, 3H), 1.75 - 1.48 (m, 7H), 1.48 - 1.09 (m, 66H), 0.92 - 0.84 (m, 15H). ESI-MS: m / z calculated for C55H111N3O3 = 861.86, found [M+H]+= 863.15.
[0687] SYNTHETIC EXAMPLE 29
[0688] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-2- (DIMETHYLAMINO)ACETAMIDO)BUTANOATE (COMPOUND 1-33)
[0689]
[0690] Synthesis of tert-butyl 4-(decylamino)butanoate
[0691]
[0692] tert-Butyl 4-(decylamino)butanoate was prepared from tert-butyl 4-bromobutyrate (1.34 mmol, 300 mg), decyl amine (2.45 mmol, 386 mg) and DIPEA (2.69 mmol, 347 mg, 0.47 mL) by following the procedure for bis(2-hexyldecyl)amine. The yield of tert-butyl 4-(decylamino)butanoate was 154 mg (37%). ESI-MS: m / z calculated for C18H37NO2 = 299.28, found [M+H]+= 300.59.
[0693] Synthesis of tert-butyl 4-(7V-decyl-2-(dimethylamino)acetamido)butanoate
[0694]
[0695] / c / V-Butyl 4-(A-decyl-2-(dimethylamino)acetamido)butanoate was prepared from tert-butyl 4-(decylamino)butanoate (1.68 mmol, 504 mg), DIPEA (5.05 mmol, 652 mg, 879 pL), 1-carboxy-7V,7V-dimethylmethanaminium chloride (2.49 mmol, 347 mg) and HATU (2.26 mmol, 896 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 50% EtOAc in Hexanes spiked with 1% EtsN) gave tert-butyl 4-(A-decyl-2-(dimethylamino)acetamido)butanoate (479 mg, 74%). ESI-MS: m / z calculated for C22H44N2O3 = 384.34, found [M+H]+= 385.64.
[0696] Synthesis of 4-(7V-decyl-2-(dimethylamino)acetamido)butanoic acid
[0697]
[0698] To / c / 7-Butyl 4-(A-decyl-2-(dimethylamino)acetamido)butanoate (529 pmol, 204 mg) in DCM (2 mL), TFA (17.0 mmol, 2.4 g, 1.3 mL) was added. The reaction mixture was stirred at room temperature for 4 h and concentrated to give crude 4-(7V-decyl-2-(dimethylamino)acetamido)butanoic acid. ESI-MS: m / z calculated for C18H36N2O3 = 328.27, found [M+H]+= 328.58.
[0699] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-( \-decyl-2-(dimethylamino)acetamido)butanoate (Compound 1-33)
[0700]
[0701] 3-(Bis(2-hexyldecyl)amino)propyl 4-(A-decyl-2-(dimethylamino)acetamido)butanoate was prepared from 4-(7V-decyl-2-(dimethylamino)acetamido)butanoic acid (529 pmol, 174 mg), DIPEA (2.65 mmol, 342 mg, 461 pL), 3-(bis(2-hexyldecyl)amino)propan-l-ol (700 pmol, 367 mg) and HATU (973 pmol, 370 mg) by following the procedure outlined for / ' / '-decyl-A4, / ' / 4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) followed by repurification (MeOH in DCM) gave 3-(bis(2-hexyldecyl)amino)propyl 4-(A-decyl-2-(dimethylamino)acetamido)butanoate (85 mg, 19%).
[0702] 'HNMR (400 MHz, CDCh) 84.16 - 4.06 (m, 2H), 3.43 - 3.25 (m, 4H), 3.18 - 3.07 (s,
[0703] 2H), 2.44 - 2.24 (m, 9H), 2.13 - 2.05 (d, J = 6.6 Hz, 3H), 1.95 - 1.80 (m, 3H), 1.80 - 1.48 (m, 12H), 1.48 - 1.09 (m, 63H), 0.92 - 0.81 (m, 15H). ESI-MS: m / z calculated for C53H107N3O3 = 833.83, found [M+H]+= 835.13.
[0704] SYNTHETIC EXAMPLE 30
[0705] SYNTHESIS OF 4-((4-(N-(2-(DIMETHYLAMINO)ETHYL)NONANAMIDO)BUTYL)(2- OCTYLDODECYL)AMINO)BUTYL NONANOATE (COMPOUND 1-51)
[0706]
[0707] Synthesis of 4-((2-octyldodecyl)amino)butan-l-ol
[0708]
[0709] 4-((2-Octyldodecyl)amino)butan-l-ol was prepared from 9-(bromomethyl)nonadecane (4.16 mmol, 1.5 g), 4-amino-l -butanol (7.28 mmol, 649 mg) and DIPEA (12.5 mmol, 1.61 g, 2.18 mL) in ACN (14.6 mL) by following the procedure for bis(2-hexyldecyl)amine. The yield of 4-((2-octyldodecyl)amino)butan-l-ol was 660 mg (43%). ESI-MS: m / z calculated for C24H51NO = 369.40, found [M+H]+= 370.70.
[0710] Synthesis of 7V-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-octyldodecan-l-amine
[0711]
[0712]
[0713] Imidazole, DCM
[0714]
[0715]
[0716] To 4-((2-octyldodecyl)amino)butan-l-ol (5.17 mmol, 1.9 g) and imidazole (15.7 mmol, 1.1 g) in DCM (40), tert-butylchlorodimethylsilane (6.38 mmol, 961 mg) dissolved in DCM (10 mL) was added dropwise over 15 minutes. The reaction was stirred at room temperature overnight. The reaction mixture was partitioned between DCM and water, and the organics were extracted with 3 x 15 mL of DCM. The combined organic phase was washed with 15 mL of brine and dried over anhydrous sodium sulfate and concentrated. Purification via flash chromatography (0 to 30% MeOH in DCM) gave M(4-(( / c / 7-butyldimethylsilyl)oxy)butyl)-2-octyldodecan-1 -amine (85 mg, 19%). ESI-MS: m / z calculated for CsoEfcsNOSi = 483.48, found [M+H]+= 484.78.
[0717] Synthesis of 4-((2-(dimethylamino)ethyl)amino)-4-oxobutanoic acid
[0718]
[0719] DMAP, DIPEA
[0720] Acetone
[0721] Dihydrofuran-2, 5-dione (21.7 mmol, 2.17 g), DIPEA (45.9 mmol, 5.95 g, 8.0 mL), DMAP (409 pmol, 50 mg) and A^A^dimethylethane-l^-diamine (17.0 mmol, 1.50 g) were dissolved in 34 mL Acetone and stirred at room temperature overnight. The solvent was removed under vacuum and crude 4-((2-(dimethylamino)ethyl)amino)-4-oxobutanoic acid, further used as is. ESI-MS: m / z calculated for C8H16N2O3 = 188.12, found [M+H]+= 189.43.
[0722] Synthesis of A7-(4-((tert-butyldimethylsilyl)oxy)butyl)-A4-(2-(dimethylamino)ethyl)-A7-(2-octyldodecyl)succinamide
[0723]
[0724] A1-(4-((tert-butyldimethylsilyl)oxy)butyl)-A4-(2-(dimethylamino)ethyl)-A1-(2-octyldodecyl)succinamide was prepared from A-(4-((ter / -butyldimethylsilyl)oxy)butyl)-2-octyldodecan-1 -amine (3.81 mmol, 1.84 g), DIPEA (11.4 mmol, 1.48 g, 1.99 mL), 4-((2-(dimethylamino)ethyl)amino)-4-oxobutanoic acid (17 mmol, 3.2 g) and HATU (5.96 mmol, 2.26 g) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide.
[0725] Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave A1-(4-((ter / -butyldimethylsilyl)oxy)butyl)-A4-(2-(dimethylamino)ethyl)-A1-(2-octyldodecyl)succinamide (1.06 g, 42%). ESI-MS: m / z calculated for C3sH79N3C>3Si= 653.59, found [M+H]+= 654.89.
[0726] Synthesis of 4-((4-((2-(dimethylamino)ethyl)amino)butyl)(2-octyldodecyl)amino)butan-l-ol
[0727]
[0728] 4-((4-((2-(dimethylamino)ethyl)amino)butyl)(2-octyldodecyl)amino)butan- 1 -ol was prepared from 7V1-(4-((tert-butyldimethylsilyl)oxy)butyl)-7V4-(2-(dimethylamino)ethyl)-7V1-(2-octyldodecyl)succinamide (1.62 mmol, 1.06 g), and LAH (15.8 mmol, 600 mg) in THF (3.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine.
[0729] The yield of the crude 4-((4-((2-(dimethylamino)ethyl)amino)butyl)(2-octyldodecyl)amino)butan-l-ol was 171 mg (21%). ESI-MS: m / z calculated for C32H69N3O = 511.54, found [M+H]+= 512.84.
[0730] Synthesis of 4-((4-(\-(2-(dinietliylaniino)ethyl)nonananiido)biityl)(2-octyldodecyl)amino)butyl nonanoate (Compound 1-51)
[0731]
[0732] 4-((4-(A-(2-(Dimethylamino)ethyl)nonanamido)butyl)(2-octyldodecyl)amino)butyl nonanoate was prepared from nonanoyl chloride (1.00 mmol, 177 mg, 181 pL), triethylamine (1.00 mmol, 101 mg, 0.14 mL), 4-((4-((2-(dimethylamino)ethyl)amino)butyl)(2-octyldodecyl)amino)butan-l-ol (334 pmol, 122 mg) and DMAP (33 pmol, 4 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 4-((4-(A-(2-(dimethylamino)ethyl)nonanamido)butyl)(2-octyldodecyl)amino)butyl nonanoate was 105 mg (40%).
[0733] 'H NMR (400 MHz, CDCh) 84.10 - 4.02 (m, 2H), 3.48 - 3.40 (m, 1H), 3.38 - 3.19 (m, 3H), 2.47 - 2.38 (m, 2H), 2.39 - 2.23 (m, 14H), 2.16 - 2.08 (m 2H), 1.68 - 1.49 (m, 17H), 1.48 -1.12 (m, 59H), 0.92 - 0.83 (m, 12H). ESI-MS: m / z calculated for C50H101N3O3 = 791.78, found [M+H]+= 793.07.
[0734] SYNTHETIC EXAMPLE 31
[0735] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-4- (DIPROPYLAMINO)BUTANAMIDO)BUTANOATE (COMPOUND 1-52)
[0736]
[0737] Synthesis of tert-butyl 4-(7V-decyl-4-(dipropylamino)butanamido)butanoate
[0738]
[0739] tert-Butyl 4-(7V-decyl-4-(dipropylamino)butanamido)butanoate was prepared from tertbutyl 4-(decylamino)butanoate (1.67 mmol, 500 mg), DIPEA (5.05 mmol, 652 mg, 879 pL), 3-carboxy-N, N-dipropylpropan-l-aminium chloride (1.84 mmol, 411 mg) and HATU (2.17 mmol, 825 mg) by following the procedure outlined for N1-decyl-N4,N4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 90% EtOAc in Hexanes spiked with 1% EtsN) gave tert-butyl 4-(7V-decyl-4-(dipropylamino)butanamido)butanoate (700 mg, 79%). ESI-MS: m / z calculated for C28H56N2O3 = 468.43, found [M+H]+= 469.73.
[0740] Synthesis of 4-(7V-decyl-4-(dipropylamino)butanamido)butanoic acid
[0741]
[0742] 4-(7V-Decyl-4-(dipropylamino)butanamido)butanoic acid was prepared by following the procedure outlined for synthesis of 4-(7V-decyl-2-(dimethylamino)acetamido)butanoic acid. ESI-MS: m / z calculated for C24H48N2O3 = 412.37, found [M+H]+= 413.67.
[0743] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-(\-decyl-4-(dipropylamino)butanamido)butanoate (Compound 1-52)
[0744]
[0745] 3-(Bis(2-hexyldecyl)amino)propyl 4-(A-decyl-4-(dipropylamino)butanamido)butanoate was prepared from 4-(7V-decyl-4-(dipropylamino)butanamido)butanoic acid (380 pmol, 200 mg), DIPEA (949 pmol, 123 mg, 166 pL), 3-(bis(2-hexyldecyl)amino)propan-l-ol (570 pmol, 298 mg) and HATU (494 pmol, 188 mg) by following the procedure outlined for / ' / '-decyl-A4, / ' / 4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave 3-(bis(2-hexyldecyl)amino)propyl 4-(A-decyl-4-(dipropylamino)butanamido)butanoate (40 mg, 11%).
[0746] 'HNMR (400 MHz, CDCh) 64.18 - 4.05 (m, 2H), 3.37 - 3.17 (m, 4H), 2.42 - 2.26 (m, 7H), 2.11 - 2.06 (m, 4H), 1.90 - 1.78 (m, 3H), 1.75 - 1.66 (m, 3H), 1.65 - 1.45 (m, 10H), 1.41 -1.12 (m, 68H), 0.98 - 0.82 (m, 21H). ESI-MS: m / z calculated for C59H119N3O3 = 917.93, found [M+H]+= 919.23.
[0747] SYNTHETIC EXAMPLE 32
[0748] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-3- (DIETHYLAMINO)PROPANAMIDO)BUTANOATE (COMPOUND 1-53)
[0749]
[0750] Synthesis of tert-butyl 4-(7V-decyl-3-(diethylamino)propanamido)butanoate
[0751]
[0752] tert-Butyl 4-(A-decyl-3-(diethylamino)propanamido)butanoate was prepared from tertbutyl 4-(decylamino)butanoate (1.34 mmol, 400 mg), DIPEA (4.01 mmol, 518 mg, 698 pL), 2-carboxy-7V,7V-diethylethan-l-aminium chloride (1.62 mmol, 294 mg) and HATU (2.15 mmol, 816 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 90% EtOAc in Hexanes spiked with 1% EtsN) gave tert-butyl 4-(A-decyl-3-(diethylamino)propanamido)butanoate (398 mg, 70%). ESI-MS: m / z calculated for C25H50N2O3 = 426.38, found [M+H]+= 427.68.
[0753] Synthesis of 4-(7V-decyl-3-(diethylamino)propanamido)butanoic acid
[0754]
[0755] 4-(7V-Decyl-3-(diethylamino)propanamido)butanoic acid was prepared by following the procedure outlined for synthesis of 4-(7V-decyl-2-(dimethylamino)acetamido)butanoic acid. ESI-MS: m / z calculated for C21H42N2O3 = 370.32, found [M+H]+= 371.62.
[0756] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-( \-decyl-3-(diethylamino)propanamido)butanoate (Compound 1-53)
[0757]
[0758] 3-(Bis(2-hexyldecyl)amino)propyl 4-(A-decyl-3-(diethylamino)propanamido)butanoate was prepared from 4-(7V-decyl-3-(diethylamino)propanamido)butanoic acid (513 pmol, 190 mg), DIPEA (716 pmol, 92 mg, 125 pL), 3-(bis(2-hexyldecyl)amino)propan-l-ol (239 pmol, 125 mg) and HATU (355 pmol, 135 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) 3-(bis(2-hexyldecyl)amino)propyl 4-(A-decyl-3-(diethylamino)propanamido)butanoate (34 mg, 17%).
[0759] ESI-MS: m / z calculated for C56H113N3O3 = 875.88, found [M+H]+= 877.18.
[0760] SYNTHETIC EXAMPLE 33
[0761] SYNTHESIS OF N-(4-(BIS(2-ETHYLHEXYL)AMINO)BUTYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-54)
[0762]
[0763] Synthesis of 4-(bis(2-ethylhexyl)amino)-4-oxobutanoic acid
[0764]
[0765] Dihydrofuran-2, 5-dione (2.02 mmol, 202 mg), and bis(2-ethylhexyl)amine (2.41 mmol, 583 mg) were dissolved in 20 mL THF and stirred at room temperature overnight. The solvent was removed under vacuum and crude product further used as is. ESI-MS: m / z calculated for C20H39NO3 341.29, found [M+H]+= 342.59.
[0766] Synthesis of V1-(3-(diniethylaniino)propyl)-\4,\4-bis(2-ethylhexyl)succinaniide
[0767]
[0768] A1-(3-(Dimethylamino)propyl)-A4, A4-bis(2-ethylhexyl)succinamide was prepared from 4-(bis(2-ethylhexyl)amino)-4-oxobutanoic acid (1.16 mmol, 397 mg), DIPEA (3.91 mmol, 506 mg, 0.68 mL), A^A^dimethylpropane-l^-diamine (979 pmol, 100 mg) and HATU (1.27 mmol, 484 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave A1-(3-(dimethylamino)propyl)-A4, A4-bis(2-ethylhexyl)succinamide (366 mg, 88%). ESIMS: m / z calculated for C25H51N3O2= 425.40, found [M+H]+= 426.70.
[0769] Synthesis of 4-(3-(dimethylamino)propyl)- 4^V4-bis(2-ethylhexyl)butane-l,4-diamine
[0770]
[0771] 7V1-(3-(Dimethylamino)propyl)-7V4,7V4-bis(2-ethylhexyl)butane-l,4-diamine was prepared from 7V1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-ethylhexyl)succinamide (482 pmol, 205 mg), and LAH (9.63 mmol, 366 mg) in THF (3.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1-^-(dimethylamino)propyl)-7V4,7V4-bis(2-ethylhexyl)butane-l,4-diamine was 152 mg (88%). ESIMS: m / z calculated for C25H55N3 = 397.44, found [M+H]+= 398.74.
[0772] Synthesis of 7V-(4-(bis(2-ethylhexyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide
[0773] (Compound 1-54)
[0774]
[0775] 7V-(4-(Bis(2-ethylhexyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (555 pmol, 98 mg, 100 pL), tri ethylamine (1.19 mmol, 120 mg, 0.17 mL), 7V1-(3-(dimethylamino)propyl)-7V4,7V4-bis(2-ethylhexyl)butane-l,4-diamine (396 pmol, 158 mg) and DMAP (40 pmol, 5 mg) by following the procedure outlined for 3-bromo-7VpV-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(4-(bis(2-ethylhexyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was 146 mg (68%).
[0776] 'H NMR (400 MHz, CDCh) 63.38 - 3.18 (m, 4H), 2.46 - 2.17 (s, 12H), 2.14 - 2.01 (m, 4H), 1.87 - 1.42 (m, 10H), 1.42 - 1.15 (m, 31H), 0.93 - 0.78 (m, 15H). ESI-MS: m / z calculated for C34H71N3O = 537.56, found [M+H]+= 537.86.
[0777] SYNTHETIC EXAMPLE 34
[0778] SYNTHESIS OF N-(4-(BIS(2-BUTYLOCTYL)AMINO)BUTYL)-N-(3- (DIMETHYLAMINO)PROPYL)NONANAMIDE (COMPOUND 1-55)
[0779]
[0780] Synthesis of bis(2-butyloctyl)amine
[0781]
[0782] Bis(2-butyloctyl)amine was prepared from 5-(bromomethyl)undecane (6.02 mmol, 1.5 g), 2-butyl-l-octanamine (8.43 mmol, 1.56 g) and DIPEA (12.5 mmol, 1.61 g, 2.18 mL) in ACN (16.9 mL) by following the procedure for bis(2-hexyldecyl)amine. The yield of bis(2-butyloctyl)amine was 1.4 g (66%). ESI-MS: m / z calculated for C24H51N = 353.40, found [M+H]+= 354.70.
[0783] Synthesis of 4-(bis(2-butyloctyl)amino)-4-oxobutanoic acid
[0784]
[0785] Dihydrofuran-2, 5-dione (2.02 mmol, 202 mg), and bis(2-butyloctyl)amine (2.14 mmol, 754 mg) were dissolved in 20 mL THF and stirred at room temperature overnight. The solvent was removed under vacuum and crude product further used as is. ESI-MS: m / z calculated for C28H55NO3 = 453.42, found [M+H]+= 454.72.
[0786] Synthesis of A^^Y1-bis(2-butyloctyl)-Az4-(3-(dimethylamino)propyl)succinamide
[0787]
[0788] 7V1,7V1-Bis(2-butyloctyl)-7V4-(3-(dimethylamino)propyl)succinamide was prepared from 4-(bis(2-butyloctyl)amino)-4-oxobutanoic acid (983 pmol, 446 mg), DIPEA (3.33 mmol, 430 mg, 0.58 mL), A Afl-dimethylpropane-l,3-diamine (105 pmol, 85 mg) and HATU (1.08 mmol, 411 mg) by following the procedure outlined for 7V1-decyl-A4,7V4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave7V1,7V1-bis(2-butyloctyl)-A4-(3-(dimethylamino)propyl)succinamide (416 mg, 93%). ESIMS: m / z calculated for C33H67N3O2= 537.52, found [M+H]+= 537.82.
[0789] Synthesis of VL\ )is(2-butyl()ctyl)-\4-(3-(dimeth l:iinino)piopyl)biitane-l.4-diamine
[0790]
[0791] 7V1,7V1-Bis(2-butyloctyl)-7V4-(3-(dimethylamino)propyl)butane-l,4-diamine was prepared from 7V1,7V1-bis(2-butyloctyl)-7V4-(3-(dimethylamino)propyl)succinamide (773 pmol, 416 mg), and LAH (15.5 mmol, 587 mg) in THF (10.0 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude N1, N1-bi s(2-butyloctyl)-7V4-(3-(dimethylamino)propyl)butane-l,4-diamine was 152 mg (88%). ESI-MS: m / z calculated for C33H71N3 = 509.56, found [M+H]+= 510.86.
[0792] Synthesis of 7V-(4-(bis(2-butyloctyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide
[0793] (Compound 1-55)
[0794]
[0795] 7V-(4-(Bis(2-butyloctyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was prepared from nonanoyl chloride (341 pmol, 60 mg, 62 pL), triethylamine (731 pmol, 74 mg, 102 pL), 7V1,7V1-bis(2-butyloctyl)-7V4-(3-(dimethylamino)propyl)butane-l,4-diamine (244 pmol, 124 mg) and DMAP (49 pmol, 6 mg) by following the procedure outlined for 3-bromo-7VpV-bis(2-hexyldecyl)propanamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 7V-(4-(bis(2-butyloctyl)amino)butyl)-7V-(3-(dimethylamino)propyl)nonanamide was 89 mg (56%).
[0796] 'H NMR (400 MHz, CDCh) 83.38 - 3.18 (m, 4H), 2.45 - 2.18 (m, 11H), 2.11 - 2.04 (m, 4H), 1.85 - 1.44 (m, 9H), 1.42 - 1.13 (m, 47H), 0.93 - 0.83 (m, 15H). ESI-MS: m / z calculated for C42H87N3O = 649.68, found [M+H]+= 650.98.
[0797] SYNTHETIC EXAMPLE 35
[0798] SYNTHESIS OF 4-((4-(BIS(2-HEXYLDECYL)AMINO)BUTYL)(3- (DIMETHYLAMINO)PROPYL)AMINO)-4-OXOBUTYL HEXYL CARBONATE (COMPOUND 1-56)
[0799]
[0800] Synthesis of hexyl 1 / / -ini idazole-1 -car boxy late
[0801]
[0802] To a solution of di(l / 7-imidazol-l-yl)methanone (20.0 mmol, 3.25 g) in DCM (30 mL), solution of 1-hexanol (10.3 mmol, 1.05 g) in DCM (10 mL) was added dropwise, followed by the addition of KOH (1.03 mmol, 60 mg). The reaction mixture was heated at 60 °C overnight. After cooling down, it was washed 3 times with saturated brine and concentrated. Purification of the crude product via flash chromatography (0-20% EtOAc in Hexanes) yielded 1.9 g (94%) of hexyl 1 / 7-imidazole-l -carboxylate. ESI-MS: m / z calculated for C10H16N2O2 = 196.12, found [M+H]+ = 196.32
[0803] Synthesis of 4-((tert-butyldimethylsilyl)oxy)butyl hexyl carbonate
[0804]
[0805] A solution of 4-((tert-butyldimethylsilyl)oxy)butan-l-ol (14.7 mmol, 3.00 g), hexyl 1H-imidazole-1 -carboxylate (15.4 mmol, 3.02 g) and KOH (1.47 mmol, 82 mg) was heated at 60 °C for Ih. After cooling down, solvent was removed under vacuum. Purification of the crude product via flash chromatography (0-20% EtOAc in Hexanes) yielded 3.5 g (72%) of 4- (tert-butyldimethylsilyl)oxy)butyl hexyl carbonate.
[0806] Synthesis of hexyl (4-hydroxybutyl) carbonate
[0807]
[0808] To a solution of 4-((tert-butyldimethylsilyl)oxy)butyl hexyl carbonate (10.5 mmol, 3.5 g) in THF (30 mL), IM THF solution of TBAF (12.6 mmol, 12.6 mL) was added dropwise. The reaction mixture was stirred at room temperature overnight. Solvent was removed under vacuum. Purification of the crude product via flash chromatography (0-50% EtOAc in Hexanes) yielded 2.2 g (96%) of hexyl (4-hydroxybutyl) carbonate.
[0809] Synthesis of 4-(((hexyloxy)carbonyl)oxy)butanoic acid
[0810]
[0811] To a solution of hexyl (4-hydroxybutyl) carbonate (2.21 mmol, 482 mg), TEMPO (44.2 pmol, 7 mg) and NaBr (442 pmol, 45 mg) in Acetone (22 mL), trichloroisocyanuric acid (4.42 mmol, 1.03 g) was slowly added under stirring. After the addition of Na2COs (2.21 mmol, 185 mg) dissolved in a minimal amount of water, the reaction mixture was stirred at room temperature for 5h. The reaction is quenched by the addition of IPA and concentrated under vacuum. The residue was taken in DCM and pH was adjusted to 14 by the addition of IM aqueous NaOH. Water phase was washed with 3 ^ 15 mL of DCM. After adjusting pH to 2 with 3M HC1, mixture was extracted with 3 x 20 mL of EtOAc. The combined organics were washed with water and dried over anhydrous sodium sulfate. The solids are filtered off, and the solvent is removed under reduced pressure. The crude 4-(((hexyloxy)carbonyl)oxy)butanoic acid (259 mg, 50%) was further used as is.
[0812] Synthesis of 4-((4-(bis(2-hexyldecyl)amino)butyl)(3-(dimethylamino)propyl)amino)-4-oxobutyl hexyl carbonate (Compound 1-56)
[0813]
[0814] 4-((4-(Bis(2-hexyldecyl)amino)butyl)(3-(dimethylamino)propyl)amino)-4-oxobutyl hexyl carbonate was prepared from 4-(((hexyloxy)carbonyl)oxy)butanoic acid (1.11 mmol, 258 mg), A1-(3-(dimethylamino)propyl)-A4, A4-bis(2-hexyldecyl)butane-l,4-diamine (630 pmol, 392 mg), DIPEA (1.35 mmol, 174 mg, 0.24 mL) and HATU (657 pmol, 250 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 4-((4-(bis(2-hexyldecyl)amino)butyl)(3-(dimethylamino)propyl)amino)-4-oxobutyl hexyl carbonate was 321 mg (85%).
[0815] 'H NMR (400 MHz, CDCh) 64.23 - 4.07 (m, 4H), 3.39 - 3.18 (m, 4H), 2.57 - 2.17 (m, 10H), 2.11 - 1.97 (m, 5H), 1.70 - 1.43 (m, 9H), 1.43 - 1.02 (m, 54H), 0.95 - 0.78 (td, J = 7.0, 6.9, 3.4 Hz, 15H). ESI-MS: m / z calculated for C52H105N3O4 = 835.81, found [M+H]+= 837.11.
[0816] SYNTHETIC EXAMPLE 36
[0817] SYNTHESIS OF 6-((4-(BIS(2-HEXYLDECYL)AMINO)BUTYL)(3- (DIMETHYLAMINO)PROPYL)AMINO)-6-OXOHEXYL HEXYL CARBONATE (COMPOUND 1-57)
[0818]
[0819] Synthesis of 4-((tert-butyldimethylsilyl)oxy)hexyl hexyl carbonate
[0820]
[0821] 4-((ter / -Butyldimethylsilyl)oxy)hexyl hexyl carbonate was prepared from hexyl 1H-imidazole-1 -carboxylate (11.3 mmol, 2.22 g), 4-((ter / -butyldimethylsilyl)oxy)hexan-l-ol (10.8 mmol, 2.5 g) and KOH (1.08 mmol, 60 mg) by following the procedure outlined for 4- (tert-butyldimethylsilyl)oxy)butyl hexyl carbonate. Purification of the crude product via flash chromatography (0-20% EtOAc in Hexanes) yielded 2.9 g (75%) of 4-(( / c / 7-butyldimethylsilyl)oxy)hexyl hexyl carbonate.
[0822] Synthesis of hexyl (4-hydroxyhexyl) carbonate
[0823]
[0824] To a solution of 4-((tert-butyldimethylsilyl)oxy)hexyl hexyl carbonate (8.04 mmol, 2.9 g) in THF (30 mL), IM THF solution of TBAF (8.85 mmol, 8.85 mL) was added dropwise. The reaction mixture was stirred at room temperature overnight. Solvent was removed under vacuum. Purification of the crude product via flash chromatography (0-50% EtOAc in Hexanes) yielded 1.8 g (91%) of hexyl (4-hydroxyhexyl) carbonate.
[0825] Synthesis of 6-(((hexyloxy)carbonyl)oxy)hexanoic acid
[0826]
[0827] 6-(((hexyloxy)carbonyl)oxy)hexanoic acid was prepared from hexyl (4-hydroxyhexyl) carbonate (2.03 mmol, 500 mg), TEMPO (40.6 pmol, 6 mg), NaBr (406 pmol, 42 mg), trichloroisocyanuric acid (4.06 mmol, 943 mg) andNa2COs (2.03 mmol, 171 mg) by following the procedure outlined for 4-(((hexyloxy)carbonyl)oxy)butanoic acid. The yield of the crude 6-(((hexyloxy)carbonyl)oxy)hexanoic acid was 500 mg (95%).
[0828] Synthesis of 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(dimethylamino)propyl)amino)-6-oxohexyl hexyl carbonate (Compound 1-57)
[0829]
[0830] 6-((4-(Bis(2-hexyldecyl)amino)butyl)(3-(dimethylamino)propyl)amino)-6-oxohexyl hexyl carbonate was prepared from 6-(((hexyloxy)carbonyl)oxy)hexanoic acid (726 pmol, 189 mg), A1-(3-(dimethylamino)propyl)-A4, A4-bis(2-hexyldecyl)butane-l,4-diamine (398 pmol, 248 mg), DIPEA (853 pmol, 110 mg, 0.15 mL) and HATU (370 pmol, 141 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(dimethylamino)propyl)amino)-6-oxohexyl hexyl carbonate was 162 mg (66%).
[0831] 'H NMR (400 MHz, CDCh) 84.17 - 4.08 (m, 4H), 3.40 - 3.18 (m, 5H), 2.56 - 2.00 (m, 15H), 1.79 - 1.48 (m, 17H), 1.48 - 1.10 (m, 57H), 0.98 - 0.70 (m, 15H). ESI-MS: m / z calculated for C54H109N3O4 = 863.84, found [M+H]+= 865.14.
[0832] SYNTHETIC EXAMPLE 37
[0833] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-4- (ETHYL(PROPYL)AMINO)BUTANAMIDO)BUTANOATE (COMPOUND 1-58)
[0834]
[0835] Synthesis of tert-butyl 4-(4-chloro-7V-decylbutanamido)butanoate
[0836]
[0837] Zc / V-Butyl 4-(4-chloro-7V-decylbutanamido)butanoate was prepared from tert-butyl 4-(decylamino)butanoate (2.00 mmol, 600 mg), 4-chlorobutanoyl chloride (3.01 mmol, 424 mg, 334 pL), triethyl amine (6.01 mmol, 608 mg, 820 pL), and DMAP (20 pmol, 2 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification via flash chromatography (0% to 90% EtOAc in Hexanes) gave tert-butyl 4-(4-chloro-7V-decylbutanamido)butanoate (515 mg, 64%). ESI-MS: m / z calculated for C22H42NO3 = 403.29, found [M+H]+= 404.59.
[0838] Synthesis of tert-butyl 4-(7V-decyl-4-(ethyl(propyl)amino)butanamido)butanoate
[0839]
[0840] / crt-butyl 4-(A-decyl-4-(ethyl(propyl)amino)butanamido)butanoate was prepared from tert-butyl 4-(4-chloro-7V-decylbutanamido)butanoate (1.10 mmol, 445 mg), ethyl propylamine (6.61 mmol, 576 mg, 0.77 mL), potassium iodide (3.36 mmol, 557 mg) and DIPEA (3.3 mmol, 427 mg, 0.56 mL) in ACN (3.4 mL) by following the procedure for bis(2-hexyldecyl)amine. The yield of tert-butyl 4-(A-decyl-4-(ethyl(propyl)amino)butanamido)butanoate was 414 mg (83%). ESI-MS: m / z calculated for C27H54N2O3 = 454.41, found [M+H]+= 455.71.
[0841] Synthesis of 4-(7V-decyl-4-(ethyl(propyl)amino)butanamido)butanoic acid
[0842]
[0843] 4-(7V-Decyl-4-(ethyl(propyl)amino)butanamido)butanoic acid was prepared from tertbutyl 4-(7V-decyl-4-(ethyl(propyl)amino)butanamido)butanoate by following the procedure outlined for synthesis of 4-(7V-decyl-2-(dimethylamino)acetamido)butanoic acid. ESI-MS: m / z calculated for C23H46N2O3 = 398.35, found [M+H]+= 399.65.
[0844] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-( \-decyl-4-(ethyl(propyl)amino)butanamido)butanoate (Compound 1-58)
[0845]
[0846] To a solution of 4-(7V-decyl-4-(ethyl(propyl)amino)butanamido)butanoic acid (534 pmol, 213 mg), 3-(bis(2-hexyldecyl)amino)propan-l-ol (771 pmol, 404 mg), and DMAP (26.7 pmol, 3 mg) in DCM (5 mL) was added DCC (560 pmol, 116 mg). The reaction mixture was stirred at room temperature over night. Reaction mixture was diluted with hexanes (10 ml), filtered, concentrated, and purified via flash chromatography (0% to 90% EtOAc in Hexanes spiked with 1% EtsN) gave tert-butyl 4-(7V-decyl-4-(dipropylamino)butanamido)butanoate (78 mg, 16%).
[0847] 'HNMR (400 MHz, CDCh) 84.16 - 4.06 (m, 2H), 3.38 - 3.18 (m, 4H), 2.66 - 2.23 (m, 11H), 2.12 - 2.05 (m, 3H), 1.92 - 1.42 (m, 17H), 1.42 - 0.98 (m, 64H), 0.98 - 0.78 (m, 18H). ESIMS: m / z calculated for C58H117N3O3 = 903.91, found [M+H]+= 905.21.
[0848] SYNTHETIC EXAMPLE 38
[0849] SYNTHESIS OF 3-((4-(N-DECYL-3-(DIETHYLAMINO)PROPANAMIDO)BUTYL)(2- HEXYLDECYL)AMINO)PROPYL DECANOATE (COMPOUND 1-59)
[0850]
[0851] Synthesis of 2-hexyl-N-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)decan-l-amine
[0852]
[0853] 2-Hexyl-N-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)decan-l -amine was prepared from 2-hexyl-l-decanamine (7.84 mmol, 1.89 g), and 2-(3-chloropropoxy)tetrahydro-2H-pyran (5.60 mmol, 1.00 g), DIPEA (11.2 mmol, 1.96 mL, 1.45 g) and potassium iodide (5.71 mmol, 948 mg) in ACN (15.7 mL), following the procedure for the synthesis bis(2-hexyldecyl)amine. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN). The yield was 40% (850 mg). ESI-MS: m / z calculated for C24H49NO2 = 383.38, found [M+H]+= 384.58.
[0854] Synthesis of 4-(decylamino)-4-oxobutanoic acid
[0855]
[0856] Dihydrofuran-2, 5-dione (23.0 mmol, 2.3 g), and decylamine (24.1 mmol, 3.8 g) were dissolved in 20 mL THF and stirred at room temperature overnight. The solvent was removedunder vacuum and crude product further used as is. ESI-MS: m / z calculated for C14H27NO3 = 257.20, found [M+H]+= 258.43.
[0857] Synthesis of \1-decyl- \4-(2-hexyldecyl)- \4-(3-((tetrahydro-2 / / -pyran-2-yl)oxy)propyl)succinimide
[0858]
[0859] To 2-hexyl-N-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)decan-l -amine (2.53 mmol, 651mg), 4-(decylamino)-4-oxobutanoic acid (2.61 mmol, 1.00 g), and DIPEA (4.55 mmol, 588 mg, 795 pL) in DCM (10.0 mL), HATU (3.29 mmol, 1.25 g) was added in one portion. The reaction mixture was stirred for 1 h and then washed with saturated aqueous NaHCCh. The organic layer was separated, dried over anhydrous Na2SC>4 and concentrated. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave N1-decyl -N4-(2-hexyldecyl)-A4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)succinimide (1.5 g, 95%). ESI-MS: m / z calculated for C38H74N2O4 = 622.56, found [M+H]+= 622.86.
[0860] Synthesis of N1-decyl-N4-(2-hexyldecyl)-N4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)butane-1,4-diamine
[0861]
[0862] 7V1-decyl-A4-(2-hexyldecyl)-A4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)succinimide (2.53 mmol, 1.58 g) was dissolved in dry THF (20.00 mL), LAH (10.10 mmol, 384 mg) was added in one portion and the reaction mixture was refluxed overnight. After this time, reaction mixture was quenched with wet diethyl ether; anhydrous Na2SC>4 was added and mixture filtered.
[0863] Solvent was removed under vacuum to yield a crude 7V1-decyl-A4-(2-hexyldecyl)-A4-(3-((tetrahydro-2Z7-pyran-2-yl)oxy)propyl)butane-l,4-diamine (1.50 g, 99%) that was not purified further. ESI-MS: m / z calculated for C38H78N2O2 = 594.61, found [M+H]+= 595.89.
[0864] Synthesis of V-decyl-3-(diethyl:imino)- \-(4-((2-hexyldecyl)(3-((tetr:ihydro-2 / / -pyran-2-yl)oxy)propyl)amino)butyl)propanamide
[0865]
[0866] A-Decyl-3-(diethylamino)-A-(4-((2-hexyldecyl)(3-((tetrahydro-2J / -pyran-2-yl)oxy)propyl)amino)butyl)propanamide was prepared from A1-decyl-A4-(2-hexyldecyl)-A4-(3-((tetrahydro-2J / -pyran-2-yl)oxy)propyl)butane-l,4-diamine (1.27 mmol, 753 mg), 2-carboxy-N, N-diethylethan-l-aminium chloride (1.52 mmol, 276 mg), DIPEA (2.53 mmol, 327 mg, 442 pL) and HATU (1.65 mmol, 625 g) by following the procedure outlined for the synthesis of N1-decyl-A4-(2-hexyldecyl)-A4-(3-((tetrahydro-2J / -pyran-2-yl)oxy)propyl)succinimide. The yield was 650 mg (71%). ESI-MS: m / z calculated for C45H91N3O3 = 721.71, found [M+H]+= 722.99.
[0867] Synthesis of 7V-decyl-3-(diethylamino)-A-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)propanamide
[0868]
[0869] To N-decyl-3-(diethylamino)-N-(4-((2-hexyldecyl)(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)amino)butyl)propanamide (762 pmol, 550 mg) in DCM (10 mL), TFA (19.0 mmol, 2.17 g, 1.46 mL) was added. The reaction mixture was stirred at room temperature for 4 h and concentrated. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave A-decyl-3-(diethylamino)-A-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)propanamide (345 mg, 71%). ESI-MS: m / z calculated for C40H83N3O2 = 637.65, found [M+H]+= 638.90.
[0870] Synthesis of 3-((4-(7V-decyl-3-(diethylamino)propanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate (Compound 1-59)
[0871]
[0872] To a solution of 7V-decyl-3-(diethylamino)-7V-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)propanamide (293 pmol, 187 mg), decanoic acid (323 pmol, 56 mg) and DMAP (29.3 pmol, 4 mg) in DCM (5 mL) was added DCC (323 pmol, 66 mg). The reaction mixture was stirred at room temperature over night. Reaction mixture was diluted with hexanes (10 ml), filtered, concentrated, and purified via flash chromatography (0% to 100% EtOAc in Hexanes, spiked with 1% Et3N) and repurified via flash chromatography (SiCh column;
[0873] DCM / MeOH gradient) to give 3-((4-(7V-decyl-3-(diethylamino)propanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate. The yield was 135 mg (59%).
[0874] 'H NMR (400 MHz, CDCh) 64.13 - 4.05 (m, 2H), 3.33 - 3.17 (m, 4H), 2.86 - 2.78 (m, 2H), 2.61 - 2.44 (m, 6H), 2.43 - 2.23 (m, 6H), 2.17 - 2.09 (m, 2H), 1.77 - 1.43 (m, 11H), 1.43 -1.14 (m, 54H), 1.12 - 1.01 (t, J = 7.1 Hz, 6H), 0.93 - 0.81 (m, 12H). ESI-MS: m / z calculated for C50H101N3O3= 791.78, found [M+H]+= 793.11
[0875] SYNTHETIC EXAMPLE 39
[0876] SYNTHESIS OF 3-((4-(N-DECYL-3-(DIETHYLAMINO)PROPANAMIDO)BUTYL)(2- HEXYLDECYL)AMINO)PROPYL 4-ETHYLOCTANOATE (COMPOUND 1-60)
[0877]
[0878] Synthesis of 3-((4-(7V-decyl-3-(diethylamino)propanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate (Compound 1-60)
[0879]
[0880] 3-((4-(7V-Decyl-3-(diethylamino)propanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyl octanoate was prepared from 7V-decyl-3-(diethylamino)-7V-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)propanamide (293 pmol, 187 mg), 4-ethyloctanoic acid (323 pmol, 56 mg), DMAP (29.3 pmol, 4 mg) and DCC (323 pmol, 66 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash
[0881] chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% Et3N) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield was 90 mg (39%).
[0882] 'HNMR (400 MHz, CDCh) 64.13 - 4.03 (m, 2H), 3.32 - 3.17 (m, 4H), 2.86 - 2.78 (m, 2H), 2.61 - 2.51 (m, 4H), 2.51 - 2.43 (m, 2H), 2.43 - 2.37 (m, 2H), 2.37 - 2.30 (m, 2H), 2.30 -2.22 (m, 2H), 2.17 - 2.09 (m, 2H), 1.99 - 1.78 (m, 1H), 1.77 - 1.65 (m, 3H), 1.63 - 1.43 (m, 7H), 1.41 - 1.12 (m, 50H), 1.09 - 1.01 (m, 6H), 0.95 - 0.80 (m, 15H). ESI-MS: m / z calculated for C50H101N3O3= 791.78, found [M+H]+= 793.11.
[0883] SYNTHETIC EXAMPLE 40
[0884] SYNTHESIS OF 6-((4-(BIS(2-HEXYLDECYL)AMINO)BUTYL)(3-(DIETHYLAMINO)PROPYL)AMINO)- 6-OXOHEXYL HEXYL CARBONATE (COMPOUND 1-61)
[0885]
[0886] Synthesis of A^-(3-(diethylamino)propyl)- V4.\4bis(2-hexyldecyl)succinamide
[0887]
[0888] A1-(3-(Diethylamino)propyl)- N4, N4bis(2-hexyldecyl)succinamide was prepared from 4-(bis(2-hexyldecyl)amino)-4-oxobutanoic acid (1.58 mmol, 895 mg), DIPEA (3.92 mmol, 506 mg, 0.68 mL), A^A'-diethylpropane-l^-diamine (1.31 mmol, 170 mg, 0.21 mL) and HATU (1.96 mmol, 744 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave A1-(3-(diethylamino)propyl)- N4, N4bis(2-hexyldecyl)succinamide (580 mg, 65%). ESI-MS: m / z calculated for C43H87N3O2= 677.68, found [M+H]+= 678.97.
[0889] Synthesis of A^-(3-(diethylamino)propyl)- A4A4bis(2-hexyldecyl)butane -1,4-diamine
[0890]
[0891] A1-(3-(Diethylamino)propyl)- N4, N4bis(2-hexyldecyl)butane -1,4-diamine was prepared from A1-(3-(diethylamino)propyl)- A4, A4bis(2-hexyldecyl)succinamide (1.71 mmol, 1.16 mg), and LAH (8.54 mmol, 324 mg) in THF (34.0 mL) by following the procedure outlined for N1-decyl-N3, N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude A1-(3-(diethylamino)propyl)- A4, A4bis(2-hexyldecyl)butane -1,4-diamine was 463 mg (42%). ESI-MS: m / z calculated for C43H91N3 = 649.72, found [M+H]+= 651.02.
[0892] Synthesis of 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(diethylamino)propyl)amino)-6-oxohexyl hexyl carbonate (Compound 1-61)
[0893]
[0894] 6-((4-(Bis(2-hexyldecyl)amino)butyl)(3-(diethylamino)propyl)amino)-6-oxohexyl hexyl carbonate was prepared was prepared from A1-(3-(diethylamino)propyl)- N4, N4bis(2-hexyldecyl)butane -1,4-diamine (338 pmol, 220 mg), DIPEA (1.02 mmol, 131 mg, 0.18 mL), 6-(((hexyloxy)carbonyl)oxy)hexanoic acid (844 pmol, 220 mg) and HATU (508 pmol, 193 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(diethylamino)propyl)amino)-6-oxohexyl hexyl carbonate was 110 mg (36%).
[0895] 'H NMR (400 MHz, CDCh) 64.24 - 3.99 (m, 4H), 3.36 - 3.17 (m, 4H), 2.73 - 2.23 (m, 10H), 2.11 - 2.02 (m, 4H), 1.82 - 1.48 (m, 15H), 1.48 - 1.13 (m, 60H), 1.13 - 0.97 (m, 6H), 0.97 -0.78 (m, 15H). ESI-MS: m / z calculated for C56H113N3O4 = 891.87, found [M+H]+= 893.17.
[0896] SYNTHETIC EXAMPLE 41
[0897] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(4-(BUTYL(METHYL)AMINO)-N- DECYLBUTANAMIDO)BUTANOATE (COMPOUND 1-62)
[0898]
[0899] Synthesis of tert-butyl 4-(4-(benzyl(butyl)amino)-7V-decylbutanamido)butanoate
[0900]
[0901] tert-Butyl 4-(4-(benzyl(butyl)amino)-7V-decylbutanamido)butanoate was prepared from tert-butyl 4-(4-chloro-7V-decylbutanamido)butanoate (815 pmol, 329 mg), Y-benzylbutyl amine (1.98 mmol, 324 mg), DIPEA (2.44 mmol, 316 mg, 0.43 mL) and potassium iodide (2.44 mmol, 406 mg) by following the procedure outlined for bis(2-hexyldecyl)amine. Purification by flash column chromatography on silica gel (0-100% EtOAc in Hex spiked with 1% EtsN) gave tertbutyl 4-(4-(benzyl(butyl)amino)-7V-decylbutanamido)butanoate (454 mg). ESI-MS: m / z calculated for C33H58N2O3 = 530.44, found [M+H]+= 531.74.
[0902] Synthesis of tert-butyl 4-(4-(butylamino)-7V-decylbutanamido)butanoate
[0903]
[0904] A 100 mL round-bottom flask was charged with Pd / C (10% w / w; 91 mg) under argon, followed by tert-butyl 4-(4-(benzyl(butyl)amino)-7V-decylbutanamido)butanoate (856 pmol, 454 mg) in methanol (18 mL). The flask was purged with argon and then stirred under a positive pressure of hydrogen at room temperature overnight. The reaction mixture was filtered through a pad of diatomaceous earth (e.g., Celite®), concentrated under reduced pressure, and dried under high vacuum to afford crude tert-butyl 4-(4-(butylamino)-7V-decylbutanamido)butanoate (265 mg, 70%), which was carried forward without further purification. ESI-MS: m / z calculated for C26H52N2O3 = 440.40, found [M+H]+= 441.70.
[0905] Synthesis of tert-butyl 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoate
[0906]
[0907] tert-Butyl 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoate was prepared from tert-butyl 4-(4-(butylamino)-7V-decylbutanamido)butanoate (600 pmol, 264 mg), formaldehyde (37% w / v solution in water; 12.00 mmol, 974 pL) and STAB (3.0 mmol, 636 mg) in methanol (4.0 mL) by following the procedure outlined for bis(2-hexyldecyl)amine. Purification by flash column chromatography on silica gel (0-100% EtOAc in Hex spiked with 1% EtsN) gave tertbutyl 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoate (203 mg, 74%). ESI-MS: m / z calculated for C27H54N2O3 = 454.41, found [M+H]+= 455.71.
[0908] Synthesis of 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoic acid
[0909]
[0910] To Zc / V-butyl 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoate (438 pmol, 199 mg) in DCM (5 mL), TFA (8.75 mmol, 998 mg, 670 pL) was added. The reaction mixture was stirred at room temperature overnight and concentrated to give crude 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoic acid. ESI-MS: m / z calculated for C23H46N2O3 = 398.35, found [M+H]+= 399.65
[0911] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoate (Compound 1-62)
[0912]
[0913] 3-(Bis(2-hexyldecyl)amino)propyl 4-(4-(butyl(methyl)amino)-V-decylbutanamido)butanoate was prepared from 3-(bis(2-hexyldecyl)amino)propan-l-ol (641 pmol, 336 mg), 4-(4-(butyl(methyl)amino)-7V-decylbutanamido)butanoic acid (436 pmol, 174 mg), DMAP (44 pmol, 5 mg) and DCC (480 pmol, 99 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiC>2 column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield was 25 mg (6%).
[0914] 'HNMR (400 MHz, CDCh) 84.15 - 4.07 (m, 2H), 3.38 - 3.18 (m, 5H), 2.47 - 2.17 (m, 13H), 2.17 - 1.99 (m, 4H), 1.96 - 1.79 (m, 4H), 1.76 - 1.05 (m, 82H), 0.95 - 0.83 (m, 18H). ESIMS: m / z calculated for C58H117N3O3 = 903.91, found [M+H]+= 905.21.
[0915] SYNTHETIC EXAMPLE 42
[0916] SYNTHESIS OF HEXYL 6-((4-(BIS(2-HEXYLDECYL)AMINO)BUTYL)(3- (DIETHYLAMINO)PROPYL)AMINO)-6-OXOHEXANOATE (COMPOUND 1-63)
[0917]
[0918] Synthesis of 6-(hexyloxy)-6-oxohexanoic acid
[0919]
[0920] 6-(Hexyloxy)-6-oxohexanoic acid was prepared from adipic acid (29.4 mmol, 4.29 g), 1-hexanol (29.4 mmol, 3.00 g), DMAP (2.94 mmol, 359 mg) and DCC (29.4 mmol, 6.1 g) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield was 2.2 g (33%). ESI-MS: m / z calculated for C12H22O4 = 230.15, found [M+H]+= 231.45.
[0921] Synthesis of hexyl 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(diethylamino)propyl)amino)-6-oxohexanoate (Compound 1-63)
[0922]
[0923] Hexyl 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(diethylamino)propyl)amino)-6-oxohexanoate was prepared from 6-(hexyloxy)-6-oxohexanoic acid (619 pmol, 143 mg), DIPEA (715 pmol, 92 mg, 125 pL), A1-(3-(diethylamino)propyl)- N4,N4bis(2-hexyldecyl)butane -1,4-diamine (238 pmol, 155 mg) and HATU (404 pmol, 154 mg) by following the procedure outlined for A1-decyl-A4, A4-bis(2-hexyldecyl)succinamide. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of hexyl 6-((4-(bis(2-hexyldecyl)amino)butyl)(3-(diethylamino)propyl)amino)-6-oxohexanoate was 63 mg (31%).
[0924] 'HNMR (400 MHz, CDCh) 64.09 - 4.01 (t, J = 6.8 Hz, 2H), 3.37 - 3.18 (m, 4H), 2.65 -2.22 (m, 11H), 2.11 - 2.04 (t, J = 6.0, 4H), 1.82 - 1.44 (m, 17H), 1.44 - 0.97 (m, 61H), 0.97 -0.81 (m, 15H). ESI-MS: m / z calculated for C55H111N3O3 = 861.86, found [M+H]+= 863.16.
[0925] SYNTHETIC EXAMPLE 43
[0926] SYNTHESIS OF 3-((4-(N-DECYL-4-(ETHYL(PROPYL)AMINO)BUTANAMIDO)BUTYL)(2- HEXYLDECYL)AMINO)PROPYL 4-ETHYLOCTANOATE (COMPOUND 1-64)
[0927]
[0928] Synthesis of 4-chloro-7V-decyl-7V-(4-((2-hexyldecyl)(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)amino)butyl)butanamide
[0929]
[0930] 4-Chloro-A-decyl-A-(4-((2-hexyldecyl)(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)amino)butyl)butanamide was prepared from A1-decyl-A4-(2-hexyldecyl)-A4-(3-((tetrahydro-27 / -pyran-2-yl)oxy)propyl)butane-l,4-diamine (1.29 mmol, 770 mg), 4-chlorobutanoyl chloride (1.42 mmol, 201 mg, 160 pL), triethyl amine (3.24 mmol, 327 mg, 558 pL), and DMAP (129 pmol, 16 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification via flash chromatography (0% to 90% EtOAc in Hexanesspiked with 1% EtsN) gave 4-chloro-A-decyl-A-(4-((2-hexyldecyl)(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)amino)butyl)butanamide (800 mg, 88%). ESI-MS: m / z calculated for C42H83CIN2O3 = 698.61, found [M+H]+= 699.91.
[0931] Synthesis of 4-chloro-7V-decyl-7V-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)butanamide
[0932]
[0933] To 4-chloro-A-decyl-A-(4-((2-hexyldecyl)(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)amino)butyl)butanamide (1.14 mmol, 800 mg) in DCM (2 mL), TFA (11.4 mmol, 1.3 g, 2.7 mL) was added. The reaction mixture was stirred at room temperature for 4 h and concentrated. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave 4-chloro-A-decyl-A-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)butanamide (160 mg, 22%). ESI-MS: m / z calculated for C37H75N2O2 = 614.55, found [M+H]+= 615.85.
[0934] Synthesis of 3-((4-(4-chloro-7V-decylbutanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate
[0935]
[0936] 3-((4-(4-Chloro-7V-decylbutanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate was prepared from 4-chloro-7V-decyl-7V-(4-((2-hexyldecyl)(3-hydroxypropyl)amino)butyl)butanamide (244 pmol, 150 mg), 4-ethyloctanoic acid (609 pmol, 105 mg), DMAP (24.4 pmol, 3 mg) and DCC (609 pmol, 126 mg) by following the procedure outlined for compound 1-58. Purification via flash chromatography (0% to 100% EtOAc in Hexanes spiked with 1% EtsN) gave 3-((4-(4-chloro-7V-decylbutanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate (125 mg, 66%). ESI-MS: m / z calculated for C47H93CIN2O3 = 768.69, found [M+H]+= 769.99.
[0937] Synthesis of 3-((4-(7V-decyl-4-(ethyl(propyl)amino)butanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate (Compound 1-64)
[0938]
[0939] 3-((4-(A-Decyl-4-(ethyl(propyl)amino)butanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyl octanoate was prepared from 3-((4-(4-chloro-A-decylbutanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate (162 pmol, 125 mg), ethyl propylamine (1.14 mmol, 99 mg) and potassium iodide (179 pmol, 30 mg) in ACN (2.3 mL) by following the procedure for bis(2-hexyldecyl)amine. Purification of the crude product was done via flash chromatography with Hexanes / EtOAc (spiked with 1% EtsN) gradient. The yield of 3-((4-(A-decyl-4-(ethyl(propyl)amino)butanamido)butyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate was 90 mg (68%).
[0940] 'HNMR (400 MHz, CDCh) 64.13 - 4.05 (m, 2H), 3.33 - 3.16 (m, 4H), 2.57 - 2.22 (m, 14H), 2.17 - 2.09 (m, 2H), 1.87 - 1.11 (m, 66H), 1.05 - 0.97 (t, J = 7.1 Hz, 3H), 0.94 - 0.75 (m, 18H). ESI-MS: m / z calculated for C52H105N3O3 = 819.82, found [M+H]+= 821.12.
[0941] SYNTHETIC EXAMPLE 44
[0942] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-3- (ETHYL(PROPYL)AMINO)PROPANAMIDO)BUTANOATE (COMPOUND 1-65)
[0943]
[0944] Synthesis of tert-butyl 4-(3-chloro-7V-decylpropanamido)butanoate
[0945]
[0946] te / 7-Butyl 4-(3-chloro-A-decylpropanamido)butanoate was prepared from te / 7-butyl 4-(decylamino)butanoate (2.52 mmol, 756 mg), 3-chloropropanoyl chloride (3.53 mmol, 449 mg), triethyl amine (7.56 mmol, 1.06 mL), and DMAP (25 pmol, 3 mg) by following the procedure outlined for 3-bromo-A, A-bis(2-hexyldecyl)propanamide. Purification via flash chromatography (0% to 20% EtOAc in Hexanes) gave mixture of tert-butyl 4-(3-chloro-A-decylpropanamido)butanoate and tert-butyl 4-(7V-decylacrylamido)butanoate (670 mg combined yield) that was forwarded further without any additional treatment. ESI-MS: m / z calculated for C21H40CINO3 = 389.27, found [M+H]+= 390.57; m / z calculated for C21H39NO3 = 353.29, found [M+H]+= 354.59.
[0947] Synthesis of tert-butyl 4-(7V-decyl-3-(ethyl(propyl)amino)propanamido)butanoate
[0948]
[0949]
[0950] Microwave, 140 °C, 30 min
[0951]
[0952] / crt-Butyl 4-(A-decyl-3-(ethyl(propyl)amino)propanamido)butanoate was prepared from tert-butyl 4-(3-chloro-7V-decylpropanamido)butanoate (1.84 mmol, 650 mg), A-ethylpropylamine (11.00 mmol, 962 mg, 1.29 mL) and DIPEA (3.68 mmol, 475 mg, 0.64 mL) by following the procedure outlined for bis(2-hexyldecyl)amine. Purification by flash column chromatography on silica gel (0-100% EtOAc in Hex spiked with 1% EtsN) gave tert-butyl 4-(A-decyl-3-(ethyl(propyl)amino)propanamido)butanoate (648 mg, 89%). ESI-MS: m / z calculated for C26H52N2O3 = 440.40, found [M+H]+= 441.70.
[0953] Synthesis of 4-(7V-decyl-3-(ethyl(propyl)amino)propanamido)butanoic acid
[0954]
[0955] To Zc / V-butyl 4-(7V-decyl-3-(ethyl(propyl)amino)propanamido)butanoate (1.47 mmol, 648 mg) in DCM (7.35 mL), TFA (20.3 mmol, 2.31 g, 1.55 mL) was added. The reaction mixture was stirred at room temperature overnight and concentrated to give crude 4-(7V-decyl-3-(ethyl(propyl)amino)propanamido)butanoic acid. ESI-MS: m / z calculated for C22H44N2C>3 = 384.34, found [M+H]+= 385.84.
[0956] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-( \-decyl-3-(ethyl(propyl)amino)propanamido)butanoate (Compound 1-65)
[0957]
[0958] 3 -(Bi s(2-hexyldecyl)amino)propyl 4-(7V -decyl-3 -(ethyl(propyl)amino)propanamido)butanoate was prepared from 4-(7V-decyl-3-(ethyl(propyl)amino)propanamido)butanoic acid (796 pmol, 306 mg), 3-(bis(2-hexyldecyl)amino)propan-l-ol (962 pmol, 504 mg), DMAP (80 pmol, 10 mg) and DCC (2.06 mmol, 425 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 3-(bis(2-hexyldecyl)amino)propyl 4-(7V-decyl-3-(ethyl(propyl)amino)propanamido)butanoate was 78 mg (11%).
[0959] 'H NMR (400 MHz, CDCh) 84.16 - 4.06 (m, 2H), 3.38 - 3.19 (m, 4H), 2.88 - 2.69 (s, 2H), 2.69 - 2.25 (m, 10H), 2.13 - 2.01 (m, 4H), 1.97 - 1.77 (m, 2H), 1.77 - 1.64 (m, 2H), 1.64 -1.43 (s, 12H), 1.43 - 0.99 (m, 65H), 0.99 - 0.79 (m, 18H). ESI-MS: m / z calculated for C57H115N3O3 = 889.89, found [M+H]+= 891.29
[0960] SYNTHETIC EXAMPLE 45
[0961] SYNTHESIS OF CIS-3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-3- (DIMETHYLAMINO)CYCLOBUTANE-1-CARBOXAMIDO)BUTANOATE (COMPOUND 1-66)
[0962]
[0963] Synthesis of tert-butyl cs-4-(7V-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoate
[0964]
[0965] tert-Butyl czA-4-(7V-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoate was prepared from tert-butyl 4-(decylamino)butanoate (698 pmol, 209 mg), cz -3 -carboxy -N, N-dimethylcyclobutan-l-aminium chloride (852 pmol, 153 mg), DIPEA (2.09 mmol, 271 mg, 365 pL), and HATU (977 pmol, 372 mg) by following the procedure outlined for A1-decyl- A4, A4-bis(2-hexyldecyl)succinamide. Purification via flash chromatography (0% to 80% EtOAc in Hexanes spiked with 1% EtsN) gave mixture of tert-butyl cz.s-4-(A-decyl-3-
[0966] (dimethylamino)cyclobutane-l-carboxamido)butanoate (192 mg, 65%). ESI-MS: m / z calculated for C25H48N2O3 = 424.37, found [M+H]+= 425.67.
[0967] Synthesis of czs-4-(7V-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoic acid
[0968]
[0969] To Zc / V-butyl cz -4-(7V-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoate
[0970] (466 pmol, 198 mg) in DCM (2.33 mL), TFA (9.32 mmol, 1.06 g, 714 pL) was added. The reaction mixture was stirred at room temperature overnight and concentrated to give crude cis-4-(7V-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoic acid. ESI-MS: m / z calculated for C21H40N2O3 = 368.30, found [M+H]+= 369.60.
[0971] Synthesis of cis-3-(bis(2-hexyldecyl)amino)propyl 4-( \-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoate (Compound 1-66)
[0972]
[0973] A mixture of cA-4-(A-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoic acid (466 pmol, 172 mg), 3-(bis(2-hexyldecyl)amino)propan-l-ol (706 pmol, 370 mg), DMAP (93 pmol, 11 mg), DIPEA (932 pmol, 121 mg, 162 pL) and EDCI (932 pmol, 179 mg) in DCM (5 mL) was stirred at room temperature over night. After that, the solvent was removed under the reduced pressure, and the crude mixture partitioned between saturated aqueous NaHCCh and EtOAc. Organic phase was washed with 10 mL of saturated brine and dried over anhydrous Na2SO4. The solids were filtered off, and the solvent removed under the reduced pressure. The crude product was purified via flash chromatography (SiO2 column; HexanesZEtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiO2 column; DCM / MeOH gradient). The yield of cA-3-(bis(2-hexyldecyl)amino)propyl 4-(A-decyl-3-(dimethylamino)cyclobutane-l-carboxamido)butanoate was 63 mg (15%).
[0974] 'HNMR (400 MHz, CDCI3) 84.17 - 4.05 (m, 2H), 3.35 - 3.07 (m, 5H), 2.90 - 2.62 (m, 3H), 2.53 - 2.15 (m, 14H), 2.15 - 2.03 (m, 4H), 1.95 - 1.77 (m, 3H), 1.77 - 1.44 (m, 12H), 1.44 -1.09 (m, 65H), 0.92 - 0.82 (m, 15H). ESI-MS: m / z calculated for C56H111N3O3 = 873.86, found [M+H]+= 875.16.
[0975] SYNTHETIC EXAMPLE 46
[0976] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(DECYL(3- (ETHYL(PROPYL)AMINO)PROPYL)AMINO)-4-OXOBUTANOATE (COMPOUND 1-67)
[0977]
[0978] Synthesis of 3-chloro-A-decylpropanamide
[0979]
[0980] 3-Chloro-A-decylpropanamide was prepared from decylamine (21.0 mmol, 3.3 g), 3-chloropropanoyl chloride (24.1 mmol, 3.06 g, 2.3 mL), triethyl amine (62.9 mmol, 6.37 g, 8.6 mL), and DMAP (2.1 mmol, 256 mg) by following the procedure outlined for 3-bromo-7V,7V-bis(2-hexyldecyl)propanamide. Purification via flash chromatography (0% to 50% EtOAc in Hexanes) gave mixture of 3-chloro-7V-decylpropanamide and 7V-decylacrylamide (4.3 g combined yield) that was forwarded further without any additional treatment. ESI-MS: m / z calculated for C13H26CINO = 247.17, found [M+H]+= 248.47; m / z calculated for C13H25NO = 211.19, found [M+H]+= 212.49.
[0981] Synthesis of 7V-decyl-3-(ethyl(propyl)amino)propanamide
[0982]
[0983] 7V-decyl-3-(ethyl(propyl)amino)propanamide was prepared from 3-chloro-M decylpropanamide (4.76 mmol, 1.18 g), Methyl propan-l -amine (9.52 mmol, 830 mg), potassium iodide (4.76 mmol, 790 mg) and DIPEA (9.52 mmol, 1.23 g, 1.66 mL) by following the procedure outlined for bis(2-hexyldecyl)amine. The yield of -decyl-3-(ethyl(propyl)amino)propanamide was 900 mg (64%). ESI-MS: m / z calculated for C18H38N2O = 298.30, found [M+H]+= 299.60.
[0984] Synthesis of A^-decyl-A^-ethyl-A^-propylpropane-l^-diamine
[0985]
[0986] 7V1-Decyl-7V3-ethyl-7V3-propylpropane-l,3-diamine was prepared from 7V-decyl-3-(ethyl(propyl)amino)propanamide (11.7 mmol, 3.5 g), and LAH (46.9 mmol, 1.78 g) in dry THF (100 mL) by following the procedure outlined for N1-decyl-N3,N3-bis(2-hexyldecyl)propane-1,3-diamine. The yield of the crude 7V1-Decyl-7V3-ethyl-7V3-propylpropane-l,3-diamine was 2.68 g (80%). ESI-MS: m / z calculated for C18H40N2 = 284.32, found [M+H]+= 285.64.
[0987] Synthesis of 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoic acid
[0988]
[0989] Dihydrofuran-2, 5-dione (1.50 mmol, 150 mg) andTV^decyl- ^-ethyl-TV’-propylpropane-1,3-diamine (1.57 mmol, 448 mg) were dissolved in 5 mL THF and stirred at room temperature overnight. The solvent was removed under vacuum to give crude 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoic acid, further used as is. ESI-MS: m / z calculated for C22H44N2O3 = 384.34, found [M+H]+= 385.64.
[0990] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoate (Compound 1-67)
[0991]
[0992] 3-(Bis(2-hexyldecyl)amino)propyl 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoate was prepared from 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoic acid (588 pmol, 226 mg), 3-(bis(2-hexyldecyl)amino)propan-l-ol (646 pmol, 339 mg), DMAP (59 pmol, 7 mg) and DCC (646 pmol, 133 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiC>2 column; DCM / MeOH gradient). The yield of 3-(bis(2-hexyldecyl)amino)propyl 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoate was 160 mg (31%).
[0993] 'HNMR (400 MHz, CDCh) 64.18 - 4.02 (m, 2H), 3.46 - 3.20 (m, 4H), 2.89 - 2.51 (m, 8H), 2.51 - 2.31 (m, 4H), 2.12 - 1.99 (m, 4H), 1.99 - 1.44 (m, 10H), 1.44 - 0.99 (m, 68H), 0.99 -0.74 (m, 18H). ESI-MS: m / z calculated for C57H115N3O3 = 889.89, found [M+H]+= 891.19.
[0994] SYNTHETIC EXAMPLE 47
[0995] SYNTHESIS OF 2-(BIS(2-HEXYLDECYL)AMINO)ETHYL 4-(DECYL(3- (ETHYL(PROPYL)AMINO)PROPYL)AMINO)-4-OXOBUTANOATE (COMPOUND 1-68)
[0996]
[0997] Synthesis of 2-(bis(2-hexyldecyl)amino)ethan-l-ol
[0998]
[0999] 2-(Bis(2-hexyldecyl)amino)ethan-l-ol was prepared from 7-(bromomethyl)pentadecane (13.1 mmol, 4.00 g), 2-amino-l -ethanol (7.5 mmol, 460 mg), and DIPEA (19.6 mmol, 2.54 g, 3.43 mL) by following the procedure outlined for bis(2-hexyldecyl)amine. The yield of 2-(bis(2-hexyldecyl)amino)ethan-l-ol was 750 mg (22%). ESI-MS: m / z calculated for C34H71NO = 509.55, found [M+H]+= 510.85.
[1000] Synthesis of 2-(bis(2-hexyldecyl)amino)ethyl 4-(decyl(3- (ethyl(propyl)amino)propyl)amino)-4-oxobutanoate (Compound 1-68)
[1001]
[1002] 2-(Bis(2-hexyldecyl)amino)ethyl 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoate was prepared from 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoic acid (569 pmol, 219 mg), 2-(bis(2-hexyldecyl)amino)ethan-l-ol (626 pmol, 319 mg), DMAP (57 pmol, 7 mg) and DCC (626 pmol, 129 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 2-(bis(2-hexyldecyl)amino)ethyl 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoate was 100 mg (20%).
[1003] 'HNMR (400 MHz, CDCh) 64.92 - 4.79 (m, 2H), 3.68 - 3.09 (m, 7H), 2.91 - 2.37 (m, 9H), 2.37 - 2.18 (m, 5H), 1.84 - 1.37 (m, 19H), 1.37 - 0.98 (m, 49H), 0.98 - 0.74 (m, 18H). ESIMS: m / z calculated for C56H113N3O3 = 875.88, found [M+H]+= 877.18.
[1004] SYNTHETIC EXAMPLE 48
[1005] SYNTHESIS OF 3-(BIS(2-HEXYLDECYL)AMINO)PROPYL 4-(N-DECYL-4-(HEXAHYDROCYCLOPENTA[C]PYRROL-2(1H)-YL)BUTANAMIDO)BUTANOATE (COMPOUND 1-74)
[1006]
[1007] Synthesis of 3-(bis(2-hexyldecyl)amino)propyl 4-(\-decyl-4- (hexahydrocyclopenta[c]pyrrol-2(lH)-yl)butanamido)butanoate (Compound 1-74)
[1008]
[1009] 3-(Bis(2-hexyldecyl)amino)propyl 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(177)-yl)butanamido)butanoate was prepared from 3-(bis(2-hexyldecyl)amino)propan-l-ol (447 pmol, 234 mg), 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(177)-yl)butanamido)butanoic acid (373pmol, 200 mg), DMAP (37 pmol, 5 mg) and DCC (373 pmol, 77 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 3-(bis(2-hexyldecyl)amino)propyl 4-(V-decyl-4-(hexahydrocyclopenta[c]pyrrol -2(177)-yl)butanamido)butanoate was 180 mg (52%).
[1010] 'HNMR (400 MHz, CDCh) 84.16 - 4.06 (m, 2H), 3.38 - 3.19 (m, 4H), 2.84 - 2.65 (m, 2H), 2.63 - 2.47 (s, 2H), 2.44 - 2.23 (m, 8H), 2.17 - 1.99 (m, 6H), 1.90 - 1.77 (m, 4H), 1.78 - 1.44 (m, 11H), 1.44 - 1.08 (m, 66H), 0.97 - 0.79 (m, 15H). ESI-MS: m / z calculated for C60H117N3O3 = 927.91, found [M+H]+= 929.21.
[1011] SYNTHETIC EXAMPLE 49
[1012] SYNTHESIS OF 8-DECYL-4-ETHYL-17-(2-HEXYLDECYL)-9,12-DIOXO-13-OXA-4,8,17- TRIAZAICOSAN-20-YL 4-ETHYLOCTANOATE (COMPOUND 1-80)
[1013]
[1014] Synthesis of 8-decyl-4-ethyl-17-(2-hexyldecyl)-9,12-dioxo-13-oxa-4,8,17-triazaicosan-20-yl
[1015] 4-ethyloctanoate (Compound 1-80)
[1016]
[1017] 8-Decyl-4-ethyl-17-(2-hexyldecyl)-9,12-dioxo-13-oxa-4,8,17-triazaicosan-20-yl 4-ethyl octanoate was prepared from 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl 4-ethyl octanoate (589 pmol, 302 mg), 4-(decyl(3-(ethyl(propyl)amino)propyl)amino)-4-oxobutanoic acid (536 pmol, 206 mg), DMAP (54 pmol, 7 mg) and DCC (536 pmol, 111 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 8-decyl-4-ethyl-17-(2-hexyldecyl)-9,12-dioxo-13-oxa-4,8,17-triazaicosan-20-yl 4-ethyloctanoate was 80 mg (17%).
[1018] 'HNMR (400 MHz, CDCh) 64.15 - 4.05 (m, 4H), 3.36 - 3.20 (m, 4H), 2.70 - 2.56 (m, 4H), 2.56 - 2.31 (m, 10H), 2.31 - 2.22 (m, 2H), 2.18 - 2.07 (m, 2H), 1.82 - 1.36 (m, 16H), 1.37 -1.13 (m, 49H), 1.03 - 0.95 (m, 3H), 0.91 - 0.76 (m, 18H). ESI-MS: m / z calculated for C54H107N3O5 = 877.82, found [M+H]+= 879.12.
[1019] SYNTHETIC EXAMPLE 50
[1020] SYNTHESIS OF 7-DECYL-3-ETHYL-16-(2-HEXYLDECYL)-6,11-DIOXO-12-OXA-3,7,16- TRIAZANONADECAN-19-YL 4-ETHYLOCTANOATE (COMPOUND 1-81)
[1021]
[1022] Synthesis of 7-decyl-3-ethyl-16-(2-hexyldecyl)-6,ll-dioxo-12-oxa-3,7,16-triazanonadecan-19-yl 4-ethyloctanoate (Compound 1-81)
[1023]
[1024] 7-Decyl-3 -ethyl- 16-(2-hexyldecyl)-6, 11 -di oxo- 12-oxa-3,7, 16-tri azanonadecan- 19-yl 4-ethyl octanoate was prepared from 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl 4-ethyl octanoate (589 pmol, 302 mg), 4-(7V-decyl-3-(diethylamino)propanamido)butanoic acid (536 pmol, 198 mg), DMAP (54 pmol, 7 mg) and DCC (536 pmol, 111 mg) by following the
[1025] procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 7-decyl-3-ethyl-16-(2-hexyldecyl)-6,ll-dioxo-12-oxa-3,7,16-triazanonadecan-19-yl 4-ethyloctanoate was 150 mg (32%).
[1026] 'HNMR (400 MHz, CDCh) 64.25 - 4.04 (m, 4H), 3.38 - 3.19 (m, 4H), 2.85 - 2.76 (m, 2H), 2.59 - 2.35 (m, 10H), 2.35 - 2.22 (m, 4H), 2.18 - 2.11 (m, 2H), 1.89 - 1.79 (m, 2H), 1.79 -1.65 (m, 4H), 1.65 - 1.47 (m, 7H), 1.47 - 1.15 (m, 48H), 1.08 - 1.00 (m, 6H), 0.93 - 0.81 (m, 15H). ESI-MS: m / z calculated for C53H105N3O5 = 863.81, found [M+H]+= 865.11.
[1027] SYNTHETIC EXAMPLE 51
[1028] SYNTHESIS OF 3-((3-((4-(N-DECYL-4-(HEXAHYDROCYCLOPENTA[C]PYRROL-2(1H)- YL)BUTANAMIDO)BUTANOYL)OXY)PROPYL)(2-HEXYLDECYL)AMINO)PROPYL DECANOATE
[1029] (COMPOUND 1-82)
[1030]
[1031] Synthesis of 3-chloropropyl decanoate
[1032]
[1033] 3 -chloropropyl decanoate was prepared from 3 -chloro- 1 -propanol (62.7 mmol, 5.93 g), decanoic acid (52.2 mmol, 9.00 g), DMAP (5.22 mmol, 638 mg) and DCC (54.9 mmol, 11.30 g) by following the procedure outlined for compound 1-58. Purification via flash chromatography (0% to 20% EtOAc in Hexanes) gave 3 -chloropropyl decanoate (12 g, 92%). ESI-MS: m / z calculated for C13H25CIO2 = 248.15, found [M+H]+= 249.45.
[1034] Synthesis of 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl decanoate
[1035]
[1036] 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl decanoate was prepared from 3-((2-hexyldecyl)amino)propan-l-ol (5.97 mmol, 1.79 g), 3 -chloropropyl decanoate (4.42 mmol, 1.10 g), potassium iodide (4.42 mmol, 734 mg) and DIPEA (8.84 mmol, 1.14 g, 1.54 mL) by following the procedure outlined for bis(2-hexyldecyl)amine. The yield of 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl decanoate was 1.7 g (75%). ESI-MS: m / z calculated for C32H65NO3 = 511.50, found [M+H]+= 512.80.
[1037] Synthesis of 3-((3-((4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(LH)-yl)butanamido)butanoyl)oxy)propyl)(2-hexyldecyl)amino)propyl decanoate (Compound I-82)
[1038]
[1039] 3-((3-((4-(7V-Decyl-4-(hexahydrocyclopenta[c]pyrrol-2(U7)-yl)butanamido)butanoyl)oxy)propyl)(2-hexyldecyl)amino)propyl decanoate was prepared from 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(U7)-yl)butanamido)butanoic acid (373 pmol, 200 mg), 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl decanoate (447 pmol, 229 mg), DMAP (37 pmol, 5 mg) and DCC (373 pmol, 77 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 3-((3-((4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(U7)-yl)butanamido)butanoyl)oxy)propyl)(2-hexyldecyl)amino)propyl decanoate was 240 mg (70%).
[1040] 'H NMR (400 MHz, CDCh) 84.16 - 4.05 (m, 4H), 3.38 - 3.19 (m, 4H), 2.81 - 2.65 (s, 2H), 2.65 - 2.49 (s, 2H), 2.46 - 2.23 (m, 12H), 2.23 - 1.96 (m, 4H), 1.94 - 1.36 (m, 21H), 1.36 -1.11 (m, 50H), 0.94 - 0.76 (m, 12H). ESI-MS: m / z calculated for C57H109N3O5 = 915.84, found [M+H]+= 917.14.
[1041] SYNTHETIC EXAMPLE 52
[1042] SYNTHESIS OF 3-((3-((4-(N-DECYL-4-(HEXAHYDROCYCLOPENTA[C]PYRROL-2(1H)- YL)BUTANAMIDO)BUTANOYL)OXY)PROPYL)(2-HEXYLDECYL)AMINO)PROPYL 4- ETHYLOCTANOATE (COMPOUND 1-83)
[1043]
[1044] Synthesis of 3-chloropropyl 4-ethyloctanoate
[1045] Chloropropyl 4-ethyloctanoate was prepared from 3 -chloro- 1 -propanol (42.3 mmol, 4.00 g), 4-ethyloctanoic acid (35.3 mmol, 6.08 g), DMAP (3.5 mmol, 431mg) and DCC (37.0 mmol, 7.64 g) by following the procedure outlined for compound 1-58. Purification via flash chromatography (0% to 20% EtOAc in Hexanes) gave 3-chloropropyl 4-ethyloctanoate (8.0 g, 91%). ESI-MS: m / z calculated for C13H25CIO2 = 248.15, found [M+H]+= 249.45.
[1046] Synthesis of tert-butyl 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(lH)-yl)butanamido)butanoate
[1047]
[1048] / c / V-Butyl 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(lrt)-yl)butanamido)butanoate was prepared from octahydrocyclopenta[c]pyrrole (9.28 mmol, 1.03 g), tert-butyl 4-(4-chloro-7V-decylbutanamido)butanoate (3.09 mmol, 1.25 g) and potassium iodide (3.09 mmol, 514 mg) by following the procedure outlined for bis(2-hexyldecyl)amine. The yield of tert-butyl 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(lrt)-yl)butanamido)butanoate was 900 mg (61%). ESI-MS: m / z calculated for C29H54N2O3 = 478.41, found [M+H]+= 479.71.
[1049] Synthesis of 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(lH)-yl)butanamido)butanoic acid
[1050]
[1051] To tert-butyl 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(lrt)-yl)butanamido)butanoate (1.88 mmol, 900 mg) in DCM (5.00 mL), TFA (37.6 mmol, 4.29 g, 2.88 mL) was added. The reaction mixture was stirred at room temperature overnight and concentrated to give crude 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(lrt)-yl)butanamido)butanoic acid. ESI-MS: m / z calculated for C25H46N2O3 = 422.35, found [M+H]+= 423.65.
[1052] Synthesis of 3-((2-hexyldecyl)amino)propan-l-ol
[1053]
[1054] 3-((2-Hexyldecyl)amino)propan-l-ol was prepared from 7-(bromomethyl)pentadecane (16.4 mmol, 5.00 g) and 3 -amino- 1 -propanol (49.1 mmol, 3.69 g) by following the procedure outlined for bis(2-hexyldecyl)amine. The yield of 3-((2-hexyldecyl)amino)propan-l-ol was 2.4 g (49%). ESI-MS: m / z calculated for C32H65NO3 = 299.32, found [M+H]+= 300.62.
[1055] Synthesis of 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl 4-ethyloctanoate
[1056]
[1057] 3-((2-Hexyldecyl)(3-hydroxypropyl)amino)propyl 4-ethyloctanoate was prepared from 3-((2-hexyldecyl)amino)propan-l-ol (5.43 mmol, 1.63 g), 3 -chloropropyl 4-ethyloctanoate (4.02 mmol, 1.00 g), potassium iodide (4.02 mmol, 667 mg) and DIPEA (8.04 mmol, 1.04 g, 1.4 mL) by following the procedure outlined for bis(2-hexyldecyl)amine. The yield of 2-(bis(2-hexyldecyl)amino)ethan-l-ol was 1.7 g (83%). ESI-MS: m / z calculated for C32H65NO3 = 511.50, found [M+H]+= 512.80.
[1058] Synthesis of 3-((3-((4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(LH)-yl)butanamido)butanoyl)oxy)propyl)(2-hexyldecyl)amino)propyl 4-ethyloctanoate (Compound 1-83)
[1059]
[1060] 3-((3-((4-(7V-Decyl-4-(hexahydrocyclopenta[c]pyrrol-2(U7)-yl)butanamido)butanoyl)oxy)propyl)(2-hexyldecyl)amino)propyl 4 -ethyl octanoate was prepared from 4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(U7)-yl)butanamido)butanoic acid (373 pmol, 200 mg), 3-((2-hexyldecyl)(3-hydroxypropyl)amino)propyl 4 -ethyl octanoate (447 pmol, 229 mg), DMAP (37 pmol, 5 mg) and DCC (373 pmol, 77 mg) by following the procedure outlined for the synthesis of compound 1-59. The crude product was purified via flash chromatography (SiCh column; Hexanes / EtOAc gradient spiked with 1% EtsN) and repurified via flash chromatography (SiCh column; DCM / MeOH gradient). The yield of 3-((3-((4-(7V-decyl-4-(hexahydrocyclopenta[c]pyrrol-2(U7)-yl)butanamido)butanoyl)oxy)propyl)(2-hexyldecyl)amino)propyl 4-ethyl octanoate was 180 mg (53%).
[1061] 'H NMR (400 MHz, CDCh) 84.14 - 4.06 (m, 4H), 3.55 - 3.11 (m, 5H), 2.88 - 2.66 (s, 2H), 2.66 - 2.51 (s, 2H), 2.51 - 2.22 (m, 12H), 2.22 - 2.00 (m, 4H), 1.91 - 1.37 (m, 21H), 1.37 -1.13 (m, 48H), 0.93 - 0.81 (m, 15H). ESI-MS: m / z calculated for C57H109N3O5 = 915.84, found [M+H]+= 917.14.
[1062] The various embodiments described above can be combined to provide further embodiments. All the U. S. patents, U. S. patent application publications, U. S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification, including U. S. Provisional Patent Application No. 63 / 805,124, filed on May 13, 2025, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications, and publications to provide yet further embodiments.
[1063] These and other changes can be made to the embodiments considering the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
Claims
CLAIMS1. A compound having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:Rlaand Rlbare each independently C2-C16 alkyl;R2ais hydrogen or C2-C16 alkyl;R2bis C2-C16 alkyl;R3is Ci-Cis alkyl, -C(=O)-Ci-Ci8 alkyl, -L3a-O-C(=O)-R3a, -L3a-C(=O)-O-R3a, -L3a-O-C(=O)-O-R3a;R3ais C2-C10 alkyl;L3ais Ci-Ce alkylene or *-C(=O)-Ci-Ce alkylene, wherein * represents a connection to the N of Formula (I) bound to R3;R4aand R4bare each independently optionally substituted C1-C4 alkyl, optionally substituted C3-C8 cycloalkyl, or R4aand R4b, together with the nitrogen to which they are attached, join to form an optionally substituted 3-8-membered heterocyclyl;L1is C1-C4 alkylene;L2is C1-C4 alkylene, *-L2a-O-C(=O)-, *-L2a-C(=O)-O-, or *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2;L2ais C1-C4 alkylene;L3is C1-C10 alkylene, -C(=O)-Ci-C8alkylene, -L3b-O-C(=O)-L3c-, -L3b-C(=O)-O-L3c-, or -L3b-O-C(=O)-O-L3c-;L3bis Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene;L3cis Ci-Cs alkylene; andL4is Ci-Cs alkylene, -C(=O)-Ci-Cs alkylene, or -C(=O)-C3-C8 cycloalkylene, wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
2. The compound of claim 1, wherein Rlais C4-C16 alkyl.
3. The compound of any one of claims 1-2, wherein Rlais C4-C12 alkyl.
4. The compound of any one of claims 1-3, wherein Rlais C4-C10 alkyl.
5. The compound of any one of claims 1-4, wherein Rlais C4 alkyl, Ce alkyl, Cs alkyl, or C10 alkyl.
6. The compound of any one of claims 1-5, wherein Rlbis C2-C16 alkyl.
7. The compound of any one of claims 1-6, wherein Rlbis C2-C12 alkyl.
8. The compound of any one of claims 1-7, wherein Rlbis C2-C10 alkyl.
9. The compound of any one of claims 1-8, wherein Rlbis C2 alkyl, C4 alkyl, Ce alkyl, Cs alkyl, or C10 alkyl.
10. The compound of any one of claims 1-9, wherein R2ais C4-C16 alkyl.
11. The compound of any one of claims 1-10, wherein R2ais C4-C12 alkyl.
12. The compound of any one of claims 1-11, wherein R2ais C4-C10 alkyl.
13. The compound of any one of claims 1-12, wherein R2ais C4 alkyl, Ce alkyl, Cs alkyl, or C10 alkyl.
14. The compound of any one of claims 1-9, wherein R2ais hydrogen.
15. The compound of any one of claims 1-14, wherein R2bis C2-C16 alkyl.
16. The compound of any one of claims 1-15, wherein R2bis C2-C12 alkyl.
17. The compound of any one of claims 1-16, wherein R2bis C2-C10 alkyl.
18. The compound of any one of claims 1-17, wherein R2bis C2 alkyl, C4 alkyl, C5 alkyl, Ce alkyl, C7 alkyl, Cs alkyl, or C10 alkyl.
19. The compound of any one of claims 1-18, wherein R3is Ci-Cis alkyl.
20. The compound of any one of claims 1-19, wherein R3is Ce alkyl, Cs alkyl, C10 alkyl, C12 alkyl, C12 alkyl, or Ci6 alkyl.
21. The compound of any one of claims 1-20, wherein R3is unbranched Cs alkyl, unbranched C10 alkyl, or branched Ci6 alkyl.
22. The compound of any one of claims 1-18, wherein R3is -C(=O)-Ci-Cis alkyl.
23. The compound of any one of claims 1-18, wherein R3is -C(=O)-Cs-Cis alkyl.
24. The compound of any one of claims 1-18, wherein R3has one of the following structures:
25. The compound of any one of claims 1-18, wherein R3is -L3a-O-C(=O)-R3aor - L3a-C(=O)-O-R3a.
26. The compound of any one of claims 1-18, wherein R3is -L3a-O-C(=O)-O-R3a.
27. The compound of claim 26, wherein L3ais Ci-Ce alkylene.
28. The compound of claim 26, wherein L3ais *-C(=O)-Ci-Ce alkylene, wherein * represents a connection to the N of Formula (I) bound to R3.
29. The compound of any one of claims 26-28, wherein R3ais C2-C6 alkyl.
30. The compound of any one of claims 26-29, wherein R3ais C7-C10 alkyl.
31. The compound of any one of claims 1-30, wherein R3has one of the following structures:
32. The compound of any one of claims 1-31, wherein R4ais methyl, ethyl, n-propyl, isopropyl, or n-butyl.
33. The compound of any one of claims 1-32, wherein R4ais methyl.
34. The compound of any one of claims 1-33, wherein R4bis methyl, ethyl, n-propyl, isopropyl, or n-butyl.
35. The compound of any one of claims 1-34, wherein R4bis methyl.
36. The compound of any one of claims 1-35, wherein R4aand R4bare both methyl.
37. The compound of any one of claims 1-31, wherein R4aand R4btogether with the nitrogen to which they are attached, join to form a 5-6-membered heterocyclyl.
38. The compound of any one of claims 1-31, wherein R4aand R4btogether with the nitrogen to which they are attached, join to form an optionally substituted pyrrolidinyl, piperidinyl, octahydrocyclopenta[c]pyrrolyl, or 7-azabicyclo[2.2.1]heptanyl.
39. The compound of any one of claims 1-31, wherein R4aand R4btogether with the nitrogen to which they are attached, join to form pyrrolidinyl or piperidinyl substituted with one or more -OH substituents.Ri4a40. The compound of any one of claims 1-39, whereinhas one of the following structures:
41. The compound of any one of claims 1-40, wherein L1is C1-C4 alkylene.
42. The compound of any one of claims 1-41, wherein L1is methylene.R1a43. The compound of any one of claims 1-42, wherein 1 has one of the following structures:
44. The compound of any one of claims 1-43, wherein L2is C1-C4 alkylene.
45. The compound of any one of claims 1-44, wherein L2is methylene.
46. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C14 alkyl.
47. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C8 alkyl.
48. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C14 alkyl, and R2bis C2-C14 alkyl.
49. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)- or *-L2a-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C8 alkyl, and R2bis C2-C8 alkyl.
50. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C14 alkyl.
51. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais hydrogen, and R2bis C2-C8 alkyl.
52. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C14 alkyl, and R2bis C2-C14 alkyl.
53. The compound of any one of claims 1-43, wherein L2is *-L2a-O-C(=O)-O-, wherein * represents a connection to the N of Formula (I) bound to L2, R2ais C2-C8 alkyl, and R2bis C2-C8 alkyl.
54. The compound of any one of claims 46-53, wherein L2ais C2 alkylene, C3 alkylene, or C4 alkylene.
55. The compound of any one of claims 46-54, wherein L2ais Ci alkylene or C2 alkylene.R2a56. The compound of any one of claims 1-55, wherein 1 has one of the following structures:
57. The compound of any one of claims 1-56, wherein L3is C3-C9 alkylene.
58. The compound of any one of claims 1-57, wherein L3is C3 alkylene, C4 alkylene, Cs alkylene, Ce alkylene, Cs alkylene, or C9 alkylene.
59. The compound of any one of claims 1-56, wherein L3is -C(=O)-C2-Ce alkylene.
60. The compound of any one of claims 1-56, wherein L3is -L3b-O-C(=O)-L3c- or - L3b-C(=O)-O-L3c-.
61. The compound of any one of claims 1-56, wherein L3is -L3b-O-C(=O)-O-L3c.
62. The compound of any one of claims 1-56, wherein L3is -L3b-C(=O)-O-L3c-.
63. The compound of any one of claims 60-62, wherein L3bis C2-C6 alkylene or -C(=O)-C2-C4alkylene.
64. The compound of any one of claims 60-63, wherein L3cis C2-C6 alkylene.
65. The compound of any one of claims 1-64, wherein L4is Ci-Cs alkylene.
66. The compound of any one of claims 1-65, wherein L4is C2-C4 alkylene.
67. The compound of any one of claims 1-64, wherein L4is -C(=O)-Ci-Ce alkylene.
68. The compound of any one of claims 1-64, wherein L4is -C(=O)-Ci alkylene, - C(=O)-C2 alkylene, -C(=O)-C3 alkylene, or -C(=O)-Cs alkylene.
69. The compound of any one of claims 1-64, wherein L4is -C(=O)-C3-Cs cycloalkylene.
70. The compound of any one of claims 1-64, wherein L4has the following structure:
71. The compound of claim 1, wherein:Rla, Rlb, R2a, and R2bare each independently C2-C16 alkyl;R3is Ci-Cis alkyl or -C(=O)-Ci-Ci8 alkyl;R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl;L1and L2are each independently C1-C4 alkylene;L3is C1-C10 alkylene; andL4is Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene,wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
72. The compound of claim 1, wherein:Rla, Rlb, and R2bare each independently C2-C16 alkyl;R2ais hydrogen or C2-C16 alkyl;R3is Ci-Cis alkyl or -C(=O)-Ci-Ci8 alkyl;R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl;L1is C1-C4 alkylene;L2is C1-C4 alkylene, *-L2a-O-C(=O)-, *-L2a-C(=O)-O-, or *-L2a-O-C(=O)-O- wherein * represents a connection to the N of Formula (I) bound to L2;L2ais C1-C4 alkylene;L3is C1-C10 alkylene; andL4is Ci-Cs alkylene or -C(=O)-Ci-Cs alkylene,wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
73. The compound of claim 1, wherein:Rla, Rlb, R2a, and R2bare each independently C2-C16 alkyl;R3is Ci-Cis alkyl, -C(=O)-Ci-Ci8 alkyl, -L3a-O-C(=O)-R3a, -L3a-C(=O)-O-R3a, or -L3a-O-C(=O)-O-R3a;R3ais C2-C10 alkyl;L3aand L3bare each independently Ci-Ce alkylene;R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl;L1and L2are each independently C1-C4 alkylene;L3is C1-C10 alkylene; andL4is Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene,wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
74. The compound of claim 1, wherein:Rla, Rlb, R2a, and R2bare each independently C2-C16 alkyl;R3is Ci-Cis alkyl or -C(=O)-Ci-Ci8 alkyl;R4aand R4bare each independently C1-C4 alkyl or R4aand R4b, together with the nitrogen to which they are attached, join to form a 3-8-membered heterocyclyl;L1and L2are each independently C1-C4 alkylene;L3is C1-C10 alkylene, -C(=O)-Ci-C8alkylene, -L3b-O-C(=O)-L3c-, -L3b-C(=O)-O-L3c-, or -L3b-C(=O)-O-L3c-;L3band L3care each independently Ci-Cs alkylene; andL4is Ci-Cs alkylene or -C(=O)-Ci-C8 alkylene,wherein each alkyl or alkylene is optionally substituted with one or more halo substituents.
75. A compound selected from the compounds of Table 1 or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
76. A lipid nanoparticle comprising the compound of any one of claims 1-75 and a therapeutic agent.
77. A composition comprising the compound of any one of claims 1-75, or the nanoparticle of claim 74, and a therapeutic agent.
78. The lipid nanoparticle or composition of any one of claims 76 or 77, further comprising one or more excipient selected from neutral lipids, steroids and polymer conjugated lipids.
79. The lipid nanoparticle or composition of claim 76-78, comprising one or more neutral lipids selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM.
80. The lipid nanoparticle or composition of claim 79, wherein the neutral lipid is DSPC.
81. The lipid nanoparticle or composition of any one of claims 78-80, wherein the molar ratio of the compound to the neutral lipid ranges from about 2: 1 to about 8:1.
82. The lipid nanoparticle or composition of any one of claims 78-81, wherein the steroid is cholesterol.
83. The lipid nanoparticle or composition of claim 82, wherein the molar ratio of the compound to cholesterol ranges from 5: 1 to 1: 1 or from 2:1 to 1:1.
84. The lipid nanoparticle or composition of any one of claims 78-83, wherein the polymer conjugated lipid is a pegylated lipid.
85. The lipid nanoparticle or composition of claim 78-84, wherein the molar ratio of the compound to pegylated lipid ranges from about 100: 1 to about 20: 1 or from about 100: 1 to about 10:1.
86. The lipid nanoparticle or composition of claim 78-85, wherein the pegylated lipid is PEG-DAG, PEG-PE, PEG-S-DAG, PEG-cer or a PEG dialkyoxypropylcarbamate.
87. The lipid nanoparticle or composition of claim 78-85, wherein the pegylated lipid has the following Formula (II):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:R5and R6are each independently a straight or branched, alkyl, alkenyl, or alkynyl from 10 to 30 carbon atoms, wherein the alkyl, alkenyl or alkynyl is optionally interrupted by one or more ester bonds; andw has a value ranging from 30 to 60.
88. The lipid nanoparticle or composition of claim 87, wherein R5and R6are each independently straight alkyl chain containing from 12 to 16 carbon atoms.
89. The lipid nanoparticle or composition of any one of claims 87-88, wherein w has a value ranging from 40 to 50.
90. The lipid nanoparticle or composition of any one of claims 87-88, wherein the lipid nanoparticle or composition comprises a plurality of compounds of Formula (II) and the average value of w for the plurality ranging from 40 to 50.
91. The lipid nanoparticle or composition of any one of claims 76-90, wherein the therapeutic agent comprises a nucleic acid.
92. The lipid nanoparticle or composition of claim 91, wherein the nucleic acid is selected from antisense and messenger RNA.
93. A method for administering a therapeutic agent to a patient in need thereof, the method comprising preparing or providing the lipid nanoparticle or composition of any one of claims 77-92 and administering the composition to the patient.
94. A pharmaceutical composition comprising the lipid nanoparticle of claim 76 and a pharmaceutically acceptable diluent or excipient.
95. A method for inducing expression of a protein in a patient in need thereof, comprising administering the pharmaceutical composition of claim 94 to the patient, wherein the lipid nanoparticle comprises an mRNA encoding the protein.
96. The method of claim 95, wherein the protein is an antigen, and the method is for inducing an immune response in the patient.
97. The method of claim 95, wherein the protein is an antigen, and the method is for vaccinating the patient against a pathogen.
98. The method of claim 95, wherein the protein is for gene editing.
